{
    "23285843": {
        "sentences": [
            "[Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].",
            "To compare the intraocular pressure (IOP)-lowering effect and safety of topical brimonidine to that of timolol, and to study the additive effect of topical brimonidine to topical prostaglandin (PG) analogues in 475 patients with either ocular hypertension or primary open angle glaucoma.",
            "The primary endpoint was the mean IOP change from the baseline at 0 and 2 hours at week 4.",
            "The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138).",
            "The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.",
            "When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).",
            "No appreciable adverse side effects were encountered.",
            "Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues, although its IOP-lowering effect was inferior to topical timolol as monotherapy."
        ],
        "labels": [
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "29463627": {
        "sentences": [
            "Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).",
            "The aim of this study is to compare spironolactone versus clonidine as the fourth drug in patients with resistant hypertension in a multicenter, randomized trial.",
            "Medical therapy adherence was checked by pill counting.",
            "Patients with resistant hypertension (no office and ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with spironolactone (12.5-50 mg QD) or clonidine (0.1-0.3 mg BID).",
            "The primary end point was BP control during office (<140/90 mm\u2009Hg) and 24-h ambulatory (<130/80 mm\u2009Hg) BP monitoring.",
            "Secondary end points included BP control from each method and absolute BP reduction.",
            "From 1597 patients recruited, 11.7% (187 patients) fulfilled the resistant hypertension criteria.",
            "Compared with the spironolactone group (n=95), the clonidine group (n=92) presented similar rates of achieving the primary end point (20.5% versus 20.8%, respectively; relative risk, 1.01 [0.55-1.88]; P=1.00).",
            "Secondary end point analysis showed similar office BP (33.3% versus 29.3%) and ambulatory BP monitoring (44% versus 46.2%) control for spironolactone and clonidine, respectively.",
            "However, spironolactone promoted greater decrease in 24-h systolic and diastolic BP and diastolic daytime ambulatory BP than clonidine.",
            "Per-protocol analysis (limited to patients with \u226580% adherence to spironolactone/clonidine treatment) showed similar results regarding the primary end point.",
            "In conclusion, clonidine was not superior to spironolactone in true resistant hypertensive patients, but the overall BP control was low (\u224821%).",
            "Considering easier posology and greater decrease in secondary end points, spironolactone is preferable for the fourth-drug therapy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim"
        ]
    },
    "29559030": {
        "sentences": [
            "Effect of SSRI and calcium channel blockers on depression symptoms and cognitive function in elderly persons treated for hypertension: three city cohort study.",
            "Emerging genetic, ex-vivo, and clinical trial evidence indicates that calcium channel blockers (CCB) can improve mood and cognitive function.",
            "The objective of this study was to examine the effect of selective serotonin reuptake inhibitor (SSRI) therapy augmented with CCB on depression and cognitive decline in an elderly population with hypertension.",
            "Prospective study of 296 persons treated with SSRI and antihypertensive drugs.",
            "Baseline and two year clinic assessments were used to categorize participants as users of SSRI + CCB (n = 53) or users of SSRI + other antihypertensives (n = 243).",
            "Clinic visits were performed up to four times in a ten-year period to assess depression and cognitive function.",
            "The sample mean age was 75.2 \u00b1 5.47 years and 78% of participants were female.",
            "At two year follow-up there was a significant group by time interaction showing lower Center for Epidemiological Studies-Depression (CESD) scores in the SSRI + CCB group, F(1,291) = 4.13, p = 0.043, \u03b72 p = 0.014.",
            "Over ten-years follow-up, SSRI + CCB use was associated with improved general cognitive function (Mini-Mental State Examination: \u03b2 = 0.97; 95% CI 0.14 to 1.81, p = 0.023) and immediate visual memory (Boston Visual Retention Test: \u03b2 = 0.69; 95% CI 0.06 to 1.32, p = 0.033).",
            "The findings provide general population evidence that SSRI augmentation with CCB may improve depression and cognitive function."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "22986111": {
        "sentences": [
            "Phacoemulsification versus trabeculectomy in medically uncontrolled chronic angle-closure glaucoma without cataract.",
            "To compare phacoemulsification versus trabeculectomy with adjunctive mitomycin C in medically uncontrolled chronic angle-closure glaucoma (CACG) without cataract.",
            "Prospective, randomized clinical trial.",
            "Fifty medically uncontrolled CACG eyes without cataract of 50 patients.",
            "Patients were randomized into undergoing either phacoemulsification or trabeculectomy with adjunctive mitomycin C. After surgery, patients were followed up every 3 months for 2 years.",
            "Intraocular pressure (IOP) and requirement for glaucoma drugs.",
            "Twenty-six CACG eyes were randomized to receive phacoemulsification, and 24 eyes underwent trabeculectomy with mitomycin C. Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs 8.9 mmHg or 36% for trabeculectomy; P=0.76).",
            "Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).",
            "However, trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs 4%; P=0.001).",
            "Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.",
            "Both phacoemulsification and trabeculectomy are effective in reducing IOP in medically uncontrolled CACG eyes without cataract.",
            "Trabeculectomy is more effective than phacoemulsification in reducing dependence on glaucoma drugs, but is associated with more complications."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29056008": {
        "sentences": [
            "[Clinical effect and safety of pegylated interferon-\u03b1-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].",
            "To investigate the clinical effect and safety of long-acting pegylated interferon-\u03b1-2b (Peg-IFN-\u03b1-2b) (Y shape, 40 kD) injection (180 \u03bcg/week) in the treatment of HBeAg-positive chronic hepatitis B (CHB) patients, with standard-dose Peg-IFN-\u03b1-2a as positive control.",
            "This study was a multicenter, randomized, open-label, and positive-controlled phase III clinical trial.",
            "Eligible HBeAg-positive CHB patients were screened out and randomized to Peg-IFN-\u03b1-2b (Y shape, 40 kD) trial group and Peg-IFN-\u03b1-2a control group at a ratio of 2:1.",
            "The course of treatment was 48 weeks and the patients were followed up for 24 weeks after drug withdrawal.",
            "Plasma samples were collected at screening, baseline, and 12, 24, 36, 48, 60, and 72 weeks for centralized detection.",
            "COBAS\u00ae Ampliprep/COBAS\u00ae TaqMan\u00ae HBV Test was used to measure HBV DNA level by quantitative real-time PCR.",
            "Electrochemiluminescence immunoassay with Elecsys kit was used to measure HBV markers (HBsAg, anti-HBs, HBeAg, anti-HBe).",
            "Adverse events were recorded in detail.",
            "The primary outcome measure was HBeAg seroconversion rate after the 24-week follow-up, and non-inferiority was also tested.",
            "The difference in HBeAg seroconversion rate after treatment between the trial group and the control group and two-sided confidence interval (CI) were calculated, and non-inferiority was demonstrated if the lower limit of 95% CI was > -10%.",
            "The t-test, chi-square test, or rank sum test was used according to the types and features of data.",
            "A total of 855 HBeAg-positive CHB patients were enrolled and 820 of them received treatment (538 in the trial group and 282 in the control group).",
            "The data of the full analysis set showed that HBeAg seroconversion rate at week 72 was 27.32% in the trial group and 22.70% in the control group with a rate difference of 4.63% (95% CI -1.54% to 10.80%, P = 0.1493).",
            "The data of the per-protocol set showed that HBeAg seroconversion rate at week 72 was 30.75% in the trial group and 27.14% in the control group with a rate difference of 3.61% (95% CI -3.87% to 11.09%, P = 0.3436).",
            "95% CI met the non-inferiority criteria, and the trial group was non-inferior to the control group.",
            "The two groups had similar incidence rates of adverse events, serious adverse events, and common adverse events.",
            "In Peg-IFN-\u03b1 regimen for HBeAg-positive CHB patients, the new drug Peg-IFN-\u03b1-2b (Y shape, 40 kD) has comparable effect and safety to the control drug Peg-IFN-\u03b1-2a."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29514030": {
        "sentences": [
            "Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.",
            "Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin.",
            "In this multicenter, double-blind clinical trial performed in Thailand, we randomly assigned hepatitis B e antigen (HBeAg)-positive pregnant women with an alanine aminotransferase level of 60 IU or less per liter to receive tenofovir disoproxil fumarate (TDF) or placebo from 28 weeks of gestation to 2 months post partum.",
            "Infants received hepatitis B immune globulin at birth and hepatitis B vaccine at birth and at 1, 2, 4, and 6 months.",
            "The primary end point was a hepatitis B surface antigen (HBsAg)-positive status in the infant, confirmed by the HBV DNA level at 6 months of age.",
            "We calculated that a sample of 328 women would provide the trial with 90% power to detect a difference of at least 9 percentage points in the transmission rate (expected rate, 3% in the TDF group vs. 12% in the placebo group).",
            "From January 2013 to August 2015, we enrolled 331 women; 168 women were randomly assigned to the TDF group and 163 to the placebo group.",
            "At enrollment, the median gestational age was 28.3 weeks, and the median HBV DNA level was 8.0 log10 IU per milliliter.",
            "Among 322 deliveries (97% of the participants), there were 319 singleton births, two twin pairs, and one stillborn infant.",
            "The median time from birth to administration of hepatitis B immune globulin was 1.3 hours, and the median time from birth to administration of hepatitis B vaccine was 1.2 hours.",
            "In the primary analysis, none of the 147 infants (0%; 95% confidence interval [CI], 0 to 2) in the TDF group were infected, as compared with 3 of 147 (2%; 95% CI, 0 to 6) in the placebo group (P=0.12).",
            "The rate of adverse events did not differ significantly between groups.",
            "The incidence of a maternal alanine aminotransferase level of more than 300 IU per liter after discontinuation of the trial regimen was 6% in the TDF group and 3% in the placebo group (P=0.29).",
            "In a setting in which the rate of mother-to-child HBV transmission was low with the administration of hepatitis B immune globulin and hepatitis B vaccine in infants born to HBeAg-positive mothers, the additional maternal use of TDF did not result in a significantly lower rate of transmission."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29654388": {
        "sentences": [
            "Insulin-mimetic effects of short-term rapamycin in type 1 diabetic patients prior to islet transplantation.",
            "The immunosuppressive drug rapamycin may influence insulin sensitivity in insulin-responsive tissues.",
            "This study aimed at evaluating the effectiveness of rapamycin pre-treatment before pancreatic islet allotransplantation (ITx) in patients with type 1 diabetes mellitus (T1DM).",
            "Forty-one T1DM patients were studied.",
            "Thirteen patients with poor glycemic control underwent a short-term rapamycin treatment before ITx (Group 1), and they were compared to 28 patients undergoing ITx without rapamycin pre-treatment (Group 2).",
            "Outcomes were daily insulin requirement (DIR), fasting blood glucose, HbA1c, C-peptide and the SUITO index of beta-cell function.",
            "A subgroup of patients pre-treated with rapamycin before ITx underwent euglycemic hyperinsulinemic clamp with [6,6-2H2] glucose before and after ITx to evaluate insulin sensitivity.",
            "We found a significant reduction in DIR after rapamycin pre-treatment (-\u20098\u2009\u00b1\u20096 U/day, mean\u2009\u00b1\u2009SD, p\u2009<\u20090.001) and 1 year after ITx.",
            "DIR reduction 1 year after ITx was greater in Group 1 as compared to Group 2 (-\u200937\u2009\u00b1\u200915 vs. -\u200919\u2009\u00b1\u200913 U/day, p\u2009=\u20090.005) and remained significant after adjusting for gender, age, glucose and baseline HbA1c (beta\u2009=\u200918.2\u2009\u00b1\u20095.9, p\u2009=\u20090.006).",
            "Fasting glucose and HbA1c significantly decreased 1 year after ITx in Group 1 (HbA1c: -\u20092.1\u2009\u00b1\u20091.4%, p\u2009=\u20090.002), while fasting C-peptide (+0.5\u2009\u00b1\u20090.3 nmol/l, p\u2009=\u20090.002) and SUITO index increased (+57.4\u2009\u00b1\u200939.7, p\u2009=\u20090.016), without differences between the two groups.",
            "Hepatic glucose production decreased after rapamycin pre-treatment (-\u20091.1\u2009\u00b1\u20091.1 mg/kg/min, p\u2009=\u20090.04) and after ITx (-\u20091.6\u2009\u00b1\u20090.6 mg/kg/min, p\u2009=\u20090.015), while no changes in peripheral glucose disposal were observed.",
            "Rapamycin pre-treatment before ITx succeeds in reducing insulin requirement, enhancing hepatic insulin sensitivity.",
            "This treatment may improve short-term ITx outcomes, possibly in selected patients with T1DM complicated by insulin resistance."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29378197": {
        "sentences": [
            "TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.",
            "The oral Toll-like receptor (TLR) 7 agonist GS-9620 has antiviral effects in woodchuck and chimpanzee models of chronic hepatitis B virus (HBV) infection.",
            "We investigated, in a clinical trial, the capacity of this agent to reconstitute protective immunity in patients with chronic HBV infection.",
            "We performed a prospective study of 28 patients with suppression of HBV infection by nucleos(t)ide analogue therapy and who tested negative for hepatitis B e antigen at 4 medical centers in Italy.",
            "Patients were randomly assigned (1:3:3:3) to groups given placebo or different doses of GS-9620 (1, 2, and 4 mg, weekly for 12 weeks).",
            "We added data from 8 patients receiving nucleos(t)ide analogue therapy to the placebo group (controls); 13 treatment-na\u00efve patients with chronic HBV infection and 15 subjects who spontaneously recovered from an acute HBV infection served as additional controls.",
            "Peripheral blood mononuclear cells were collected at baseline, during administration of GS-9620 or placebo, and 12 weeks afterward.",
            "Phenotype and function of natural killer (NK) and HBV-specific T cells were analyzed by flow cytometry.",
            "T cells were expanded by incubation with peptides from the entire HBV proteome and studied after overnight or 10 days culture.",
            "NK-cell inhibition of T-cell responses was measured by assessing cytokine production by T cells stimulated with peptides in the presence or absence of NK cells.",
            "T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-na\u00efve patients, based on cytokine production in response to HBV peptides.",
            "However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.",
            "NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.",
            "Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.",
            "Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.",
            "Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.",
            "GS-9620 might therefore be included in therapies to increase the immune response to HBV."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29428751": {
        "sentences": [
            "Randomized double-blind controlled clinical trial of the blood pressure-lowering effect of fermented milk with Lactococcus lactis: A pilot study.",
            "The blood pressure-lowering effect of fermented milk with Lactococcus lactis NRRL B-50571 was evaluated in a double-blind randomized controlled clinical trial with prehypertensive subjects.",
            "Participants were randomized into 2 groups (n = 18 each group): one group treated with fermented milk with Lactococcus lactis NRRL B-50571 and a control group treated with artificially acidified milk.",
            "Results revealed that during daily consumption of fermented milk for 5 wk, systolic [(116.55 \u00b1 12.26 mmHg vs. 124.77 \u00b1 11.04 mmHg) and diastolic blood pressure (80.7 \u00b1 9 vs. 84.5 \u00b1 8.5 mmHg)] from the fermented milk group was lower than the control group.",
            "Additionally, triglyceride, total cholesterol, and low-density lipoprotein in blood serum were lower in the fermented milk group than in the control group.",
            "Results demonstrated that daily consumption of fermented milk with Lactococcus lactis (NRRL B-50571) had a blood pressure-lowering effect on prehypertensive subjects.",
            "Regular consumption of this product may be used as a potential functional food."
        ],
        "labels": [
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "29605574": {
        "sentences": [
            "Efficacy of cinnamon in patients with type II diabetes mellitus: A\u00a0randomized controlled clinical trial.",
            "Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.",
            "Differences in Baseline Body Mass Index (BMI) of patients may be able to explain the observed differences in the results.",
            "This study was designed to evaluate the effect of cinnamon supplementation on anthropometric, glycemic and lipid outcomes of patients with DM type II based on their baseline BMI.",
            "The study was designed as a triple-blind placebo-controlled randomized clinical trial, using a parallel design.",
            "One hundred and forty patients referred to Diabetes Clinic of Yazd University of Medical Sciences with diagnosis of DM type II were randomly assigned in four groups: cinnamon (BMI \u2265 27, BMI < 27) and Placebo (BMI \u2265 27, BMI < 27).",
            "Patients received cinnamon bark powder or placebo in 500 mg capsules twice daily for 3 months.",
            "Anthropometric, glycemic and lipid outcomes were measured before and after the intervention.",
            "Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).",
            "All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI \u2265 27).",
            "Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.",
            "These benefits are significantly more prominent in patients with higher baseline BMI (BMI \u2265 27)."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29588138": {
        "sentences": [
            "Effect of Eicosapentaenoic acid (EPA) supplementation on cardiovascular markers in patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.",
            "Cardiovascular complications are one of main cause of increased mortality and morbidity among Diabetes Mellitus (DM) patients.",
            "Altered metabolism of sulphur amino acids in diabetes reflected as increases in concentration of methionine and cysteine/cystine in the blood which known as a markers of Cardiovascular Diseases (CVD).",
            "The aim of present study was to determine the effect of Eicosapentaenoic acid (EPA) supplementation on sulfhydryl amino acids and Atherogenic Index of Plasma (AIP) in patients with type 2 DM (T2DM).",
            "A randomized, double-blind, placebo-controlled clinical trial was performed in 36 control and patients with DM.",
            "The subjects were randomly assigned to obtain 2\u202fg/d EPA (n\u202f=\u202f18) or placebo (n\u202f=\u202f18) for 8 weeks.",
            "Fasting serum level of Cystein and Methionine were measured using HPLC method and atherogenic index of plasma (AIP) as a proxy measure of atherosclerosis was computed.",
            "Eight weeks supplementation with EPA led to significant reductions in Met (p\u202f<\u202f0.002) and Cys (p\u202f<\u202f0.001) compared with the placebo (p\u202f<\u202f0.06).",
            "In addition, compared to placebo a significant reduction in AIP were seen after taking EPA (p\u202f<\u202f0.04).",
            "EPA supplementation in patients with T2DM for eight weeks had beneficial effects on Met, Cys and AIP, which may attribute to the prevention of vascular complications in the T2DM patients."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "28178150": {
        "sentences": [
            "The effects of selective laser trabeculoplasty and travoprost on circadian intraocular pressure fluctuations: A randomized clinical trial.",
            "To compare the effect of selective laser trabeculoplasty (SLT) and travoprost on 24-hour IOP fluctuations in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG).",
            "Sixty eyes were included.",
            "Sixteen and 14 eyes of POAG patients were randomized to receive 360\u00b0 SLT or 0.004% travoprost, respectively.",
            "Fourteen and 16 eyes of NTG patients were randomized to receive either SLT or travoprost, respectively.",
            "The 24-hour IOP data were collected before treatment and 6 to 8 weeks after treatment.",
            "IOP was measured at 2 hours intervals in the sitting position during daytime (9 AM to 7 PM) and in the supine position during nighttime (9 PM to 7 AM).",
            "Main outcome measure was the percentage of eyes that achieved posttreatment 24-hour IOP fluctuations <3\u200amm\u200aHg.",
            "Success in fluctuation reduction was defined as at least a 50% reduction in these fluctuations.",
            "Fifty-eight eyes were analyzed.",
            "Overall, eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7\u200amm Hg [P\u200a=\u200a0.002] vs -4.1\u200amm Hg [P\u200a<\u200a0.001], respectively).",
            "There was no significant difference in IOP reduction in both groups according to type of glaucoma.",
            "During the diurnal period, 100% of POAG eyes in the travoprost group achieved posttreatment IOP fluctuations <3\u200amm Hg, and 87% of eyes in the SLT group achieved the same level of fluctuations (P\u200a<\u200a0.001).",
            "Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3\u200amm Hg (P\u200a=\u200a0.01).",
            "Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P\u200a=\u200a0.005).",
            "The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime, while the SLT's effect was significant only during the nighttime.",
            "Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.",
            "Based on habitual positions, travoprost better controls IOP fluctuations than SLT, especially during the daytime."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            null,
            null,
            "Evidence",
            null,
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "29610590": {
        "sentences": [
            "Effects of Appropriate Nutrition Training in Small Groups on Laboratory Parameters in Hemodialysis Patients from Iran.",
            "Adherence to appropriate nutrition and fluid intake is one of the essential parts of chronic renal failure treatment for achieving the desirable results among the patients with hemodialysis.",
            "Among various training methods, the \"small groups' method\", as an advanced method, can be performed by nurses in achieving desirable therapeutic results.",
            "The present study was aimed to investigate the effect of appropriate nutrition training in small groups on laboratory parameters in hemodialysis patients.",
            "In this clinical trial, 64 patients who met the inclusion criteria were randomly selected and divided into an intervention group and a control group.",
            "Subsequently, an appropriate nutritional training program, including lectures along with appropriate nutrition pamphlets in three one hour question and answer sessions were performed.",
            "Thirty two patients in each group were assigned to intervention groups of five.",
            "Then, the laboratory indicators for each patient were measured in each group one month after training.",
            "Thereafter, data analysis was performed using descriptive and analytical statistics (statistical tests including independent t-test, paired t-test, repeated measures, and ANOVA) in SPSS V.16 software.",
            "The mean age of the patients was 50.1 \u00b1 13.1 years; 47.5% of them had undergone dialysis due to hypertension and 55.7% had a history of 1-5 years of hemodialysis.",
            "There was a significant difference in post-intervention levels of urea, creatinine, sodium, potassium, calcium, and phosphorus between the two groups.",
            "Appropriate nutrition training via small-group method for patients on hemodialysis can impose positive effects on laboratory parameters."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim"
        ]
    },
    "29456079": {
        "sentences": [
            "Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.",
            "Efficacy of sequential therapy with nucleos(t)ide analogues and interferons versus monotherapy in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) remains unexplored.",
            "We aimed to assess efficacy and safety of sequential therapy with adefovir (ADV) or entecavir (ETV) followed by peginterferon (PEG-IFN) alfa-2a in Taiwanese patients with HBeAg-positive.",
            "This randomized, placebo-controlled, double-blind trial was conducted at nine sites in Taiwan from April 2010 to October 2013.",
            "Patients (N = 280) were randomized 1:1:1 to receive placebo, ETV or ADV alone for four weeks, combined with PEG-IFN alfa-2a for two weeks, then PEG-IFN alfa-2a alone for 46 weeks.",
            "The primary efficacy end point was HBeAg seroconversion at 48 weeks post-treatment.",
            "No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).",
            "However, hepatitis B virus DNA levels were higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa+ETV at week 64 (p = 0.0412), 76 (p = 0.0311), and 88 (p = 0.0113), and alanine aminotransferase (ALT) normalization rate was higher with PEG-IFN alfa-2a+placebo than PEG-IFN alfa-2a+ADV (p = 0.0283) or PEG-IFN alfa-2a+ETV (p = 0.0369) at week 88.",
            "Sub-analysis of results revealed an association between on-treatment HBsAg and ALT levels and efficacy 48 weeks post-treatment.",
            "Safety was comparable among treatment groups.",
            "Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29596950": {
        "sentences": [
            "One-year effects of a group-based lifestyle intervention in adults with type 2 diabetes: A randomized encouragement trial.",
            "To estimate the real-world effects of offering a group-based lifestyle intervention (GLI) to adults with diabetes.",
            "This randomized encouragement trial included adult primary care patients in metropolitan Chicago with type 2 diabetes and body mass index \u226524\u202fkg/m2.",
            "Participants were randomized to standard care (brief dietary and lifestyle counseling) or standard care plus being encouraged, but not required, to participate in a free-of-charge GLI offered by the YMCA.",
            "The GLI was a group-based adaptation of the Look AHEAD lifestyle intervention.",
            "Of 331 participants, 167 were randomized to standard care and 164 to the GLI encouragement arm.",
            "About one third of participants were non-Hispanic White (34.4%).",
            "In the GLI arm, 75 (45.7%) attended \u22651 GLI visits.",
            "In the primary intention-to-treat analysis, the effect of GLI encouragement was 0.95% weight loss at six months (95% confidence interval [CI], 0.13-1.77%; P\u202f=\u202f0.02), and 1.20% weight loss at 12\u202fmonths (95% CI, 0.05-2.36%; P\u202f=\u202f0.04).",
            "At 12\u202fmonths, there was a 0.30% (3.3\u202fmmol/mol) reduction in hemoglobin A1c, but this result did not achieve statistical significance (P\u202f=\u202f0.054).",
            "In instrumental variable analysis estimating effects among the subgroup of participants who attended any GLI visits, the effect of GLI attendance was 2.30% weight loss at six months (95% CI, 0.30-4.30%; P\u202f=\u202f0.02), and 2.07% weight loss at 12\u202fmonths (95% CI, 0.25-3.88%; P\u202f=\u202f0.02).",
            "We detected no significant blood pressure or cholesterol effects.",
            "Among adults with type 2 diabetes, a group-based lifestyle intervention in a community-based setting achieved modest weight loss at 6 and 12\u202fmonths."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "29329305": {
        "sentences": [
            "Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.",
            "The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.",
            "In this non-inferiority trial, patients with LAM-resistant CHB and undetectable serum HBV DNA (<20 IU/mL) for >6 months after initiating LAM+ADV combination therapy were randomized (1:2) either to continue the combination therapy (LAM+ADV group, n = 58) or switched to TDF monotherapy (TDF group, n = 111).",
            "They were followed-up with serum biochemistry tests and HBV DNA measurement at 12-week intervals for 96 weeks.",
            "The primary endpoint of this study was the proportion of patients with viral reactivation at week 96.",
            "Patients with CHB enrolled in this study (n = 169) included 74 patients with compensated liver cirrhosis.",
            "In total, 9 patients (4 in the LAM+ADV group and 5 in the TDF group) dropped-out from the study.",
            "After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).",
            "None of the subjects in either group experienced viral reactivation based on per protocol analysis.",
            "No serious adverse reactions were observed.",
            "In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).",
            "Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.",
            "However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "28291960": {
        "sentences": [
            "Trabeculectomy with Ologen versus Mitomycin C in Juvenile Open-Angle Glaucoma: A 1-Year Study.",
            "We assessed bleb morphology and the intraocular pressure (IOP)-lowering effect of trabeculectomy with ologen compared to mitomycin C (MMC) in juvenile open-angle glaucoma (JOAG).This is a prospective interventional comparative study conducted on 40 eyes (20 patients) with medically uncontrolled JOAG, randomly operating one eye for trabeculectomy with ologen (group A: 20 eyes) and the other with MMC (group B: 20 eyes).",
            "IOP measurement, SITA standard perimetry, and spectral domain optical coherence tomography (OCT) for retinal nerve fiber layer (RNFL) thickness were all done pre- and postoperatively.",
            "Postoperative blebs were assessed clinically using the Moorfields bleb grading system (MBGS) and anterior segment OCT (AS-OCT).",
            "All patients were examined for up to 1 year postoperatively.",
            "The mean postoperative IOP was statistically significantly lower than the mean preoperative IOP at each follow-up in each group.",
            "At 1 year, the mean postoperative IOP was significantly lower in group A.",
            "According to the MBGS, blebs with an ologen implant showed significantly better scoring than those with MMC.",
            "AS-OCT showed that ologen-induced blebs had significantly more fluid-filled spaces, cleavage planes, and less fibrosis.",
            "Ologen resulted in a lower long-term postoperative IOP, a better bleb morphology, and fewer complications.",
            "Our results suggest that ologen may be a useful alternative to MMC in JOAG."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "12118027": {
        "sentences": [
            "Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.",
            " To compare protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin (MMC) in patients with advanced pancreatic cancer in a multicenter, prospectively randomized study.",
            "Two hundred eight patients were randomized to PVI 5-FU (300 mg/m(2)/d for a maximum of 24 weeks) or PVI 5-FU plus MMC (7 mg/m(2) every 6 weeks for four courses).",
            "The major end points were tumor response, survival, toxicity, and quality of life (QOL).",
            "The two treatment groups were balanced for baseline demographic factors, and 62% had metastatic disease.",
            "The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).",
            "Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).",
            "Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).",
            "Toxicities in both arms were mild.",
            "There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.",
            "No patients developed hemolytic uremic syndrome.",
            "Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC, although there was no statistically significant difference in QOL between arms.",
            "PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer, but this did not translate into a survival advantage.",
            "These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29498351": {
        "sentences": [
            "Effect of increased calcium consumption from fat-free milk in an energy-restricted diet on the metabolic syndrome and cardiometabolic outcomes in adults with type 2 diabetes mellitus: a randomised cross-over clinical trial.",
            "We investigated the effects of high-Ca fat-free milk phase (MD) (prescription of approximately 1500 mg of Ca/d) v. low-Ca phase (CD) (prescription of approximately 800 mg of Ca/d) in an energy-restricted diet on the metabolic syndrome (MetS) and cardiometabolic measures in individuals with type 2 diabetes mellitus (T2DM) and low habitual Ca consumption (<600 mg/d).",
            "In this randomised cross-over design, fourteen adults with T2DM (49\u00b75 (sd 8\u00b76) years, BMI 29\u00b74 (sd 4\u00b75) kg/m2) consumed either MD or CD for 12 weeks, with a washout of 18 weeks between phases.",
            "A breakfast shake containing 700 mg (MD) or 6\u00b74 mg (CD) of Ca was consumed in the laboratory.",
            "In addition, energy-restricted diets were prescribed (800 mg of dietary Ca/d).",
            "Waist circumference (WC), fasting glucose, fasting TAG, systolic (SBP) and diastolic blood pressure (DBP), fasting total cholesterol, fasting LDL-cholesterol, fasting HDL-cholesterol, HDL:LDL ratio, HDL:TAG ratio and lipid accumulation product (LAP) index were assessed at baseline and after each phase.",
            "Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.",
            "There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.",
            "HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.",
            "The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence"
        ]
    },
    "12004217": {
        "sentences": [
            "Neorectal reservoir is not the functional principle of the colonic J-pouch: the volume of a short colonic J-pouch does not differ from a straight coloanal anastomosis.",
            " Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.",
            "However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.",
            "Therefore, the colonic J-pouch was originally constructed to create a stool reservoir.",
            "In a randomized, prospective study, the short (5 cm) colonic J-pouch was tested for function and continence vs. straight coloanal anastomosis.",
            "Over a period of 30 months, 74 consecutive patients (55 males) with rectal cancer in the lower and middle third of the rectum were included and randomized into two groups.",
            "Anastomosis was performed either as a coloanal or a colon-pouch-anal anastomosis.",
            "The standardized surgical procedure included mobilization of the left hemicolon, central ligation of the inferior mesenteric artery and vein, preaortal lymph node dissection, autonomic nerve preservation, and total mesorectal excision.",
            "The anastomosis was performed at the upper anal canal or at the intersphincteric level.",
            "All patients were evaluated preoperatively and six months postoperatively for fecal continence, including sphincter manometry and defecation habits.",
            "In addition, quality of life was determined by use of a standardized questionnaire (European Organization for Research and Treatment of Cancer, EORTC-QLQ-C30).",
            "Thirty-seven patients were randomized into each group.",
            "In general, problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.",
            "The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).",
            "Importantly, in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.",
            "Thus, the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.",
            "The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.",
            "Furthermore, stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.",
            "However, because neorectal capacity decreased equally in both groups, we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility."
        ],
        "labels": [
            null,
            "Claim",
            "Evidence",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Evidence"
        ]
    },
    "28371482": {
        "sentences": [
            "Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients.",
            "To compare the additive effects and safety of 1% brinzolamide/0.5% timolol fixed combination (BTFC) versus the low-dose regimen of 1% dorzolamide/0.5% timolol fixed combination (DTFC) in patients with open-angle glaucoma and ocular hypertension (OAG/OH) following treatment with prostaglandin analogues (PGAs).",
            "A prospective, randomized, double-masked, multicentre, parallel-group and active-controlled study included 201 Japanese OAG/OH patients who had been treated with PGA.",
            "Efficacy was assessed as the change in intra-ocular pressure (IOP) from baseline after weeks 4 and 8.",
            "Safety was assessed with adverse event rates, ocular discomfort score, blur scale, blood pressure and heart rates, best-corrected visual acuity (BCVA) and slit lamp examinations.",
            "Intra-ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was -3.3/-3.3 mmHg in the BTFC group and -2.9/-3.4 mmHg in the DTFC group, demonstrating non-inferiority of BTFC to DTFC.",
            "Ocular irritation was frequently seen in DTFC group.",
            "Although blurred vision was frequently seen in BTFC group, it was transient and blurring became the equivalent 3 min after instillation between two groups.",
            "No noteworthy issue was observed in other safety outcome.",
            "Non-inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients.",
            "Although the score of blurred vision was transiently higher in BTFC than DTFC, treatment difference decreased and disappeared with time.",
            "Thus, BTFC can be considered as a safe and effective agent for glaucoma treatment."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "29510792": {
        "sentences": [
            "Acetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial.",
            "The carbonic anhydrase inhibitor acetazolamide (AZT) modulates blood pressure at high altitude and reduces sleep-disordered breathing in patients with obstructive sleep apnea (OSA).",
            "We aimed to investigate the treatment effect of AZT and in combination with continuous positive airway pressure (CPAP) on blood pressure in patients with hypertension and OSA.",
            "In a prospective, randomized, three-way crossover study, 13 male patients with hypertension and moderate to severe OSA (age 64 \u00b1 7 years, body mass index 29 \u00b1 4 kg/m2, and mean apnea-hypopnea index 37 \u00b1 23 events/h) received AZT, CPAP, or AZT plus CPAP for 2-week periods.",
            "Antihypertensive medication was washed out.",
            "Office and 24-hour blood pressure, arterial stiffness, polygraphic sleep study data, and blood chemistry were compared.",
            "AZT alone and AZT plus CPAP, but not CPAP alone, reduced office mean arterial pressure compared to baseline (-7 [95% CI -11 to -4], -7 [95% CI -11 to -4] and -1 [95% CI -5 to 4] mmHg, respectively; repeated- measures analysis of variance (RM-ANOVA; P = .015).",
            "Aortic systolic pressure and augmentation index, assessed by radial artery oscillatory tonometry, were unaffected by CPAP but decreased after AZT and AZT plus CPAP (RM-ANOVA P = .030 and .031, respectively).",
            "The apnea-hypopnea index was significantly reduced in all three treatment arms, most prominently by AZT plus CPAP (RM-ANOVA P = .003).",
            "The reduction of venous bicarbonate concentration following AZT was correlated with the change of apnea-hypopnea index (r = 0.66, P = .013).",
            "AZT reduced blood pressure, vascular stiffness, and sleep-disordered breathing in patients with OSA and comorbid hypertension.",
            "Carbonic anhydrase inhibition may constitute a potential target for drug therapy in patients with sleep apnea and comorbid hypertension."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "29620663": {
        "sentences": [
            "Effects of a low salt diet on isolated systolic hypertension: A community-based population study.",
            "Evidence has shown that long-term sodium reduction can not only reduce blood pressure, but also provide cardiovascular benefits.",
            "To date, there is little evidence related to the effects of salt reduction on isolated systolic hypertension (ISH).A total of 126 hypertensive patients were divided into an ISH group (n\u200a=\u200a51) and a non-ISH (NISH) group (n\u200a=\u200a75).",
            "The members of each group were then randomly assigned to low sodium salt (LSSalt) or normal salt (NSalt) diets for 6 months.",
            "Their blood pressure was measured every 2 months.",
            "Serum plasma renin-angiotensin activity, blood biochemical assays and urinary measurements were determined at the baseline and at the end of the 6 months.",
            "At the end of the study, the mean systolic blood pressure (SBP) of the ISH LSSalt group had significantly decreased by 10.18 mm Hg (95% confidence interval (CI): 3.13 to 17.2, P\u200a=\u200a.006) compared with that of the ISH NSalt group, while the mean SBP only decreased by 5.10 mm Hg (95% CI: -2.02 to 12.2, P\u200a=\u200a.158) in the NISH LSSalt group compared with that of the NISH NSalt group.",
            "The mean diastolic blood pressure (DBP) had no significant differences in the ISH and NISH groups.",
            "No obvious renin angiotensin system activation was found after LSSalt intervention.",
            "Regarding the urinary excretion of electrolytes and blood biochemical assays, the LSSalt treatment had the same effects on the ISH group as on the NISH group.",
            "The present study showed that the SBP of ISH patients was significantly decreased with the LSSalt intervention, while neither the SBP of the NISH patients nor the DBP of either group were similarly decreased, which indicated that ISH patients were more sensitive to salt restriction."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29601076": {
        "sentences": [
            "Syncope, Hypotension, and Falls in the Treatment of Hypertension: Results from the Randomized Clinical Systolic Blood Pressure Intervention Trial.",
            "To determine predictors of serious adverse events (SAEs) involving syncope, hypotension, and falls, with particular attention to age, in the Systolic Blood Pressure Intervention Trial.",
            "Academic and private practices across the United States (N = 102).",
            "Adults aged 50 and older with a systolic blood pressure (SBP) of 130 to 180 mmHg at high risk of cardiovascular disease events, but without diabetes, history of stroke, symptomatic heart failure or ejection fraction less than 35%, dementia, or standing SBP less than 110 mmHg (N = 9,361).",
            "Treatment of SBP to a goal of less than 120 mmHg or 140 mmHg.",
            "Outcomes were SAEs involving syncope, hypotension, and falls.",
            "Predictors were treatment assignment, demographic characteristics, comorbidities, baseline measurements, and baseline use of cardiovascular medications.",
            "One hundred seventy-two (1.8%) participants had SAEs involving syncope, 155 (1.6%) hypotension, and 203 (2.2%) falls.",
            "Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).",
            "Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.",
            "Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.",
            "Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.",
            "The greater risk of developing these events associated with intensive treatment did not vary according to age."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "29141712": {
        "sentences": [
            "Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus-Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa.",
            "Antiretroviral treatment (ART) interruptions increase the risk of severe morbidity/mortality in human immunodeficiency virus (HIV)-infected individuals from subSaharan Africa.",
            "We aimed to determine whether the risk is further increased among HIV-hepatitis B virus (HBV) co-infected patients in this setting.",
            "In this sub-analysis of a randomized-control trial, 632 participants from C\u00f4te d'Ivoire randomized to receive continuous-ART (C-ART), structured ART interruptions of 2-months off, 4-months on (2/4-ART), and CD4-guided ART interruptions (CD4GT, interruption at 350/mm3 and reintroduction at 250/mm3) were analyzed.",
            "Incidence rates (IR) of serious HIV- and non-HIV-related morbidity were compared between patients stratified on hepatitis B surface antigen (HBsAg) status.",
            "Overall, 65 (10.3%) were HBsAg-positive, 29 (44.6%) of whom had HBV-DNA levels > 10,000 copies/mL.",
            "After a median 2.0 year (range = 0.2-3.1) follow-up, \u2265 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3), whereas the highest incidence was observed in co-infected patients with baseline HBV-replication > 10,000 copies/mL (IR = 24.0/100 person/years, P versus HIV mono-infected = 0.002).",
            "Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).",
            "The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).",
            "No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).",
            "In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "23203707": {
        "sentences": [
            "Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.",
            "\ufeff",
            "To compare efficacy (intraocular pressure (IOP) reduction) and safety of preservative-free latanoprost (T2345) to benzalkonium chloride (BAK)-preserved latanoprost (BPL; Xalatan) in ocular hypertension (OHT) or primary open angle glaucoma (POAG) patients.",
            "Prospective, international, multicentre, randomised, investigator-masked, parallel-group trial.",
            "After a wash-out period, POAG or OHT patients, previously managed by BPL monotherapy, randomly received T2345 or BPL (one drop into the affected eye(s)) once daily from D0 to D84.",
            "Change in IOP was measured at 09:00 ( \u00b11 h) from D0 to D84 in the worse eye.",
            "Mean IOP reduction (D0-D84) was -8.6 \u00b12.6 mm Hg (-36%) on T2345 and -9.0 \u00b12.4 mm Hg (-38%) on BPL, confirming non-inferiority of T2345 to BPL.",
            "Non-inferiority of T2345 was observed from D15.",
            "The most frequent ocular adverse event, drug intolerance, was reported in 1 (0.5%) patient on T2345 versus 4 (2.1%) patients on BPL.",
            "Moderate to severe conjunctival hyperaemia was less frequent on T2345 than on BPL at D42 (20.2% vs 30.6%; p=0.003) and D84 (21.4% vs 29.1%; p=0.02).",
            "Upon instillation, the global subjective ocular symptom score was significantly lower on T2345 than BPL on D42 (0.15 vs 0.41; p=0.001) and D84 (0.18 vs 0.46; p=0.001).",
            "Preservative-free latanoprost has the same efficacy as BPL, with improved local tolerance."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "23429621": {
        "sentences": [
            "Bimatoprost/timolol versus travoprost/timolol fixed combinations in an Egyptian population: a hospital-based prospective randomized study.",
            "To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC) fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population.",
            "Patients with primary open angle glaucoma were randomized to receive either BTFC or TTFC.",
            "IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months.",
            "The primary outcome measure was the mean change in IOP from baseline at each visit.",
            "Secondary outcome measures included the incidence of adverse events.",
            "Eighty patients (80 eyes) were included finally: 40 eyes in each group.",
            "Baseline mean IOPs were 24.78\u00b13.53 and 25.26\u00b13.51 mm Hg for BTFC and TTFC, respectively (P=0.344).",
            "Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).",
            "BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).",
            "Mean IOP reductions were 11.34 and 6.42 mm Hg at 2 weeks (P=0.000), and 11.17 and 7.89 mmHg at 6 months (P=0.001) for BTFC and TTFC, respectively.",
            "IOPs at 2 weeks were 18 mm Hg in 36 (90.8%) versus 22 (55%) eyes and 16 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, 18 mm Hg in 38 (95%) versus 28 (70%) eyes and 16 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).",
            "Both drops provided effective IOP reduction that was greater and patients were more likely to achieve lower target pressures with BTFC than with TTFC."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12721239": {
        "sentences": [
            "Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes.",
            " To determine the effects of exercise training on cardiopulmonary function and quality of life (QOL) in postmenopausal breast cancer survivors who had completed surgery, radiotherapy, and/or chemotherapy with or without current hormone therapy use.",
            "Fifty-three postmenopausal breast cancer survivors were randomly assigned to an exercise (n = 25) or control (n = 28) group.",
            "The exercise group trained on cycle ergometers three times per week for 15 weeks at a power output that elicited the ventilatory equivalent for carbon dioxide.",
            "The control group did not train.",
            "The primary outcomes were changes in peak oxygen consumption and overall QOL from baseline to postintervention.",
            "Peak oxygen consumption was assessed by a graded exercise test using gas exchange analysis.",
            "Overall QOL was assessed by the Functional Assessment of Cancer Therapy-Breast scale.",
            "Fifty-two participants completed the trial.",
            "The exercise group completed 98.4% of the exercise sessions.",
            "Baseline values for peak oxygen consumption (P =.254) and overall QOL (P =.286) did not differ between groups.",
            "Peak oxygen consumption increased by 0.24 L/min in the exercise group, whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).",
            "Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).",
            "Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).",
            "Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29654849": {
        "sentences": [
            "Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes.",
            "Fracture risk is increased in individuals with type 2 diabetes (T2D).",
            "The pathophysiological mechanisms accentuating fracture risk in T2D are convoluted, incorporating factors such as hyperglycaemia, insulinopenia, and antidiabetic drugs.",
            "The objectives of this study were to assess whether different insulin regimens, metformin and rosiglitazone influence bone metabolism.",
            "We explored if the concentration of metformin and rosiglitazone in blood or improved glycaemic control altered bone turnover.",
            "Two-year clinical trial designed to investigate effects of antidiabetic treatment in 371 T2D patients.",
            "Participants were randomized to short or long-acting human insulin (non-blinded) and then further randomized to metformin\u202f+\u202fplacebo, rosiglitazone\u202f+\u202fplacebo, metformin\u202f+\u202frosiglitazone or placebo\u202f+\u202fplacebo (blinded).",
            "Fasting bone turnover markers (BTM) representing bone resorption (CTX) and formation (PINP) including HbA1c were measured at baseline and after 3, 12 and 24\u202fmonths.",
            "Trough steady-state plasma concentrations of metformin and rosiglitazone were measured after 3, 6 and 9\u202fmonths of treatment.",
            "Associations between treatments and BTMs during the follow-up of the trial were analysed in mixed-effects models that included adjustments for age, gender, BMI, renal function and repeated measures of HbA1c.",
            "BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p\u202f<\u202f0.001), respectively.",
            "Allocation of insulin regimens was not associated with different levels of BTMs.",
            "Metformin and metformin\u202f+\u202frosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).",
            "Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.",
            "HbA1c was inversely associated with CTX but not P1NP.",
            "The choice of insulin treatment is not influencing BTMs, metformin treatment may decrease BTMs, and improvement of glycaemic control may influence bone resorption activity."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12011126": {
        "sentences": [
            "Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.",
            " To investigate the effect of recombinant human erythropoietin (epoetin beta) on anemia, transfusion need, and quality of life (QOL) in severely anemic patients with low-grade non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), or multiple myeloma (MM).",
            "Transfusion-dependent patients with NHL (n = 106), CLL (n = 126), or MM (n = 117) and a low serum erythropoietin concentration were randomized to receive epoetin beta 150 IU/kg or placebo subcutaneously three times a week for 16 weeks.",
            "Primary efficacy criteria were transfusion-free and transfusion- and severe anemia-free survival (hemoglobin [Hb] > 8.5 g/dL) between weeks 5 to 16.",
            "Response was defined as an increase in Hb > or = 2 g/dL with elimination of transfusion need.",
            "QOL was assessed by the Functional Assessment of Cancer Therapy scale.",
            "Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.",
            "The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).",
            "After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05); this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).",
            "A target Hb that could be generally recommended could not be identified.",
            "Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "28912358": {
        "sentences": [
            "Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.",
            "We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS).",
            "We conducted a randomized, parallel, open-label, clinical trial comparing COC (30\u2009\u03bcg of ethinylestradiol and 150\u2009\u03bcg of desogestrel) plus spironolactone (100\u2009mg/day) with metformin (850\u2009mg b.i.d.)",
            "for one year in women with PCOS (EudraCT2008-004531-38).",
            "The composite primary outcome included efficacy (amelioration of hirsutism, androgen excess and menstrual dysfunction) and cardiometabolic safety (changes in the frequencies of disorders of glucose tolerance, dyslipidemia and hypertension).",
            "A complete anthropometric, biochemical, hormonal and metabolic evaluation was conducted every three months and data were submitted to intention-to-treat analyses.",
            "Twenty-four patients were assigned to COC plus spironolactone and 22 patients to metformin.",
            "Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1\u2009nmol/L, 0.4-1.7), free testosterone (25\u2009pmol/L, 12-39), androstenedione (5.5\u2009nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7\u2009\u03bcmol/L, 1.4-4.0).",
            "Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).",
            "No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).",
            "No major adverse events occurred and biochemical markers were similarly safe with both treatments.",
            "COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29507099": {
        "sentences": [
            "Relation of Dietary Sodium (Salt) to Blood Pressure and Its Possible Modulation by Other Dietary Factors: The INTERMAP Study.",
            "Available data indicate that dietary sodium (as salt) relates directly to blood pressure (BP).",
            "Most of these findings are from studies lacking dietary data; hence, it is unclear whether this sodium-BP relationship is modulated by other dietary factors.",
            "With control for multiple nondietary factors, but not body mass index, there were direct relations to BP of 24-hour urinary sodium excretion and the urinary sodium/potassium ratio among 4680 men and women 40 to 59 years of age (17 population samples in China, Japan, United Kingdom, and United States) in the INTERMAP (International Study on Macro/Micronutrients and Blood Pressure), and among its 2195 American participants, for example, 2 SD higher 24-hour urinary sodium excretion (118.7 mmol) associated with systolic BP 3.7 mm\u2009Hg higher.",
            "These sodium-BP relations persisted with control for 13 macronutrients, 12 vitamins, 7 minerals, and 18 amino acids, for both sex, older and younger, blacks, Hispanics, whites, and socioeconomic strata.",
            "With control for body mass index, sodium-BP-but not sodium/potassium-BP-relations were attenuated.",
            "Normal weight and obese participants manifested significant positive relations to BP of urinary sodium; relations were weaker for overweight people.",
            "At lower but not higher levels of 24-hour sodium excretion, potassium intake blunted the sodium-BP relation.",
            "The adverse association of dietary sodium with BP is minimally attenuated by other dietary constituents; these findings underscore the importance of reducing salt intake for the prevention and control of prehypertension and hypertension."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29643323": {
        "sentences": [
            "Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.",
            "Treatment-related quality of life (QOL) is an important aspect of diabetes management.",
            "However, no studies have compared the influence of dipeptidyl peptidase-4 inhibitors versus alpha-glucosidase inhibitors on treatment-related QOL.",
            "This prespecified sub-analysis of the Linagliptin Study of Effects on Postprandial blood glucose (L-STEP) compared the effects of linagliptin (5 mg once daily) and voglibose (0.2 mg/meal thrice daily) on treatment-related QOL in Japanese patients with type 2 diabetes (T2DM) inadequately controlled with diet and exercise therapy.",
            "Among 366 subjects in the original study, 182 in the linagliptin group and 173 in the voglibose group were included in this analysis.",
            "The outcome of this study was change in QOL as assessed by the Diabetes Therapy-Related Quality of Life 17 (DTR-QOL17) questionnaire from baseline to week 12.",
            "Compared with baseline data, total DTR-QOL17 scores were significantly higher after 12 weeks of linagliptin and voglibose treatment.",
            "The change in the total DTR-QOL17 score and the score of one domain, burden on social activities and daily activities, was significantly greater in the linagliptin group than in the voglibose group.",
            "In addition, only linagliptin treatment was identified as a factor associated with an increased total DTR-QOL17 score.",
            "Linagliptin is superior to voglibose in terms of improving treatment-related QOL in Japanese patients with T2DM."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29478187": {
        "sentences": [
            "Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial.",
            "Despite the lack of evidence, a growing number of people are using herbal medicine to attenuate the burden of diabetes.",
            "There is an urgent need to investigate the clinical potential of herbs.",
            "Preliminary observations suggest that American ginseng (Panax quinquefolius [AG]) may reduce postprandial glycemia.",
            "Thus, we aimed to evaluate the efficacy and safety of AG as an add-on therapy in individuals with type 2 diabetes (T2DM) controlled by conventional treatment.",
            "24 individuals living with T2DM completed the study (F:M\u2009=\u200911:13; age\u2009=\u200964\u2009\u00b1\u20097 year; BMI\u2009=\u200927.8\u2009\u00b1\u20094.6 kg/m2; HbA1c\u2009=\u20097.1\u2009\u00b1\u20091.2%).",
            "Utilizing a double-blind, cross-over design, the participants were randomized to receive either 1 g/meal (3 g/day) of AG extract or placebo for 8 weeks while maintaining their original treatment.",
            "Following a\u2009\u2265\u20094-week washout period, the participants were crossed over to the opposite 8-week treatment arm.",
            "The primary objective was HbA1c, and secondary endpoints included fasting blood glucose and insulin, blood pressure, plasma lipids, serum nitrates/nitrites (NOx), and plasominogen-activating factor-1 (PAI-1).",
            "Safety parameters included liver and kidney function.",
            "Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p\u2009=\u20090.041) and fasting blood glucose (- 0.71 mmol/L; p\u2009=\u20090.008).",
            "Furthermore, AG lowered systolic blood pressure (- 5.6\u2009\u00b1\u20092.7 mmHg; p\u2009<\u20090.001), increased NOx (+\u20091.85\u2009\u00b1\u20092.13 \u00b5mol/L; p\u2009<\u20090.03), and produced a mean percent end-difference of - 12.3\u2009\u00b1\u20093.9% in LDL-C and -\u200913.9\u2009\u00b1\u20095.8% in LDL-C/HDL.",
            "The safety profiles were unaffected.",
            "AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.",
            "Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim"
        ]
    },
    "10506606": {
        "sentences": [
            "Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.",
            " To evaluate the efficacy and safety of a slow-release formulation of cytarabine (DepoCyt; Chiron Corp, Emeryville, CA, and Skye Pharma, Inc, San Diego, CA) that maintains cytotoxic concentrations of cytarabine (ara-C) in the CSF of most patients for more than 14 days.",
            "Twenty-eight patients with lymphoma and a positive CSF cytology were randomized to receive DepoCyt 50 mg once every 2 weeks or free ara-C 50 mg twice a week for 1 month.",
            "Patients whose CSF cytology converted to negative and who did not have neurologic progression received an additional 3 months of consolidation therapy and then 4 months of maintenance therapy.",
            "All patients received dexamethasone 4 mg orally bid on days 1 through 5 of each 2-week cycle.",
            "The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).",
            "All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.",
            "Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).",
            "DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).",
            "The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.",
            "DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29477688": {
        "sentences": [
            "Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up.",
            "To report 1-year treatment outcomes in the Primary Tube Versus Trabeculectomy (PTVT) Study.",
            "Two hundred forty-two eyes of 242 patients with medically uncontrolled glaucoma and no previous incisional ocular surgery, including 125 in the tube group and 117 in the trabeculectomy group.",
            "Patients were enrolled at 16 clinical centers and assigned randomly to treatment with a tube shunt (350-mm2 Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes).",
            "Intraocular pressure (IOP), glaucoma medical therapy, visual acuity, visual fields, surgical complications, and failure (IOP of more than 21 mmHg or reduced by less than 20% from baseline, IOP of 5 mmHg or less, reoperation for glaucoma, or loss of light perception vision).",
            "The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).",
            "Mean \u00b1 standard deviation IOP was 13.8\u00b14.1 mmHg in the tube group and 12.4\u00b14.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1\u00b11.4 in the tube group and 0.9\u00b11.4 in the trabeculectomy group (P < 0.001).",
            "Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).",
            "Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).",
            "Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.",
            "Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.",
            "The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "29625440": {
        "sentences": [
            "Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.",
            "To compare blood pressure and urine albumin-creatinine ratio over time for participants receiving aflibercept, bevacizumab, or ranibizumab.",
            "Preplanned secondary analyses from a randomized trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME).",
            "The Diabetic Retinopathy Clinical Research Network (DRCR.net) enrolled 660 participants with DME and visual acuity 20/32 or worse in at least one eye.",
            "Eyes received intravitreous injections of 2.0 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab based on a structured retreatment protocol over 2 years.",
            "Main outcome measures were (1) a change in blood pressure at 2 years, and (2) a change in urine albumin-creatinine ratio (UACR) at 1 year.",
            "At baseline, 95 participants (14%) had normal blood pressure, 220 (33%) had borderline blood pressure elevation, 206 (31%) had mild blood pressure elevation, and 139 (21%) had moderate blood pressure elevation.",
            "Average change in mean arterial pressure from baseline to 2 years was -1.2 \u00b1 15, -1.8 \u00b1 13.5, -2.6 \u00b1 14.4 mm Hg in the aflibercept, bevacizumab, and ranibizumab groups, respectively (global P = 0.69).",
            "At baseline 247 participants (38%) had no albuminuria (<30 mg/g), 195 (30%) had microalbuminuria (30-300 mg/g), and 212 (32%) had macroalbuminuria (>300 mg/g).",
            "Changes in UACR category were not different among treatment groups at the 52-week visit (global P = 0.29).",
            "There do not appear to be treatment group differences for changes in blood pressure or UACR as a reflection of kidney function in patients with DME treated with aflibercept, bevacizumab, or ranibizumab."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Claim"
        ]
    },
    "29406428": {
        "sentences": [
            "Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.",
            "Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV.",
            "Our objective was to determine risk factors for hepatotoxicity in severely immunosuppressed individuals taking IPT and ART.",
            "Multicenter study in resource-limited settings with high burden of tuberculosis.",
            "We conducted a secondary analysis of data from 1 randomized arm of the REMEMBER trial.",
            "The analysis includes participants with pre-ART CD4 cell counts of <50 cells/\u03bcL receiving IPT and ART for 24 weeks.",
            "Hepatotoxicity was defined as elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 \u00d7 upper limit of normal or symptomatic hepatitis during IPT and ART.",
            "Logistic regression was used to identify baseline risk factors for hepatotoxicity.",
            "Time to occurrence of hepatotoxicity was estimated by the Kaplan-Meier method.",
            "Among 426 participants (53% male, median age 35 years, median CD4 count 19 cells/\u00b5L), 31 developed hepatotoxicity (7.3%).",
            "Raised pretreatment AST/ALT (odds ratio [OR] 3.6, 95% confidence interval [CI]: 1.7 to 7.7) and hepatitis B surface antigen (HBsAg) seropositivity at baseline (OR 4.7, 95% CI: 1.7 to 12.9) were significantly associated with an increased risk of developing hepatotoxicity.",
            "Participants with both raised AST/ALT and positive HBsAg had a higher risk (OR 19.9, 95% CI: 5.3 to 74.3) and earlier onset of hepatotoxicity than participants who did not have these conditions at baseline.",
            "The incidence of hepatotoxicity during IPT and ART was high.",
            "Severely immunosuppressed individuals with raised pretreatment AST/ALT or HBsAg seropositivity need closer monitoring for hepatotoxicity."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29452204": {
        "sentences": [
            "Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.",
            "Chronic infection with hepatitis B virus (HBV) in children is a serious health problem worldwide.",
            "How to treat children with immune-tolerant chronic hepatitis B infection, commonly characterized by hepatitis B e antigen (HBeAg) positivity, high viral load, normal or mildly elevated alanine aminotransferase and no or minimal inflammation in liver histology, remains unresolved.",
            "This trial aims to study the benefits of antiviral therapy in children with these characteristics.",
            "This is a pilot open-label randomized controlled study.",
            "From May 2014 to April 2015, 69 treatment-naive chronically HBV-infected children, aged 1 to 16\u202fyears, who had immune-tolerant characteristics were recruited to this trial and randomly assigned, in a 2:1 ratio, to treatment group and control group.",
            "Patients in the treatment group received either interferon-\u03b1 (IFN) monotherapy or consecutively received IFN monotherapy, combination therapy of IFN and lamivudine (LAM), and LAM therapy alone.",
            "All patients were observed until week 96.",
            "At baseline, epidemiological, biochemical, serological, virological and histological indices were consistent across the treatment and control groups.",
            "Of the 46 patients in the treatment group, 73.91% had undetectable serum HBV DNA, 32.61% achieved HBeAg seroconversion and 21.74% lost hepatitis B surface antigen (HBsAg) at the endpoint.",
            "No LAM resistance emerged at week 96.",
            "In the control group, only one (4.35%) patient underwent spontaneous HBeAg seroconversion and had undetectable serum HBV DNA during observation, and moreover, none developed HBsAg clearance.",
            "For all patients, no serious adverse events were observed.",
            "Antiviral treatment with a sequential combination of IFN and LAM resulted in a significant improvement in the rates of undetectable serum HBV DNA, HBeAg seroconversion and HBsAg loss in children with chronic HBV infection and immune-tolerant characteristics.",
            "There is a lack of data regarding treatment of immune-tolerant chronic hepatitis B (CHB).",
            "It remains unresolved how children with immune-tolerant CHB should be treated.",
            "This paper reports the outcomes from a pilot open-label randomized controlled trial on antiviral therapy in children with immune-tolerant characteristics.",
            "It shows that a sequential combination of interferon-\u03b1 and lamivudine was beneficial."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            null,
            null,
            "Claim"
        ]
    },
    "22344189": {
        "sentences": [
            "Comparison of trabeculectomy and Ex-PRESS implantation in fellow eyes of the same patient: a prospective, randomised study.",
            "To compare intraocular pressure (IOP) over time after standard trabeculectomy vs Ex-PRESS implantation in patients with bilateral primary open-angle glaucoma (POAG).",
            "Prospective, randomised study.",
            "This study included adult patients with bilateral POAG necessitating surgery.",
            "Each patient underwent trabeculectomy in one eye and Ex-PRESS implantation under a scleral flap in the other eye according to randomised contralateral allocations.",
            "Efficacy was assessed by IOP values and success rates (IOP threshold and/or need for topical glaucoma medication) during 30 months.",
            "Statistical analysis included Generalised Estimate Equation and Cox Survival models, and paired t-tests.",
            "Thirty eyes of 15 patients were studied for a mean of 23.6 months (SD, \u00b1 6.9).",
            "At the last follow-up visit, mean pre-operative IOP decreased from 31.1 (\u00b1 14.2) to 16.2 (\u00b1 1.5) mm Hg after trabeculectomy, and from 28.1 (\u00b1 9.0) to 15.7 (\u00b1 1.8) mm Hg after Ex-PRESS implantation (P=0.001).",
            "The mean number of anti-glaucoma medicines prescribed at the last follow-up decreased from 3.7 pre-operatively (both groups) to 0.9 after trabeculectomy vs 0.3 after Ex-PRESS implantation (P=0.001).",
            "Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).",
            "Postoperative complications were more frequent after trabeculectomy (33%) compared with Ex-PRESS (20%), with four trabeculectomy eyes (27%) needing postoperative interventions, compared with none with Ex-PRESS.",
            "Trabeculectomy and Ex-PRESS implantation provided similar IOP control, but the Ex-PRESS group had a lower rate of complications, fewer postoperative interventions, and needed less glaucoma medications."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12118024": {
        "sentences": [
            "Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.",
            " The study was designed to compare the effects of treatment with a combination of trastuzumab (Herceptin; Genentech, Inc, South San Francisco, CA) and chemotherapy versus chemotherapy alone on health-related quality of life (HRQL) in patients with HER-2/neu overexpressing, metastatic breast cancer.",
            "A sample of 400 patients, not previously treated for metastatic disease and randomized to receive either trastuzumab plus chemotherapy (208 patients) or chemotherapy alone (192 patients), completed the European Organization for Research and Treatment Care Quality of Life Questionnaire at baseline and on at least one subsequent occasion at 8, 20, 32, 44, and 56 weeks.",
            "HRQL improvement or worsening was defined as a >or= 10-point change (range, 0 to 100 points) in the scores of six preselected domains (global quality of life [QOL], physical, role, social, and emotional functioning, and fatigue).",
            "Stable HRQL was defined as a change of less than 10.",
            "A Bonferroni correction was applied for multiple testing.",
            "After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.",
            "Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.",
            "Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group, but the differences were not statistically significant.",
            "There were no differences in the proportions of patients in the two groups that reported worsening.",
            "Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12657097": {
        "sentences": [
            "Neoadjuvant flutamide monotherapy for locally confined prostate cancer.",
            " We compared the clinical effects and impact on quality of life (QOL) of patients who received a 3-month course of flutamide monotherapy before radical prostatectomy with those who received a 3-month course of luteinizing hormone-releasing hormone (LHRH) agonist monotherapy.",
            "Thirty-seven patients with non-metastatic prostate cancer were enrolled in this study (19, flutamide; 18, LHRH agonist).",
            "The rates of change of serum prostate-specific antigen (PSA) and testosterone levels, downsizing of prostate volume, the rate of organ confined disease, adverse effects and perioperative scores measured using the European Organization for Research and Treatment of Cancer Prostate Cancer Quality of Life Questionnaire (EORTC-P) and the Sapporo Medical University Sexual Function Questionnaire (SMUF) were analyzed.",
            "At radical prostatectomy, pathological variables were not significantly different in the two groups.",
            "Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001), complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.",
            "After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.",
            "At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.",
            "This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29527973": {
        "sentences": [
            "A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops.",
            "Uncontrolled hypertension is a major problem among non-Hispanic black men, who are underrepresented in pharmacist intervention trials in traditional health care settings.",
            "We enrolled a cohort of 319 black male patrons with systolic blood pressure of 140 mm Hg or more from 52 black-owned barbershops (nontraditional health care setting) in a cluster-randomized trial in which barbershops were assigned to a pharmacist-led intervention (in which barbers encouraged meetings in barbershops with specialty-trained pharmacists who prescribed drug therapy under a collaborative practice agreement with the participants\u2019 doctors) or to an active control approach (in which barbers encouraged lifestyle modification and doctor appointments).",
            "The primary outcome was reduction in systolic blood pressure at 6 months.",
            "At baseline, the mean systolic blood pressure was 152.8 mm Hg in the intervention group and 154.6 mm Hg in the control group.",
            "At 6 months, the mean systolic blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 28.4; P<0.001).",
            "A blood-pressure level of less than 130/80 mm Hg was achieved among 63.6% of the participants in the intervention group versus 11.7% of the participants in the control group (P<0.001).",
            "In the intervention group, the rate of cohort retention was 95%, and there were few adverse events (three cases of acute kidney injury).",
            "Among black male barbershop patrons with uncontrolled hypertension, health promotion by barbers resulted in larger blood-pressure reduction when coupled with medication management in barbershops by specialty-trained pharmacists."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29580746": {
        "sentences": [
            "REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat.",
            "The REVEAL risk score (RRS) was developed to predict survival in patients with pulmonary arterial hypertension (PAH), based on multiple patient characteristics.",
            "Herein we calculated RRS for patients in the randomized CHEST-1 study and open-label CHEST-2 extension study of riociguat in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).",
            "We investigated the effect of riociguat vs placebo on RRS in the CHEST-1 study, and the relationship between RRS and long-term outcomes in the CHEST-2 study.",
            "RRS was calculated post hoc for baseline and Week 16 of CHEST-1 and Week 12 of CHEST-2, based on 9 evaluable elements.",
            "Patients were grouped into risk strata by RRS.",
            "Relationships between RRS and both survival and clinical worsening-free survival were examined by Kaplan-Meier and Cox proportional hazards analyses.",
            "Overall, 237 patients completed CHEST-1 and entered CHEST-2.",
            "In CHEST-1, riociguat significantly improved RRS (p < 0.0001) and risk stratum (p < 0.001) vs placebo from baseline to Week 16.",
            "RRS at baseline, and at Week 16, and change in RRS during CHEST-1 were significantly associated with survival (hazard ratios for a 1-point reduction in RRS: 0.702, 0.692, and 0.682, respectively) and clinical worsening-free survival (hazard ratios: 0.697, 0.719, and 0.754, respectively) over 2 years in CHEST-2.",
            "Riociguat improved RRS in patients with inoperable and persistent/recurrent CTEPH.",
            "RRS at baseline and Week 16, and change in RRS from baseline, predicted survival and clinical worsening-free survival.",
            "This analysis of RRS in patients with inoperable or persistent/recurrent CTEPH suggests utility for the RRS in indications beyond PAH."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "28454526": {
        "sentences": [
            "Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study.",
            "The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study.",
            "Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized enrolled.",
            "Group 1 (\"NPT to PT\") patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then changed to preservative containing 0.0015% tafluprost(PT) for 6 months.",
            "Group 2 (\"PT to NPT\") patients used preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for 6 months.",
            "At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion, tear break-up time (TBUT), and subjective discomfort.",
            "A total of 20 patients and 20 eyes were enrolled.",
            "In Group 1 and 2, intraocular pressure was well controlled to approximately 14 mmHg (9.38-18.46% decrease).",
            "Generally, subjective satisfaction was improved after changing from PT to NPT (p\u2009=\u20090.03) and TBUT using PT was numerically inferior to that using NPT (p\u2009=\u20090.06) but not when changing from NPT to PT.",
            "Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure significantly.",
            "In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break up time."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "11387359": {
        "sentences": [
            "Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.",
            " This randomized, double-blind, placebo-controlled clinical trial assessed the effects of epoetin alfa on transfusion requirements, hematopoietic parameters, quality of life (QOL), and safety in anemic cancer patients receiving nonplatinum chemotherapy.",
            "The study also explored a possible relationship between increased hemoglobin and survival.",
            "Three hundred seventy-five patients with solid or nonmyeloid hematologic malignancies and hemoglobin levels < or = 10.5 g/dL, or greater than 10.5 g/dL but < or = 12.0 g/dL after a hemoglobin decrease of > or = 1.5 g/dL per cycle since starting chemotherapy, were randomized 2:1 to epoetin alfa 150 to 300 IU/kg (n = 251) or placebo (n = 124) three times per week subcutaneously for 12 to 24 weeks.",
            "The primary end point was proportion of patients transfused; secondary end points were change in hemoglobin and QOL.",
            "The protocol was amended before unblinding to prospectively collect and assess survival data 12 months after the last patient completed the study.",
            "Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).",
            "Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.",
            "Although the study was not powered for survival as an end point, Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test), and Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.",
            "Adverse events were comparable between groups.",
            "Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.",
            "Encouraging results regarding increased survival warrant another trial designed to confirm these findings."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29432772": {
        "sentences": [
            "The effects of synbiotic supplementation on insulin resistance/sensitivity, lipid profile and total antioxidant capacity in women with gestational diabetes mellitus: A randomized double blind placebo controlled clinical trial.",
            "The role of gut microbiota in the management of diabetes is shown.",
            "In this randomized clinical trial we assessed the effects of synbiotic supplementation on insulin, lipid profile and antioxidative status among women with gestational diabetes mellitus (GDM).",
            "Ninety pregnant women with GDM were randomly assigned into two groups to receive either a daily synbiotic capsule - consisting of L. acidophilus, L. plantarum, L. fermentum, L. gasseri (1.5-7.0\u202f\u00d7\u202f109-10\u202fCFU/g) - with fructooligosaccharide (38.5\u202fmg), or placebo for 6\u202fweeks.",
            "Fasting plasma glucose (FPG), insulin, homeostasis model assessment-insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), high- and low density lipoprotein cholesterol (HDL-C, LDL-C), total cholesterol (TC), triglycerides (TG), total antioxidant capacity (TAC), and systolic and diastolic blood pressure (SBP, DSP) were assessed before and after the intervention.",
            "No significant changes in FPG, insulin resistance/sensitivity, lipid profile and TAC indices were seen in synbiotic group compared to the placebo one (p\u202f>\u202f0.05).",
            "Significant within group increases for HDL-C and TAC levels in synbiotic group were observed (p\u202f<\u202f0.05).",
            "LDL-C showed significant increment in the placebo group compared to the baseline of the study (6.9\u202fmg/dL, p\u202f<\u202f0.05).",
            "Between group comparison showed significant decrease in SBP and DBP in synbiotic group compared to placebo (-2.5 vs. 8.6\u202fmmHg, and -1.8 vs. 2.1\u202fmmHg, p\u202f<\u202f0.05).",
            "The results showed that, in women with GDM, synbiotic supplementation had no effect on FPG and insulin resistance/sensitivity indices.",
            "Lipid profile and TAC status may be affected by synbiotic supplementation.",
            "Synbiotic is effective in reducing of blood pressure in women with GDM."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "28266150": {
        "sentences": [
            "Two-year results of microcatheter-assisted trabeculotomy in paediatric glaucoma: a randomized controlled study.",
            "To compare the outcomes of microcatheter-assisted circumferential trabeculotomy to standard rigid probe trabeculotomy in childhood glaucomas.",
            "Eyes of children requiring trabeculotomy for primary congenital or secondary paediatric glaucoma were randomized to undergo either trabeculotomy using the Glaucolight illuminated microcatheter, or a rigid probe trabeculotomy.",
            "Complete success was defined as an intraocular pressure (IOP) of <18 mmHg without medications.",
            "A total of 62 eyes of 62 patients were included.",
            "Of these 30 eyes of 30 patients aged 5.6 \u00b1 4.8 months underwent microcatheter-assisted trabeculotomy, with 15 eyes (50%) having a complete 360\u00b0 cut, while 15 eyes (50%) had an incomplete cut ranging from 250 to 350 degrees.",
            "The rigid probe trabeculotomy group included 32 eyes of 32 patients aged 4.4 \u00b1 3.8 months.",
            "At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).",
            "There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).",
            "The mean survival time was significantly longer for the microcatheter group (p = 0.01).",
            "At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.",
            "The need for reoperation for glaucoma was significantly lower in the microcatheter group."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence"
        ]
    },
    "28777224": {
        "sentences": [
            "Short-term Results of Trabeculectomy Using Adjunctive Intracameral Bevacizumab Versus Mitomycin C: A Randomized Controlled Trial.",
            "To compare the outcome of trabeculectomy using adjunctive intracameral bevacizumab versus intraoperative mitomycin C (MMC).",
            "In this double-blind, randomized clinical trial 87 eyes of 87 patients with primary open-angle or pseudoexfoliation glaucoma were assigned to each treatment group (44 cases received 1.25\u2009mg intracameral bevacizumab at the end of operation and in 43 cases MMC was applied during surgery).",
            "Success was defined as intraocular pressure (IOP) between 6 and 21\u2009mm\u2009Hg and at least 30% IOP drop with (qualified) or without (complete) glaucoma medications without additional glaucoma surgery.",
            "The follow-up time was 17.12\u00b12.58 months in the bevacizumab group and 17.23\u00b12.42 months in the MMC group (P=0.845).",
            "The preoperative IOP was 29.17\u00b13.94 and 28.8\u00b14.08\u2009mm\u2009Hg in the bevacizumab and MMC groups, respectively (P=0.689).",
            "Last visit IOP was 17.41\u00b13.11\u2009mm\u2009Hg in the bevacizumab group and 15.34\u00b13.62\u2009mm Hg in the MMC group (P<0.009).",
            "Compared with baseline, IOP drop at last visit was 11.76\u00b15.51 and 13.43\u00b15.92 in the bevacizumab and MMC groups, respectively (P=0.207).",
            "At last visit, complete success was achieved in 25 cases (61%) of bevacizumab group and 23 cases (66%) of MMC group (P=0.669).",
            "Early filtering bleb leak was more prevalent in bevacizumab group (29% vs. 11%).",
            "A single 1.25\u2009mg dose of intracameral bevacizumab improves the success of trabeculectomy comparable with MMC; however, it increases the risk of early filtering bleb leakage."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29364091": {
        "sentences": [
            "Observation of combined/optimized therapy of Lamivudine and Adefovir Dipivoxyl for hepatitis B-induced decompensated cirrhosis with baseline HBV DNA>1,000 IU/mL.",
            "This study aimed to observe and compare the efficacy and safety of the combined therapy and two different optimized therapies of lamivudine (LAM) and adefovir dipivoxil (ADV), as well as entecavir (ETV) monotherapy in patients with hepatitis B-induced decompensated cirrhosis.",
            "A total of 127 patients with decompensated cirrhosis were divided into four groups, and each group received different doses of regimens: initial combination of LAM and ADV, ADV add-on therapies with previous 12-week LAM, ADV add-on therapies with previous 24-week LAM, and ETV monotherapy.",
            "At the end of the treatment, the level of alanine amino-transferase (ALT), albumin (ALB) and total bilirubin (TBIL) in the combination therapy group and 12-week optimized therapy group were significantly improved.",
            "For the 24-week optimized therapy group, only ALT levels revealed a significant improvement.",
            "There were no obvious differences in the normalization rate of ALT, negative conversion rate of HBV DNA and HBeAg, as well as improvement in Child-Pugh scores among the combination therapy group, 12-week optimized therapy group, and ETV monotherapy group.",
            "However, the difference among these three groups and the 24-week optimized therapy group were significant.",
            "Differences were not observed in the HBeAg seroconversion between each group.",
            "Differences in blood urea nitrogen, serum creatinine, creatine kinase, or other serious adverse effects were not observed in each group at the end of the 96-week treatment.",
            "Combination therapy and early ADV addition were the preferred approaches in the antiviral strategy for the treatment of hepatitis B-induced decompensated cirrhosis."
        ],
        "labels": [
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "22458918": {
        "sentences": [
            "Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.",
            "To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of fixed-combination brimonidine 0.2%-timolol 0.5% compared with latanoprost 0.005% in patients with glaucoma or ocular hypertension.",
            "This was a prospective, randomized, multicenter, investigator-masked clinical trial.",
            "After washout of any previous IOP-lowering medications, patients with IOP of 24\u2009mmHg or higher were randomized to twice-daily fixed-combination brimonidine 0.2%-timolol 0.5% (n\u2009=\u200973) or once-daily latanoprost 0.005% (n\u2009=\u200975, dosed in the evening, with vehicle control in the morning to maintain masking) for 12 weeks.",
            "IOP was measured at 8 a.m. (before dosing), 10 a.m., and 3 p.m. at baseline, week 6, and week 12.",
            "The primary efficacy endpoint was diurnal IOP (averaged over 8 a.m., 10 a.m., and 3 p.m.) at week 12.",
            "Safety measures included biomicroscopy.",
            "There was no statistically significant difference between the treatment groups in mean diurnal IOP at baseline (p = 0.118).",
            "At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794).",
            "The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131).",
            "Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.",
            "Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension.",
            "Both treatments demonstrated favorable ocular tolerability.",
            "The duration of the study was 12 weeks, and additional studies will be needed to compare the efficacy and safety of fixed-combination brimonidine-timolol and latanoprost during long-term treatment."
        ],
        "labels": [
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim",
            null
        ]
    },
    "28911991": {
        "sentences": [
            "A Randomized Controlled Trial Comparing Outcomes of Cataract Surgery in Nanophthalmos With and Without Prophylactic\u00a0Sclerostomy.",
            "To prospectively evaluate visual outcomes and complications during and after cataract surgery with or without prophylactic sclerostomy in nanophthalmic eyes with visually significant cataract.Sixty nanophthalmic eyes of 60 patients with visually significant cataract were randomly assigned to cataract surgery alone (control group, n = 31) or cataract surgery with concomitant prophylactic sclerostomy (sclerostomy group, n = 29).",
            "Surgery was performed using phacoemulsification or manual small-incision cataract surgery (SICS) based on the LOCS III grading score.",
            "Group differences in intraoperative and postoperative complications were analyzed and risk factors assessed.",
            "Fewer complications were noted in eyes receiving sclerostomy (5/29, 17.2%) as compared to control group eyes (12/31, 38.7%), though differences were marginally significant (P = .065).",
            "Four control group, but no sclerostomy group, eyes developed postoperative uveal effusions (P = .04).",
            "In multivariable models, sclerostomy decreased the odds of an intraoperative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.04-0.92, P = .039); SICS was associated with a significantly higher risk of complications as compared to phacoemulsification (OR = 5.95, 95% CI = 1.49-23.73, P = .012), while high preoperative intraocular pressure (OR = 4.54, 95% CI = 0.99-20.9, P = .052) and greater lens thickness (OR = 3.38, 95% CI = 0.88-12.91, P = .075) demonstrated a marginally significant association.",
            "Cataract surgery in eyes with nanophthalmos is associated with a high risk for vision-threatening complications.",
            "Performing a simultaneous prophylactic sclerostomy with cataract surgery reduces complication rates, particularly uveal effusions.",
            "Cataract surgery at earlier stages by phacoemulsification may be more beneficial than undergoing manual SICS."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            null
        ]
    },
    "22775229": {
        "sentences": [
            "A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.",
            "\ufeff",
            "Ocular blood flow dysregulation has been implicated in the pathogenesis of glaucoma.",
            "Whereas the effect of single antiglaucoma substances on ocular blood flow has been addressed in various experiments, evidence for fixed combinations is sparse.",
            "In the present study, we set out to compare the effects of latanoprost 0.005%/timolol 0.5% (LT) fixed combination and brimonidine 0.2%/timolol 0.5% (BT) fixed combination on intraocular pressure (IOP) and ocular blood flow.",
            "In the present study, which followed a randomized, double-masked 2-way crossover design, 16 patients with primary open-angle glaucoma and 2 patients with ocular hypertension were included.",
            "The patients underwent a 6-week treatment with LT and a 6-week treatment with BT after a washout for previous antiglaucoma medication.",
            "Optic nerve head blood flow (ONHBF) was measured using laser Doppler flowmetry; retrobulbar flow velocities were measured using color Doppler imaging in the ophthalmic artery, the central retinal artery, and the posterior ciliary arteries.",
            "IOP was measured at 8 AM, 12 PM, and 4 PM.",
            "The mean baseline IOP was 25.3 \u00b12.8 mmHg.",
            "Both drugs were equally effective in reducing IOP (LT: -35.0% \u00b110.0%; BT: -33.6% \u00b18.8%, P=0.463 between groups).",
            "In addition, no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).",
            "Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment) and no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.",
            "In the present study, a 6-week treatment with LT or BT was equally effective in reducing IOP.",
            "In addition, none of the administered drugs induced a significant effect on ocular blood flow parameters."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "22835512": {
        "sentences": [
            "Risk factors for visual field progression in the low-pressure glaucoma treatment study.",
            "To investigate risk factors associated with visual field progression in the Low-pressure Glaucoma Treatment Study, a prospective trial designed to compare the effects of the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% on visual function in low-pressure glaucoma.",
            "Prospective cohort study.",
            "Low-pressure Glaucoma Treatment Study patients with \u22655 visual field tests during follow-up were included.",
            "Progression was determined using pointwise linear regression analysis, defined as the same 3 or more visual field locations with a slope more negative than -1.0 dB/year at P < 5%, on 3 consecutive tests.",
            "Ocular and systemic risk factors were analyzed using Cox proportional hazards model and further tested for independence in a multivariate model.",
            "A total of 253 eyes of 127 subjects (mean age, 64.7  10.9 years; mean follow-up, 40.6  12 months) were analyzed.",
            "Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38  0.9 vs 0.02  0.7 dB/y, P < .01).",
            "In the final multivariate model adjusting for all tested covariates, older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression whereas randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).",
            "While randomization to brimonidine 0.2% was protective compared to timolol 0.5%, lower mean ocular perfusion pressure increased the risk for reaching a progression outcome in the Low-pressure Glaucoma Treatment Study.",
            "This suggests that the beneficial effect of randomization to the brimonidine arm was independent of possible differences in ocular perfusion pressures between the 2 treatment arms.",
            "The current results and large number of drop-outs in the brimonidine 0.2% arm suggest that more research is necessary before altering clinical practice paradigms."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29133641": {
        "sentences": [
            "Simultaneous use of amniotic membrane and Mitomycin C in trabeculectomy for primary glaucoma.",
            "This study aimed to propose the role of amniotic membrane transplantation (AMT) as an additional modulator in primary Mitomycin C (MMC)-augmented trabeculectomy.",
            "This was a randomized prospective interventional study.",
            "Forty eyes of 39 adult patients with uncontrolled primary glaucoma were randomly divided into two equal groups.",
            "Control group underwent trabeculectomy augmented with MMC while the study group underwent additional AMT.",
            "Patients were followed up for 12 months and outcomes measured were intraocular pressure (IOP), need for additional intervention, and bleb morphology.",
            "Complete success (defined as IOP <16 mmHg on no medication) could be achieved in 85% eyes in study group while it was 60% in control group (P = 0.04).",
            "IOP reduced by 71.1% in study group from 41.9 \u00b1 10.6 to 12.1 \u00b1 2.7 mmHg and from 40.5 \u00b1 8.5 to 12.8 \u00b1 4.5 mmHg in control group, a decline of 68.29%.",
            "Blebs in AMT group showed better bleb morphology in terms of significantly better extent (E3) on day 1 (P = 0.03) and better height (H2 and H3) (P = 0.04), according to the Indiana Bleb Appearance Grading Scale, at all follow-up visits along with normal vascularity.",
            "The study group required significantly lesser (P = 0.03) bleb needlings as compared to control group.",
            "Amnion enhanced the efficacy of MMC-modulated trabeculectomy in terms of eyes with complete success and lesser interventions such as bleb needling.",
            "This reiterates the role of amnion as a safe and effective bleb modulator.",
            "A diffusely elevated bleb with healthier conjunctiva can go a long way in predicting better health and longevity of the bleb."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null,
            null
        ]
    },
    "10526263": {
        "sentences": [
            "Intra-arterial preoperative cytostatic treatment versus preoperative irradiation: A prospective, randomized study of lingual and sublingual carcinomas.",
            " For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.",
            "Unfortunately, arguments have often been put forward in favor of one or other of the two methods, but without the performance of an objective, randomized investigation.",
            "To resolve this situation, the authors have carried out a multicenter, randomized prospective study of selected patients with a view to deciding which method affords better results in complex tumor therapy from the aspects of survival and postoperative quality of life.",
            "One hundred thirty-one patients with operable sublingual or lingual squamous cell carcinoma in stages T2NXM0 to T4MXM0 were randomized into 2 groups: 1 group participated in preoperative chemotherapy with cisplatin and epirubicin (total doses: 200 mg cisplatin, 120 mg epirubicin) via the external carotid artery, whereas the other group received preoperative radiation therapy (46 grays).",
            "Following subsequent radical surgery, the patients received regular follow-up for 5 years.",
            "By the end of the 5 years, 95 of the 131 patients had conformed to the protocol.",
            "Of those 95, 47 had received preoperative chemotherapy and 48 preoperative irradiation.",
            "After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.",
            "A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).",
            "Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).",
            "Overall, the survival rates were by-and-large the same for the two groups.",
            "Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.",
            "The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.",
            "Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.",
            "The authors consider it important to stress these findings, as they are not aware of a similar randomized study of patients with tumors of the oral cavity."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim",
            null,
            null
        ]
    },
    "12711121": {
        "sentences": [
            "Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.",
            " We previously reported that treatment of patients with symptomatic advanced non-small cell lung cancer with single agent Gemcitabine (GEM) resulted in a superior clinical-benefit response rate (RR) compared to cisplatin-based combination chemotherapy.",
            "We now report the detailed individual symptom control analysis, and the influence of cisplatin-use, age, performance status (PS) and duration of treatment.",
            "Patients received either GEM (1000 mg/m(2), days 1, 8 and 15) or cisplatin (100 mg/m(2), day 1) plus Vindesine (3 mg/m(2), days 1 and 15) (PV), both every 4 weeks.",
            "Scores of 9 symptoms were listed weekly by the patient on visual analogue scales.",
            "Improvement of a symptom was defined as 2 consecutive cycles of improvement over baseline.",
            "Baseline symptoms in the 169 patients were well balanced between the 2 arms (84 GEM, 85 PV).",
            "Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.",
            "Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.",
            "Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).",
            "Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.",
            "Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.",
            "Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.",
            "GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.",
            "Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Evidence"
        ]
    },
    "29577107": {
        "sentences": [
            "Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study.",
            "Observational data support a role for vitamin D in type 2 diabetes, but evidence from trials is inconclusive.",
            "To evaluate the effect of vitamin D supplementation on \u03b2-cell function and hemoglobin A1c (HbA1c) in patients with well-controlled type 2 diabetes.",
            "Double-blind, randomized, placebo-controlled clinical trial.",
            "Tufts Medical Center, Boston, MA; VA Medical Center, Cincinnati, OH.",
            "A total of 127 patients (mean age, 60 years) with stable (HbA1c \u22647.5%) diabetes managed with lifestyle only or lifestyle plus metformin.",
            "Subjects were given 4000 units of vitamin D3 (cholecalciferol) daily or placebo for 48 weeks.",
            "Insulin secretion rate (ISR) was estimated from peripheral plasma C-peptide levels after a 3-hour 75-g oral glucose tolerance test done at baseline and week 24.",
            "Changes in HbA1c were assessed at 16, 24, 36, and 48 weeks.",
            "Baseline mean plasma 25-hydroxyvitamin D [25(OH)D] concentration was 26.6 ng/mL, mean HbA1c was 6.6%, and 78% of patients were on metformin.",
            "At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).",
            "The vitamin D and placebo groups did not differ in change in ISR or HbA1c.",
            "Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.",
            "This result was not observed at the other time points and could be due to chance.",
            "Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Evidence"
        ]
    },
    "29553852": {
        "sentences": [
            "The effect of cardiovascular risk factors on the carotid intima-media thickness in an old-aged cohort with hypertension: a longitudinal evolution with 4-year follow-up of a random clinical trial.",
            "Hypertension is a generally accepted atherogenic risk factor.",
            "The aim of this prospective longitudinal study was to evaluate changes in carotid intima-media thickness (c-IMT) and explore the association of cardiovascular risk factors and the carotid intima thickness in adults with hypertension using standardized methods.",
            "We used data from a subgroup of Beijing Vascular Disease Patients Evaluation Study (BEST), a population-based study of community-dwelling adults.",
            "The c-IMT, biomarkers, and carotid-femoral-pulse wave velocity (PWV) were measured at baseline, and lifestyles such as smoking status, sleeping habits, and oil or salt intake level were determined with the use of a validated questionnaire in the follow-up.",
            "We reevaluated c-IMT in all the initial 1284 (540 female and 744 male) patients with hypertension after 4 years.",
            "At reevaluation, mean (\u00b1 SD) age was 66 \u00b1 1.2 years, systolic blood pressure was 138 \u00b1 19 mmHg, and diastolic blood pressure was 91 \u00b1 10 mmHg.",
            "The results showed that mean c-IMT z-scores increased significantly during 4 years (0.002 \u00b1 0.003, p < 0.001) as well as carotid-femoral PWV (13.99 \u00b1 2.74, p < 0.01) and total cholesterol (6.97 \u00b1 1.08, p < 0.001).",
            "Linear regression showed statistically significant associations between systolic blood pressure, diastolic blood pressure, C-reactive protein, lip-line, and heart rate with c-IMT z-scores of >1.5SD in the fully adjusted models and the p values were 0.000, 0.000, 0.017, 0.001, and 0.044, respectively .",
            "There were significant predictors for the mean effect on c-IMT z-score.",
            "In a full-model logistic regression, significant risk factors for an increase in IMT of \u22651.5 z-scores were carotid-femoral PWV (odds ratio: 1.119, confidence interval: 1.018, 1.230, p = 0.020 < 0.05) at first measurement.",
            "The conclusion of the study was that longitudinal c-IMT measurements revealed progression in subclinical atherosclerosis during a four-year period in a hypertensive old-aged cohort.",
            "Systolic or diastolic blood pressure, homocysteine, carotid-femoral PWV, and waistline were significantly related to c-IMT increment.",
            "By lifestyle and medical intervention to control these risk factors may prevent progression of c-IMT in old-aged cohort with hypertension."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Claim",
            "Claim",
            null
        ]
    },
    "29654381": {
        "sentences": [
            "Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.",
            "The purpose of this review is to correlate predictions based on pre-clinical data with outcomes from clinical trials that examine the effects of incretin-based diabetes treatments on the kidney.",
            "The incretin-based treatments include agonists of the glucagon-like peptide 1 receptor (GLP-1R) and inhibitors of the enzyme, dipeptidyl peptidase-4 (DPP-4).",
            "In addition, what is known about the incretin-based therapies will be compared to what is known about the renal effects of SGLT2 inhibitors.",
            "Large-scale clinical trials have shown that SGLT2 inhibitors reduce albuminuria and preserve estimated glomerular filtration rate (eGFR) in patients with diabetic nephropathy.",
            "A concise and plausible hemodynamic mechanism is supported by pre-clinical research on the physiology and pharmacology of SGLT2.",
            "Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria but have not shown beneficial effects on eGFR.",
            "Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).",
            "But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.",
            "There may be salutary effects of incretin-based treatments on the diabetic kidney, but the system is complex and not amenable to simple explanation or prior prediction.",
            "This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29633159": {
        "sentences": [
            "Impact of Anthracyclines on Diabetes Mellitus\u00a0Development in B-Cell Lymphoma Patients: A Nationwide Population-based Study.",
            "Although anthracyclines are effective chemotherapeutic agents for treating B-cell lymphoma, adverse effects, such as bone marrow suppression and cardiotoxicity, limit their clinical application.",
            "We assessed whether anthracycline treatment also increases the risk for diabetes mellitus in patients with B-cell lymphoma.",
            "Using data obtained from the Taiwanese National Health Insurance Research Database from 2004 to 2011, we compared overall survival and clinical features for B-cell lymphoma patients administered anthracyclines (n\u2009=\u20093147) and those not administered anthracyclines (n\u2009=\u2009837).",
            "The impact of anthracycline treatment on diabetes risk was further investigated using a Gray's test and multivariate competing-risk regression models in a dose-dependent manner.",
            "Anthracycline administration was associated with a higher incidence of diabetes (HR: 1.75; 95% CI 1.11-2.75; p\u2009=\u20090.0163) after adjustments for age, gender, cumulative dose of prednisolone, and co-morbidities.",
            "Cumulative anthracycline doses of 253-400 mg (HR: 2.35; 95% CI 1.41-3.91; p\u2009=\u20090.0010), 401-504 mg (HR: 2.26; 95% CI 1.26-4.05; p\u2009=\u20090.0063), and\u2009>\u2009504 mg (HR: 2.29; 95% CI 1.25-4.18; p\u2009=\u20090.0072) increased the incidence density of diabetes in a dose-dependent manner (p\u2009=\u20090.0006).",
            "The annual alteration of adapted diabetes complications severity index score was not significantly different between B-cell lymphoma patients with or without anthracycline treatment (p\u2009=\u20090.4924).",
            "Anthracycline therapy increases diabetes risk in a dose-dependent manner in B-cell lymphoma patients.",
            "Intensive blood glucose monitoring and control should be recommended for B-cell lymphoma patients receiving anthracycline treatment."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "27629859": {
        "sentences": [
            "Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.",
            "In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.",
            "To identify baseline and on-treatment factors associated with HBsAg loss at Week 72 and provide a model for predicting HBsAg loss in patients receiving combination therapy for 48 weeks.",
            "A secondary analysis of data from an open-label study where patients were randomised to TDF (300 mg/day, oral) plus PEG-IFN (PI, 180 \u03bcg/week, subcutaneous) for 48 weeks (TDF/PI-48w); TDF plus PEG-IFN for 16 weeks, TDF for 32 weeks (TDF/PI-16w+TDF-32w); TDF for 120 weeks (TDF-120w) or PEG-IFN for 48 weeks (PI-48w).",
            "Logistic regression methods were used to identify models that best predicted HBsAg loss at Week 72.",
            "Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).",
            "The only baseline factor associated with response was genotype A. HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).",
            "HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.",
            "HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29658370": {
        "sentences": [
            "Changes in endothelial function, arterial stiffness and blood pressure in pregnant women after consumption of high-flavanol and high-theobromine chocolate: a double blind randomized clinical trial.",
            "The aim of this 2-group, parallel, double blind single-centre RCT was to evaluate the acute and chronic impacts of high flavanol high theobromine (HFHT) chocolate consumption on endothelial function, arterial stiffness and blood pressure (BP) in women at risk of preeclampsia.",
            "131 pregnant women considered at risk of preeclampsia based on uterine artery Doppler ultrasound were divided into two groups (HFHT or low flavanol and theobromine chocolate (LFLT).",
            "Acute changes in plasma flavanol and theobromine, peripheral arterial tonometry and BP were evaluated at randomization (0, 60 and 120 min after a single 40-g dose of chocolate) and again 6 and 12 weeks after daily 30-g chocolate intake.",
            "The EndoPAT 2000 provided reactive hyperemia index (RHI) and adjusted augmentation index (AIx) as markers for endothelial function and arterial stiffness, respectively.",
            "Compared with LFLT, acute HFHT intake significantly increased plasma epicatechin and theobromine (p < 0.0001), decreased AIx (p < 0.0001) and increased diastolic BP (3.49 \u00b1 3.40 mmHg increase in HFHT group vs 1.55 \u00b1 2.59 mmHg increase in LFLT group, p = 0.0008).",
            "Chronic HFHT compared with LFLT intake significantly increased plasma theobromine (p < 0.0001).",
            "No other significant within group or between group changes were observed.",
            "Acute consumption of HFHT, compared to LFLT, increased plasma epicatechin and theobromine concentrations and decreased arterial stiffness, with no effect on endothelial function and a marginal increase in diastolic BP.",
            "Chronic HFHT intake increased plasma theobromine, though it did not have positive impacts on endothelial function, arterial stiffness or BP when compared to LFLT in pregnant women at risk of PE."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim"
        ]
    },
    "11970761": {
        "sentences": [
            "Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).",
            " Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.",
            "As part of a multicenter, randomized phase III trial in patients with heavily pretreated advanced and/or recurrent CTCL, the effects of an interleukin-2 receptor-targeted fusion protein, denileukin diftitox (DAB389IL-2, ONTAK), on patient-rated overall quality of life (QOL), skin appearance, and pruritus severity were evaluated.",
            "A total of 71 patients with stage IB-IVA CTCL received intravenous denileukin diftitox 9 microg/kg/day or 18 microg/kg/day over 15-60 minutes for 5 consecutive days on an outpatient basis; cycles were planned for every 21 days for a total of 8 cycles over 6 months.",
            "Prior to each treatment cycle, patients were evaluated for disease response and were asked to self-rate their overall QOL via the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, skin appearance (7-point scale), and pruritus severity (10-cm visual analogue scale).",
            "Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.",
            "Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.",
            "Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.",
            "Denileukin diftitox was not associated with any clinically significant myelosuppression.",
            "Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "12047964": {
        "sentences": [
            "Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.",
            " This randomised trial compared three chemotherapy regimens in the first-line treatment of advanced colorectal cancer, in terms of their effect on overall and progression-free survival; other endpoints included toxicity, symptom palliation, and quality of life.",
            "905 patients were randomly assigned the de Gramont regimen (n=303; folinic acid 200 mg/m(2), fluorouracil bolus 400 mg/m(2), and infusion 600 mg/m(2) on days 1 and 2, repeated every 14 days), the Lokich regimen (n=301; protracted venous infusion of fluorouracil 300 mg/m(2) daily), or raltitrexed (n=301; 3 mg/m(2) intravenously every 21 days).",
            "Analyses were by intention to treat.",
            "Median follow-up of survivors was 67 weeks.",
            "For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.",
            "The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.",
            "An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.",
            "Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.",
            "The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.",
            "The Lokich regimen was associated with more central line complications and hand-foot syndrome.",
            "Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer, but resulted in greater toxicity and inferior quality of life."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "22814041": {
        "sentences": [
            "Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up.",
            "To assess the long-term safety and efficacy of a single trabecular micro-bypass stent with concomitant cataract surgery versus cataract surgery alone for mild to moderate open-angle glaucoma.",
            "Twenty-nine investigational sites, United States.",
            "Prospective randomized controlled multicenter clinical trial.",
            "Eyes with mild to moderate glaucoma with an unmedicated intraocular pressure (IOP) of 22 mm Hg or higher and 36 mm Hg or lower were randomly assigned to have cataract surgery with iStent trabecular micro-bypass stent implantation (stent group) or cataract surgery alone (control group).",
            "Patients were followed for 24 months postoperatively.",
            "The incidence of adverse events was low in both groups through 24 months of follow-up.",
            "At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).",
            "Overall, the mean IOP was stable between 12 months and 24 months (17.0 mm Hg \u00b1 2.8 [SD] and 17.1 \u00b1 2.9 mm Hg, respectively) in the stent group but increased (17.0 \u00b1 3.1 mm Hg to 17.8 \u00b1 3.3 mm Hg, respectively) in the control group.",
            "Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.",
            "Patients with combined single trabecular micro-bypass stent and cataract surgery had significantly better IOP control on no medication through 24 months than patients having cataract surgery alone.",
            "Both groups had a similar favorable long-term safety profile."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "27603149": {
        "sentences": [
            "Effects of Complementary Combination Therapy of Korean Red Ginseng and Antiviral Agents in Chronic Hepatitis B.",
            "Chronic hepatitis B management is commonly targeted at reducing viral replication.",
            "However, the currently available antiviral therapies are associated with some problems, including resistance and numerous adverse effects.",
            "Ginseng has been reported to be effective for treating viral infections such as influenza and human immunodeficiency virus.",
            "However, there are currently few studies on the effects of ginseng in chronic hepatitis B.",
            "Thus, this study investigated the effects of ginseng together with antiviral agents in chronic hepatitis B.",
            "This was a prospective, single-blinded, randomized controlled trial, and single-center study.",
            "Thirty-eight patients were enrolled.",
            "The control group (n\u2009=\u200919) was administered antiviral agents alone.",
            "The experimental group (n\u2009=\u200919) was administered antiviral agents along with Korean Red Ginseng powder capsules (each dose is 1 gram (two capsules), a one-day dose is 3 grams).",
            "The baseline characteristics did not differ between the two groups.",
            "Differences in several non-invasive fibrosis serologic markers (type IV collagen, hyaluronic acid, transforming growth factor-\u03b2) and in the hepatitis B virus DNA levels were compared between the groups.",
            "The non-invasive fibrosis serologic markers were further decreased in the experimental group, with significant differences after treatment observed for hyaluronic acid (p\u2009=\u20090.032) and transforming growth factor-\u03b2 (p\u2009=\u20090.008), but not for type IV collagen (p\u2009=\u20090.174).",
            "This study suggests the possibility of Korean Red Ginseng as a complementary therapy for chronic hepatitis B."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "23059481": {
        "sentences": [
            "Early efficacy and complications of releasable sutures for trabeculectomy in primary angle-closure glaucoma: a randomized clinical trial.",
            "To compare the postoperative intraocular pressure (IOP) and incidence of early complications after trabeculectomy with releasable suture to standard trabeculectomy in Chinese patients with primary angle-closure glaucoma.",
            " One hundred seventy-five patients diagnosed as primary angle-closure glaucoma with 6 clock-hours or more of peripheral anterior synechia were randomly allocated to 2 treatment groups: 87 underwent standard trabeculectomy (S group: 2 interrupted permanent sutures to the scleral flap) and 88 received trabeculectomy with 2 permanent and 2 releasable sutures (R group).",
            "The postoperative IOP and complications during the first 3 months after surgery were compared.",
            " One hundred seventy-one patients (97.7%) attended the 3-month visit.",
            "The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3 \u00b1 8.6 versus 12.7 \u00b1 6.0 mm Hg (P<0.001); day 3, 18.0 \u00b1 7.3 versus 12.9 \u00b1 6.3 mm Hg (P<0.001); day 7, 14.8 \u00b1 6.3 versus 12.0 \u00b1 4.9 mm Hg (P=0.001), but no difference was observed after the second week (P=0.659 to 0.753).",
            "The incidence of transient hypotony was higher in S group (20.4%) than the R group (9.1%) (P=0.046); hypotony recovered in 80.8% (21/26) within 1 week.",
            "There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).",
            " The technique of releasable sutures for trabeculectomy used in this study did not demonstrate significant advantages over standard trabeculectomy.",
            "Releasable sutures were associated with some decrease in visual acuity and increase in postoperative complaints."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29588137": {
        "sentences": [
            "Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial.",
            "Low serum vitamin D has been associated with metabolic syndrome and Non-alcoholic fatty liver disease (NAFLD).",
            "This study aimed to investigate the impact of vitamin D supplementation in treatment of patients with NAFLD.",
            "In a double blind, randomized, placebo controlled trial patients with NAFLD were randomized to receive one weekly pearl of placebo, 50,000\u202fU vitamin D3 (cholecalciferol) pearl per week and 0.25\u202fmg calcitriol (1,25 dihydroxycholecalciferol) pearl per day for 3 months.",
            "106 NAFLD patients were randomized to receive calcitriol, vitamin D3 and placebo pearls for 12 weeks and data for 91 patients were analyzed.",
            "After 12 weeks of treatment, serum alkaline phosphatase levels was significantly decreased from baseline levels in vitamin D and calcitriol treated groups (P\u202f<\u202f0.05).",
            "Serum and gamma glutamyl transferase (GGT) level was also significantly decreased compared to the baseline levels after 12 weeks of treatment with vitamin D. There was no statistically significant difference between placebo, calcitriol, vitamin D groups in terms of serum aminotransferase, alkaline phosphatase, serum GGT and lipid profile (P\u202f>\u202f0.05).",
            "While significant reduction of serum alkaline phosphatase and GGT were seen with vitamin D and calcitriol supplementation from baseline levels, no beneficial effects was seen when comparing vitamin D, calcitriol and placebo groups at the end of trial."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29571976": {
        "sentences": [
            "The effect of vitamin C and/or E supplementations on type 2 diabetic adult males under metformin treatment: A single-blinded randomized controlled clinical trial.",
            "Recently, there has been an increasing interest in the influence of antioxidant vitamins on the efficacy of oral hypoglycemic therapy in type 2 diabetic patients (T2DM).",
            "This single-blinded randomized controlled clinical trial aimed to investigate the effect of vitamin C and/or E supplementation on the efficacy of oral hypoglycemic therapy in T2DM Palestinian male patients from the Gaza Strip.",
            "Forty T2DM male patients aged 40-60 years on metformin treatment were randomly divided into four groups, each group received an additional one of the following daily oral supplements for 90\u202fdays: placebo; vitamin C; vitamin E and vitamin C plus vitamin E. After overnight fasting, venous blood specimens were collected from all individuals into K3-EDTA tubes and serum tubes for measuring the biochemical and hematological parameters of the study at baseline and after 90\u202fdays of vitamins supplementation.",
            "The results revealed that vitamin C and/or E improve fasting blood sugar (FBS), HbA1c, lipid profile, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), reduced glutathione (GSH); and Quantitative Insulin Sensitivity Check Index (QISCI) compared with diabetic patients group that received placebo.",
            "This study provided additional evidence on the beneficial effects of supplementing antioxidant vitamins in T2DM which could improve the clinical condition and attenuate or prevent diabetic pathogenesis and complications that, secondly to poor glycemic control, could attribute to the imbalance between the decline in the endogenous antioxidants and increasing production of the reactive oxygen species leading to the oxidant-mediated damage present in the diabetic context."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim"
        ]
    },
    "29316213": {
        "sentences": [
            "Comparative effects of valsartan plus either cilnidipine or hydrochlorothiazide on home morning blood pressure surge evaluated by information and communication technology-based nocturnal home blood pressure monitoring.",
            "The authors tested the hypothesis that a valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension, defined as systolic BP (SBP) \u2265135 mm Hg or diastolic BP \u226585 mm Hg assessed by a self-measuring information and communication technology-based home BP monitoring device more than three times before either combination's administration.",
            "This was an 8-week prospective, multicenter, randomized, open-label clinical trial.",
            "The HMBPS, which is a new index, was defined as the mean morning SBP minus the mean nocturnal SBP, both measured on the same day.",
            "The authors randomly allocated 129 patients to the valsartan/cilnidipine (63 patients; mean 68.4 years) or valsartan/hydrochlorothiazide (66 patients; mean 67.3 years) combination groups, and the baseline HMBPS values were 17.4 mm Hg vs 16.9 mm Hg, respectively (P = .820).",
            "At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.",
            "HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).",
            "Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.",
            "Large-scale randomized controlled studies are needed to assess how reducing HMBPS will affect future cardiovascular outcomes.",
            "The information and communication technology-based home BP monitoring device may become an alternative to ambulatory BP monitoring, which has been a gold standard to measure nocturnal BP and the morning BP surge."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            null,
            null
        ]
    },
    "12748244": {
        "sentences": [
            "Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].",
            " To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC).",
            "This was a randomized, double-blind, parallel-group, multicenter phase II trial.",
            "Two hundred ten patients with advanced NSCLC who were previously treated with one or two chemotherapy regimens (at least one containing platinum) were randomly assigned to receive either 250-mg or 500-mg oral doses of gefitinib once daily.",
            "Efficacy was similar for the 250- and 500-mg/d groups.",
            "Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.",
            "Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.",
            "Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.",
            "Drug-related toxicities were more frequent in the higher-dose group.",
            "Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.",
            "Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.",
            "At 250 mg/d, gefitinib had a favorable AE profile.",
            "Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "29507944": {
        "sentences": [
            "Effect of Standard vs Intensive Blood Pressure Control on Cerebral Blood Flow in Small Vessel Disease: The PRESERVE Randomized Clinical Trial.",
            "Blood pressure (BP) lowering is considered neuroprotective in patients with cerebral small vessel disease; however, more intensive regimens may increase cerebral hypoperfusion.",
            "This study examined the effect of standard vs intensive BP treatment on cerebral perfusion in patients with severe small vessel disease.",
            "To investigate whether standard vs intensive BP lowering over 3 months causes decreased cerebral perfusion in small vessel disease.",
            "This randomized clinical trial took place at 2 English university medical centers.",
            "Patients were randomized via a central online system (in a 1:1 ratio).",
            "Seventy patients with hypertension and with magnetic resonance imaging-confirmed symptomatic lacunar infarct and confluent white matter hyperintensities were recruited between February 29, 2012, and October 21, 2015, and randomized (36 in the standard group and 34 in the intensive group).",
            "Analyzable data were available in 62 patients, 33 in the standard group and 29 in the intensive group, for intent-to-treat analysis.",
            "This experiment examines the 3-month follow-up period.",
            "Patients were randomized to standard (systolic, 130-140 mm Hg) or intensive (systolic, <125 mm Hg) BP targets, to be achieved through medication changes.",
            "Cerebral perfusion was measured using arterial spin labeling; the primary end point was change in global perfusion between baseline and 3 months, compared between treatment groups by analysis of variance.",
            "Linear regression compared change in perfusion against change in BP.",
            "Magnetic resonance imaging scan analysis was masked to treatment group.",
            "Among 62 analyzable patients, the mean age was 69.3 years, and 60% (n\u2009=\u200937) were male.",
            "The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P\u2009<\u2009.001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively.",
            "Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial \u03b72, 0.004; 95% CI, -3.551 to 5.818; P\u2009=\u2009.63).",
            "No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP.",
            "The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P\u2009=\u2009.44).",
            "Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "28624326": {
        "sentences": [
            "Randomized Trial on Illuminated-Microcatheter Circumferential Trabeculotomy Versus Conventional Trabeculotomy in Congenital Glaucoma.",
            "To compare 1-year outcomes of illuminated microcatheter-assisted circumferential trabeculotomy (IMCT) vs conventional partial trabeculotomy (CPT) for primary congenital glaucoma (PCG).",
            "Forty eyes of 31 patients with unilateral or bilateral primary congenital glaucoma aged less than 2 years were randomized to undergo IMCT (20 eyes) or CPT (20 eyes).",
            "Primary outcome measure was intraocular pressure (IOP) reduction.",
            "The success criterion was defined as IOP \u2264 12 mm Hg without and with antiglaucoma medications (absolute success and qualified success, respectively).",
            "The mean age of our study population was 8.35 \u00b1 1.2 months.",
            "The mean preoperative IOP was 24.70 \u00b1 3.90 mm Hg in the IMCT group and 24.60 \u00b1 3.31 mm Hg in the CPT group.",
            "Both groups were comparable with respect to preoperative IOP, corneal clarity, corneal diameter, vertical cup-to-disc ratio, and refractive error.",
            "In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.",
            "For the IMCT group and CPT groups, respectively, the absolute success rates were 80% (16/20) and 60% (12/20) (P < .001) and qualified success rates were 90% (18/20) and 70% (14/20) (P < .001).",
            "Both procedures produced a statistically significant reduction in IOP, and eyes undergoing IMCT achieved a lower IOP than CPT group eyes at 12 months follow-up (9.5 \u00b1 2.4 mm Hg and 11.7 \u00b1 2.1 mm Hg, respectively, P < .001).",
            "In primary congential glaucoma, illuminated microcatheter-assisted 360-degree circumferential trabeculotomy performed better than conventional partial trabeculotomy at 1 year follow-up and resulted in significantly lower IOP measurements."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12837811": {
        "sentences": [
            "Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.",
            " To investigate whether docetaxel plus platinum regimens improve survival and affect quality of life (QoL) in advanced non-small-cell lung cancer (NSCLC) compared with vinorelbine plus cisplatin as first-line chemotherapy.",
            "Patients (n = 1,218) with stage IIIB to IV NSCLC were randomly assigned to receive docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin area under the curve of 6 mg/mL * min every 3 weeks (DCb); or vinorelbine 25 mg/m2/wk and cisplatin 100 mg/m2 every 4 weeks (VC).",
            "Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).",
            "The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.",
            "Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).",
            "Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.",
            "Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.",
            "Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.",
            "Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.",
            "DC resulted in a more favorable overall response and survival rate than VC.",
            "Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.",
            "These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC."
        ],
        "labels": [
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "28889724": {
        "sentences": [
            "Effects of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance.",
            "To observe the effect of the combined administration of entecavir and adefovir dipivoxil to improve hepatic fibrosis in hepatitis B patients with interferon resistance.",
            "This study comprised 90 hepatitis B patients with hepatic fibrosis and interferon (IFN) resistance who were admitted in the hospital's department of infectious disease for diagnosis and treatment between January 2013 and September 2015.",
            "They were randomly divided into two groups in accordance with the random number table: the combination treatment group (N.=45) and the entecavir group (N.=45).",
            "They were observed for any variations in the indexes of liver function and fibrosis, as well as the Model for end-stage liver disease (MELD) scores, before and after treatment.",
            "After treatment, the levels of the indexes in both groups (the combination treatment group vs. the entecavir group) were as follows: bilirubin (67.5\u00b17.7 vs. 82.4\u00b113.5 \u03bcmol/L); International Normalized Ratio (INR) (1.21\u00b10.8 vs. 1.14\u00b10.7); creatinine (147.3\u00b112.4 vs. 287.4\u00b121.6 mg/dL); GGT (67.4\u00b123.2 vs. 88.4\u00b123.7 U/L); and ALT (63.4\u00b140.8 vs. 96.5\u00b123.5 U/L).",
            "In comparison of the indexes of hepatic fibrosis between the two groups, we found the following differences: PCIII (67.5\u00b17.7 vs. 82.4\u00b113.5 \u03bcg/L); IV-C (61.3\u00b118.7 vs. 74.5\u00b117.9 \u03bcg/L); HA (147.3\u00b112.4 vs. 87.4\u00b131.6 \u03bcg/L); and LN (88.7\u00b113.2 vs 102.5\u00b123.4 \u03bcg/L).",
            "The results showed that the differences in comparison of the indexes before and after the treatment were statistically significant (P<0.05).",
            "After treatment, the MELD score of patients in the combination treatment group was significantly lower than that in the entecavir group (18.7\u00b13.2 vs. 22.5\u00b13.4), with a statistically significant difference (P<0.05).",
            "In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores.",
            "The results highlight the need to promote the benefits of this drug combination in helping chronic hepatitis B patients with interferon resistance, and to promote its application in clinical practices."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "29608107": {
        "sentences": [
            "A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3).",
            "To evaluate the effects of continuous glucose monitoring (CGM) on nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with multiple daily insulin injections (MDI); we also evaluated factors related to differences in hypoglycemia confidence in this population.",
            "Evaluations were performed from the GOLD randomized trial, an open-label multicenter crossover randomized clinical trial (n\u2009=\u2009161) over 69 weeks comparing CGM to self-measurement of blood glucose (SMBG) in persons with type 1 diabetes treated with MDI.",
            "Masked CGM and the hypoglycemia confidence questionnaire were used for evaluations.",
            "Time with nocturnal hypoglycemia, glucose levels <70\u2009mg/dL was reduced by 48% (10.2 vs. 19.6\u2009min each night, P\u2009<\u20090.001) and glucose levels <54\u2009mg/dL by 65%.",
            "(3.1 vs. 8.9\u2009min, P\u2009<\u20090.001).",
            "For the corresponding glucose cutoffs, daytime hypoglycemia was reduced by 40% (29 vs. 49\u2009min, P\u2009<\u20090.001) and 54% (8 vs. 18\u2009min., P\u2009<\u20090.001), respectively.",
            "Compared with SMBG, CGM use improved hypoglycemia-related confidence in social situations (P\u2009=\u20090.016) and confidence in more broadly avoiding serious problems due to hypoglycemia (P\u2009=\u20090.0020).",
            "Persons also reported greater confidence in detecting and responding to decreasing blood glucose levels (thereby avoiding hypoglycemia) during CGM use (P\u2009=\u20090.0033) and indicated greater conviction that they could more freely live their lives despite the risk of hypoglycemia (P\u2009=\u20090.022).",
            "CGM reduced time in both nocturnal and daytime hypoglycemia in persons with type 1 diabetes treated with MDI and improved hypoglycemia-related confidence, especially in social situations, thus contributing to greater well-being and quality of life."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "28928855": {
        "sentences": [
            "Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study.",
            "Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare subtype of lymphoma that is often associated with poor clinical prognosis.",
            "Several studies have shown that hepatitis B virus (HBV) infection may be associated with increased risk of B-cell non-Hodgkin lymphoma; however, because of the rarity of ENKTL, little is known about its association with HBV.",
            "Our study aimed to assess whether HBV infection was associated with increased odds of ENKTL.",
            "We conducted a hospital-based case-control study including 417 ENKTL cases and 488 age- and sex-matched subjects with nonmalignant diseases unrelated to HBV infection.",
            "Multivariable unconditional logistic regression analyses were performed to estimate adjusted odds ratios [AOR] and their corresponding 95% confidence intervals (CI).",
            "The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).",
            "After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).",
            "The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.",
            "The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29116050": {
        "sentences": [
            "Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results.",
            "In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of various nucleos(t)ide analogue (NUC) regimens in treatment-na\u00efve patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations.",
            "This longitudinal observational study therefore investigated the real-world clinical management and efficacy of NUC therapy in treatment-na\u00efve CHB patients in China.",
            "Treatment-na\u00efve CHB patients initiated on NUC therapy were enrolled from 63 hospitals in tier-2 Chinese cities.",
            "Demographic and treatment-specific data were collected, with the objective of reporting real-world treatment patterns and comparing the effectiveness of entecavir (ETV) treatment and lamivudine (LAM)-based treatment.",
            "We herein report the first-year data.",
            "3,408 NUC-na\u00efve patients were enrolled and treated with NUCs (53% ETV, 18% LAM-based, 29% other).",
            "Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs (P<0.05).",
            "At week 52, the virologic response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%, P<0.0001).",
            "LAM-based treatment was associated with a higher probability of virologic breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively) (P<0.0001).",
            "Treatment-related adverse events or serious adverse events were uncommon.",
            "In this nationwide observational study, more than 50% of patients with CHB in tier-2 city hospitals in China initially received ETV therapy.",
            "Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with treatment modification being relatively low in ETV-treated patients."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "29506674": {
        "sentences": [
            "The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning Study (EURO-CRIPS CardioGroup I): A randomized controlled trial.",
            "The potential protective effects of remote ischemic preconditioning (RIPC) on contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) remain to be defined.",
            "A double blind, randomized, placebo controlled multicenter study was performed.",
            "Patients younger than 85years old, with a renal clearance of 30-60ml/min/1.73m2, who were candidates for PCI for all clinical indications except for primary PCI, were allocated 1:1 to RIPC or to standard therapy.",
            "The primary endpoint was incidence of CIN.",
            "The secondary endpoint was incidence of peri-procedural myocardial infarction (PMI).",
            "From February 2013 to April 2014, 3108 patients who were scheduled for coronary angiography were screened for the study.",
            "442 fulfilled the inclusion criteria and 223 received PCI.",
            "These patients were randomized to sham RIPC (n=107) or treatment group (n=116).",
            "The only pre-specified subgroup of diabetic patients included 85 (38%) cases.",
            "RIPC significantly reduced CIN incidence in the overall population (12.1% vs. 26.1%, p=0.01, with a NNT=9) and in non-diabetic patients (9.2% vs. 25.0%, p=0.02), but showed no benefit in diabetics (16.7% vs. 28.2%, p=0.21).",
            "A trend for lower PMI was seen in the intervention arm (creatine kinase - muscle brain >5 URL; 8.4% vs. 16.4%, p=0.07; troponin T >5 URL; 27% vs. 38%, p=0.21).",
            "Remote ischemic preconditioning significantly reduces the incidence of acute kidney injury in non-diabetic patients undergoing PCI.",
            "Larger sample size is presumably needed to assess the effect of RIPC for patients with diabetes mellitus."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29375225": {
        "sentences": [
            "Low Dose Spironolactone Monotherapy in the Management of Stage I Essential Hypertension: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial.",
            "High blood pressure (BP) is a common chronic disease needs long life drug consumption to control.",
            "Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.",
            "However, there is no study to determine the effects of low dose spironolactone as a first line therapy in treatment of essential hypertension.",
            "The aim of this study is to investigate the effect of low dose spironolactone monotherapy in management of essential hypertension.",
            "In this double blind randomized clinical trial, 40 patients who had stage I essential hypertension were randomly divided into two groups: intervention group received spironolactone 25 milligram once daily for one month and control group received placebo once daily.",
            "At the baseline and after one month, 24-hour BP holter-monitoring and serum potassium assay were done.",
            "Systolic BP was reduced from 143.5 \u00b1 8.2 mmHg to 137.10 \u00b1 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).",
            "There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).",
            "Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29104121": {
        "sentences": [
            "Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.",
            "Vesatolimod (GS-9620) is an oral agonist of toll-like receptor 7, an activator of innate and adaptive immune responses.",
            "Herein the safety and efficacy of vesatolimod is assessed after once-weekly treatment in patients with chronic hepatitis B (CHB) infection suppressed on oral antiviral treatment.",
            "In a phase II, double-blind, randomized, placebo (PBO)-controlled study, 162 patients stratified by hepatitis B surface antigen (HBsAg) levels and serum hepatitis B e antigen (HBeAg) status were randomized 1:3:3:3 to once-weekly oral PBO or vesatolimod (1-, 2-, or 4-mg doses) for 4, 8 or 12\u202fweeks per cohort.",
            "Efficacy was assessed by change in baseline HBsAg (log10 IU/ml) at the primary endpoint (Week 24).",
            "Safety assessments included adverse events (AE) and laboratory abnormality monitoring.",
            "Pharmacodynamic assessments included peripheral cytokine level quantification and interferon-stimulated gene (ISG) mRNA expression evaluation.",
            "The majority of patients were male (76%) and HBeAg-negative (79%) at baseline.",
            "Most (41-80%) experienced \u22651 AE during the study with the majority of AEs mild or moderate in severity.",
            "No significant declines in HBsAg were observed at the primary (Week 24) or secondary endpoints (Weeks 4, 8, 12, and 48).",
            "ISG15 induction was dose-dependent and consistent after repeat dosing, returning closer to baseline by one week after treatment at all dose levels; no patient demonstrated significant serum interferon alpha (IFN\u03b1) expression at any timepoint evaluated.",
            "Multivariate analyses showed that \u22652-fold ISG15 induction is associated with 2- or 4-mg vesatolimod dose and female sex.",
            "Vesatolimod was safe and well-tolerated in patients with CHB, demonstrating consistent dose-dependent pharmacodynamic induction of ISG15 without significant systemic induction of IFN\u03b1 expression or related symptoms.",
            "However, no significant HBsAg declines were observed."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "28370419": {
        "sentences": [
            "Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.",
            "Combination therapy has been recommended for the treatment of patients harboring multiple drug-resistant hepatitis B virus (HBV).",
            "However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed noninferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir.",
            "Nonetheless, whether prolonged TDF monotherapy would be safe and increase the virologic response rate in these patients was unclear.",
            "Among 192 patients with HBV-resistance mutations to ETV and/or adefovir, who were randomized to receive TDF monotherapy (n = 95) or TDF/ETV combination therapy (n = 97) for 48 weeks, 189 agreed to continue TDF monotherapy (TDF-TDF group) or to switch to TDF monotherapy (TDF/ETV-TDF group) and 180 (93.8%) completed the 144-week study.",
            "Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80).",
            "At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46).",
            "By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144.",
            "Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence.",
            "At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV.",
            "No patients developed additional resistance mutations throughout the study period.",
            "TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "28874133": {
        "sentences": [
            "Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.",
            "Few controlled clinical trials exist to support oral combination therapy in pulmonary arterial hypertension (PAH).",
            "Patients with PAH (idiopathic [IPAH] or associated with connective tissue disease [APAH-CTD]) taking bosentan (62.5 or 125 mg twice daily at a stable dose for \u22653 months) were randomized (1:1) to sildenafil (20 mg, 3 times daily; n = 50) or placebo (n = 53).",
            "The primary endpoint was change from baseline in 6-min walk distance (6MWD) at week 12, assessed using analysis of covariance.",
            "Patients could continue in a 52-week extension study.",
            "An analysis of covariance main-effects model was used, which included categorical terms for treatment, baseline 6MWD (<325 m; \u2265325 m), and baseline aetiology; sensitivity analyses were subsequently performed.",
            "In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference [sildenafil-placebo], -2.4 m [90% CI: -21.8 to 17.1 m]; P = 0.6); mean \u00b1 SD changes from baseline were 26.4 \u00b1 45.7 versus 11.8 \u00b1 57.4 m, respectively, in IPAH (65% of population) and -18.3 \u00b1 82.0 versus 17.5 \u00b1 59.1 m in APAH-CTD (35% of population).",
            "One-year survival was 96%; patients maintained modest 6MWD improvements.",
            "Changes in WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ.",
            "Headache, diarrhoea, and flushing were more common with sildenafil.",
            "Sildenafil, in addition to stable (\u22653 months) bosentan therapy, had no benefit over placebo for 12-week change from baseline in 6MWD.",
            "The influence of PAH aetiology warrants future study."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "11346336": {
        "sentences": [
            "Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.",
            " To determine the safety and efficacy of oral bexarotene (Targretin capsules; Ligand Pharmaceuticals Incorporated, San Diego, Calif).",
            "The effects of 2 randomized doses of 6.5 mg/m(2) per day (with crossover for progression) vs 650 mg/m(2) per day (later modified to 300 mg/m(2) per day) were evaluated in an open-label, multicenter, phase 2 and 3 study conducted between February 1997 and November 1998.",
            "Eighteen international cutaneous T-cell lymphoma clinics at academic referral centers.",
            "Fifty-eight patients with biopsy-proven stage IA through IIA cutaneous T-cell lymphoma that was refractory to (or patients were intolerant of) treatment or had reached at least a 6-month response plateau under at least 2 forms of prior therapy (median of 3.5 prior therapies).",
            "Bexarotene (Targretin capsules) administered once daily with meal for 16 weeks or longer.",
            "Primary end point classification of overall response rate of complete and partial remissions determined by either the Physician's Global Assessment of Clinical Condition or the objective Composite Assessment of Index Lesion Severity.",
            "Body surface area, time to response, duration of disease control, time to disease progression, individual index lesion signs and symptoms, and quality of life parameters were secondary outcomes.",
            "Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).",
            "The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.",
            "Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.",
            "The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.",
            "The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).",
            "No cases of drug-related neutropenic fever, sepsis, or death occurred.",
            "Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.",
            "Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.",
            "Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Claim",
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "12915593": {
        "sentences": [
            "CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.",
            " To investigate whether the relative dose-intensity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in elderly patients with aggressive non-Hodgkin's lymphoma (NHL).",
            "Patients aged 65 to 90 years (median, 72 years) with stage II to IV aggressive NHL were randomly assigned to receive standard CHOP every 3 weeks or CHOP plus G-CSF every 3 weeks on days 2 to 11 of each cycle.",
            "In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.",
            "The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).",
            "The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.",
            "Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).",
            "Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.",
            "The number of hospital admissions and the number of days in hospital were not different.",
            "In elderly patients, G-CSF improved the RDI of CHOP, but this did not lead to a higher complete response rate or better overall survival.",
            "G-CSF did not prevent serious infections."
        ],
        "labels": [
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29332633": {
        "sentences": [
            "Impact of psychological factors on the health-related quality of life of patients treated for pulmonary arterial hypertension.",
            "Pulmonary arterial hypertension (PAH) is a rare and life-threatening disease well-marked by under diagnosis, delayed diagnosis and atypical treatments.",
            "Few data are available on the quality of life (QoL) and psychosocial characteristics of patients with PAH.",
            "Our aim is to describe the impact of psychological factors on the health-related quality of life (HRQoL) of treated PAH patients in a cross-sectional study.",
            "Consecutive patients presenting at our Competency Centre for PAH were recruited.",
            "The aetiology, New York Heart Association (NYHA) stage, haemodynamics, 6-min walk distance (6MWD), delta SPO2 (Pulse oximeter oxygen saturation; baseline lowest value during 6-min walk test (6MWT), current treatments and psychological history were recorded.",
            "HRQoL, anxiety, depression and coping strategies were explored using self-administered questionnaires (SF-36, HADS, STAI-Y, CHIP and WCC).",
            "A total of 55 patients were included.",
            "The HRQoL of PAH patients was poor with altered results on several scales.",
            "Anxiety and depression were high and coping was focused on medical information strategies.",
            "Multivariate analysis indicated a positive relationship between 6MWD and the Physical Composite Score for QoL (p=0.004), as well as a negative relationship between delta SPO2 and the Mental Composite Score (p=0.02), irrespective of other known prognostic factors (such as haemodynamics at right heart catheterization).",
            "Depression and Trait-Anxiety were associated with a lower physical (p=0.001) and mental (p<0.001) QoL, respectively.",
            "Psychological factors impact the HRQoL of treated patients.",
            "A longitudinal and qualitative study should refine these results."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29577550": {
        "sentences": [
            "Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.",
            "Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.",
            "This Phase 1 clinical trial assessed the safety and tolerability, pharmacokinetics, and preliminary efficacy of a novel MetAP2 inhibitor, ZGN-1061.",
            "This clinical trial included a single ascending dose (SAD) phase in healthy subjects (BMI 23 to <30 kg/m2 ) and a multiple ascending dose (MAD) phase in otherwise healthy subjects with BMI 27 to 40 kg/m2 .",
            "SAD phase doses, administered subcutaneously (SC) were 0.2, 0.6, 1.2, 2.4, 3.6, and 4.8 mg, and MAD phase evaluated 0.2, 0.6, and 1.8 mg twice weekly SC for 4 weeks.",
            "SAD phase included 39 subjects (ZGN-1061 N=28, placebo N=11), 90% male and BMI 26.4 kg/m2 .",
            "ZGN-1061 was well tolerated across all doses with most frequent adverse events of mild headache and procedural-related irritation.",
            "There were no severe or serious adverse events.",
            "All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks.",
            "The MAD phase included 29 subjects (ZGN-1061 N=22, placebo N=7), 76% male and BMI 33.5 kg/m2 .",
            "Safety observations were consistent with SAD findings.",
            "Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes.",
            "ZGN-1061 was well tolerated with no safety signals in all doses tested.",
            "In addition, the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29565948": {
        "sentences": [
            "A Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic Neuropathy.",
            "Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.",
            "To evaluate the safety and efficacy of 40 and 80 mg, BID, of an oral sustained release formulation of sodium nitrite (SR-nitrite) in patients suffering from diabetic neuropathy, and to determine whether SR-nitrite would reduce the frequency of headaches reported previously by subjects receiving the same doses of an immediate release formulation.",
            "Phase II, single-center, randomized, double-blind, placebo controlled clinical trial.",
            "Twenty-four patients were randomized to 40 mg or 80 mg SR-nitrite or placebo twice daily for 12 weeks.",
            "The primary objective was to determine whether headaches would be reduced using SR-nitrite.",
            "The primary efficacy endpoint was the mean difference in the change of the Neuropathic Pain Symptom Inventory (NPSI) pain score from baseline to that reported after 12 weeks of treatment.",
            "Secondary endpoints included changes from baseline for the Brief Pain Inventory (BPI) Scale, the RAND 36 questionnaire, Short Form McGill Questionnaire, daily patient reported score for neuropathic pain, changes in HbA1c, PulseOx and quantitative sensory testing.",
            "The number of subjects reporting adverse events and the number of adverse events did not change with dose.",
            "There were no reports of treatment-related headaches.",
            "Although no significant differences were identified in patient responses to the questionnaires, a trend was observed.",
            "In the NPSI assessment, patients in the 40 mg and 80 mg dose group reported a 12.7% and 22.0% reduction in pain, respectively, compared to an 8.4% reduction by patients in the placebo group.",
            "A trend was also observed with the BPI total severity score.",
            "However, the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores, where the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores reported by subjects in either of the other two groups.",
            "Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory Conductance and Nerve Sensory Velocity.",
            "No changes were observed in HbA1c levels or PulseOx.",
            "Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium nitrite.",
            "In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically significant reduction in reported pain, similar trends were observed at the end of the trial period for most of the pain questionnaires used in the study.",
            "The 80 mg BID treatment had the more pronounced affect on bioactivity (quantitative sensory testing), which was similar to the PAD study, where this dose group had the greatest improvement in FMD {AU: spell out FMD}.",
            "The ability to alleviate pain with BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29428785": {
        "sentences": [
            "Micronutrient supplementation during pregnancy and the risk of pregnancy-induced hypertension: A randomized clinical trial.",
            "Increasing evidence suggests that iron-containing multiple micronutrient may reduce the risk of pregnancy-induced hypertension including gestational hypertension or preeclampsia.",
            "We aimed to examine whether 30 mg iron plus folic acid or multiple micronutrients during pregnancy reduces the risk of pregnancy-induced hypertension.",
            "We conducted a secondary data analysis by the dataset from a double-blind randomized controlled trial in China from 2006 to 2009 that was conducted to investigate the effects of multiple micronutrient supplements on adverse pregnancy outcomes when provided to pregnant women with no/mild anemia.",
            "We used logistic regression to estimate the adjusted odds ratio and 95% confidence interval and test for effect modification.",
            "The incidence of pregnancy-induced hypertension was 7.1% (423/5923), 6.3% (374/5933) and 6.3% (372/5914) among the pregnant women who took folic acid only, iron-folic acid and multiple micronutrient supplements, respectively.",
            "The adjusted odds ratios associated with iron-folic acid supplements and multiple micronutrient supplements for pregnancy-induced hypertension were both nearly 0.88 (95% confidence interval, 0.76-1.02), compared with folic acid supplements only.",
            "Among pregnant women aged 20-24 years, iron-folic acid (adjusted odds ratios: 0.81, 95% confidence interval: 0.67-0.96) or multiple micronutrient supplementation (adjusted odds ratios: 0.83, 95% confidence interval: 0.70-0.99) can significantly reduce the risk of pregnancy-induced hypertension compared to folic acid supplementation.",
            "Overall, there were no significant differences in pregnancy-induced hypertension across supplement groups.",
            "However, among pregnant women aged 20-24 years, iron-containing multiple micronutrient supplementation was associated with a reduced risk of pregnancy-induced hypertension compared with folic acid supplements only."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "12783373": {
        "sentences": [
            "Quality of life on imatinib.",
            " Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).",
            "This phase III international study evaluated QoL outcomes in 1,106 newly diagnosed patients with chronic-phase chronic myeloid leukemia (CML) who were randomized to receive either imatinib 400 mg daily or IFN up to 5 MU/m(2)/d with cytarabine (Ara-C) 20 mg/m(2)/d added for 10 days every month (IFN + LDAC).",
            "Crossover to the other treatment arm was permitted due to a lack of efficacy or treatment intolerance.",
            "QoL was assessed with the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) at baseline, monthly for 6 months and then at months 9, 12, and 18.",
            "The Trial Outcome Index (TOI; a composite endpoint of physical/functional/treatment-specific subscales) was the primary endpoint.",
            "Secondary endpoints measured were social/family well-being (SFWB) and emotional well-being (EWB).",
            "QoL was analyzed for the first 18 months of treatment using mixed effects growth curve models.",
            "The primary analyses were intention-to-treat (ITT); secondary analyses incorporated crossover as a time-dependent covariate.",
            "A total of 1,049 patients completed at least one QoL assessment.",
            "Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.",
            "There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).",
            "Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).",
            "After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.",
            "Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.",
            "In addition, patients who crossed over to imatinib reported higher QoL than those who remained on IFN."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "27545497": {
        "sentences": [
            "Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.",
            "Long-term treatment with tenofovir disoproxil fumarate (TDF) alone, or in combination with emtricitabine (FTC) is associated with sustained viral suppression in patients with lamivudine resistant (LAM-R) chronic hepatitis B (CHB).",
            "LAM-R CHB patients were randomised 1:1 to receive TDF 300mg or FTC 200mg and TDF 300mg once daily in a prospective, double blind, study.",
            "The proportion of patients with plasma hepatitis B virus (HBV) DNA <69IU/ml (<400copies/ml) at week 96 (primary efficacy endpoint) was reported previously.",
            "Here we present week 240 follow-up data.",
            "Overall, 280 patients were randomised to receive TDF (n=141) or FTC/TDF (n=139), and 85.4% completed 240 weeks of treatment.",
            "At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96).",
            "Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively).",
            "Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively).",
            "Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240.",
            "No TDF resistance was observed up to week 240.",
            "Treatment was generally well tolerated, and renal events were mild and infrequent (\u223c8.6%).",
            "The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively.",
            "TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240 weeks.",
            "The goal of oral antiviral treatment for chronic hepatitis B (CHB) is to achieve and maintain undetectable HBV DNA levels.",
            "Treatment options with enhanced potency, and low risk of resistance development for patients infected with lamivudine resistant (LAM-R) HBV are required.",
            "Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks."
        ],
        "labels": [
            "Claim",
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null,
            null,
            null
        ]
    },
    "11370551": {
        "sentences": [
            "Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94).",
            " The standard treatment for patients with clinically resectable rectal cancer is surgery.",
            "Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).",
            "In recent years, encouraging results of preoperative radiotherapy have been reported.",
            "This prospective randomized phase-III trial (CAO/ARO/AIO-94) compares the efficacy of neoadjuvant radiochemotherapy to standard postoperative radiochemotherapy.",
            "We report on the design of the study and first results with regard to toxicity of radiochemotherapy and postoperative morbidity.",
            "Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre- or postoperative radiochemotherapy: A total dose of 50.4 Gy (single dose 1.8 Gy) was applied to the tumor and the pelvic lymph nodes.",
            "5-FU (1,000 mg/m2/d) was administered concomitantly in the first and fifth week of radiation as 120-h continuous infusion.",
            "Four additional cycles of 5-FU chemotherapy (500 mg/m2/d, i.v.",
            "bolus) were applied.",
            "Radiochemotherapy was identical in both arms except for a small-volume boost of 5.4 Gy in the postoperative setting.",
            "Time interval between radiochemotherapy and surgery was 4-6 weeks in both arms.",
            "Techniques of surgery were standardized and included total mesorectal excision.",
            "In addition, stratification according to surgeons involved has been provided for.",
            "Primary endpoints of the study are 5-year overall-survival, local and distant control, secondary endpoints include rate of curative (R0) resections and sphincter saving procedures, toxicity of radiochemotherapy, surgical complications and quality of life.",
            "As of 15th November 2000, 628 patients were randomized from 26 participating institutions: 310 patients were randomized to postoperative radiochemotherapy, 318 patients to preoperative radiochemotherapy.",
            "Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity: The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.",
            "Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.",
            "Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.",
            "The patient accrual of our trial is satisfactory, neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity."
        ],
        "labels": [
            "Claim",
            null,
            "Claim",
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "28898281": {
        "sentences": [
            "Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.",
            "Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal.",
            "The role of HBV prophylaxis in this setting is uncertain.",
            "The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy.",
            "PREBLIN is a phase IV, randomized, prospective, open-label, multicenter, parallel-group trial conducted in 17 hospitals throughout Spain.",
            "Anti-HBc-positive, HBsAg-negative patients with undetectable HBV DNA were randomized to receive TDF 300 mg once daily (Group I) or observation (Group II).",
            "The primary endpoint was the percentage of patients showing HBV reactivation during 18 months following initiation of RTX treatment.",
            "Patients with detectable HBV DNA (Group III) received the same dose of TDF and were analyzed together with Group I to investigate TDF safety.",
            "Sixty-one patients were enrolled in the study, 33 in the TDF treatment group and 28 in the observation group.",
            "By ITT analysis, HBV reactivation was 0% (0/33) in the study group and 10.7% (3/28) in the observation group (p = 0.091).",
            "None of the patients in either group showed significant differences in liver function parameters between baseline and the last follow-up sample.",
            "TDF was generally well tolerated and there were no severe treatment-related adverse events.",
            "In patients with hematological malignancy and resolved hepatitis B infection receiving RTX-based regimens, HBV reactivation did not occur in patients given TDF prophylaxis."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "28603112": {
        "sentences": [
            "Alternative treatment in Hepatitis B by using polyherbal formulation.",
            "The hepatitis B is most prevalent diseases (along with morbidities) in Asian countries.",
            "This research study has been conducted to provide an alternative treatment which is safe, effective and cost-effective to comprehend relations of disease, symptoms, patients response and the clinical response via better management of hepatitis B.",
            "The goal of this research is to evaluate efficacy and safety of herbal medicine as compared to allopathic medicine in patients suffering from hepatitis B.",
            "This was a single blind, randomized controlled clinical trial conducted at Shifa-ul-Mulk Memorial Hospital Hamdard University, Karachi and Dar ul Shifa Unani Dawakhana Karachi, Pakistan.",
            "The patients of both genders ranging from 25 to 50 years with symptoms and diagnosed for hepatitis B that fulfilled the criteria for membership, and consented for participation were registered.",
            "Ethical committee clearance and permission was obtained from the concerned committee at Faculty of Eastern Medicine, Hamdard University, Karachi, Pakistan.",
            "No significant difference was identified after treatment and it was found that the efficacy of Alpha (Control drug) is same as Safoof akseer e jigar (Test drug).",
            "The data offered support to the null hypothesis and therefore research hypothesis was rejected.",
            "According to the statistical analysis by chi square, hepatitis B was recorded as negative in 26 patients (57.77%) out of 45 patients by the use of Interferon Alpha (control therapy) and in 27 patients (64.28%) out of 42 patients by the use of Safoof akseer e jigar (test drug).",
            "Comparison of the data recorded of the patients was determined as both drugs showed significant improvement and p value>0.05.",
            "The efficacy response is equal in both drugs while test drug showed more safety response.",
            "It is concluded that Safoof akseer e jigar possesses as effective a therapeutic value in treating hepatitis B as allopathic medicine."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "29436152": {
        "sentences": [
            "Immersion-enhanced fluid redistribution can prevent intradialytic hypotension: A prospective, randomized, crossover clinical trial.",
            "Intradialytic hypotension (IDH) is an important cause of morbidity and mortality among hemodialysis patients.",
            "We used an immersion model to evaluate the role of reduced effective circulating volume, and to examine whether facilitated refilling can prevent IDH.",
            "Ten male hemodialysis patients who had frequent episodes of IDH were randomized to a mid-week \"wet\" or \"dry\" hemodialysis session, and subsequently underwent the other session in a crossover manner.",
            "The wet sessions were performed while immersed up to the neck in a 34 to 35\u00b0C bath, and the dry session was standard hemodialysis.",
            "Ultrafiltration goals were determined as the mean ultrafiltration during the 10 sessions preceding the first study session\u2009\u00b1\u200910%.",
            "Mean ultrafiltration was similar for the wet and dry sessions (2.99\u2009\u00b1\u20090.64 kg vs. 2.96\u2009\u00b1\u20090.74 kg).",
            "Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.",
            "Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P\u2009=\u20090.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P\u2009=\u20090.02.",
            "Diastolic blood pressure did not change during the sessions.",
            "Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P\u2009=\u20090.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P\u2009=\u20090.167.",
            "Aldosterone blood levels did not change.",
            "Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "29652567": {
        "sentences": [
            "A Khorasan Wheat-Based Replacement Diet Improves Risk Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD): A Randomized Clinical Trial.",
            "KAMUT khorasan is an ancient grain with widely acclaimed health benefits.",
            "The aim of this study was to investigate the effects of a replacement diet with ancient khorasan wheat products in patients with NAFLD, in comparison to a similar replacement diet with control products made from organic semi-whole-grain modern wheat.",
            "Forty NAFLD patients (12 M/28 F; age 55.2 \u00b1 10.4 years) with mild to moderate liver steatosis were included.",
            "The experimental design was a randomized, double-blind, parallel-arm study with 20 participants assigned to consume either KAMUT khorasan or control wheat products (pasta, bread, crackers, biscuits) over a 3-month period.",
            "Anthropometric measurements, blood analyses, and ultrasonography examination were performed at both the beginning and end of each dietary intervention.",
            "After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).",
            "Similarly, significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).",
            "Finally, significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.",
            "This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12721238": {
        "sentences": [
            "Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.",
            " Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.",
            "These physical changes can negatively affect health-related quality of life.",
            "Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.",
            "In a two-site study, 155 men with prostate cancer who were scheduled to receive androgen deprivation therapy for at least 3 months after recruitment were randomly assigned to an intervention group that participated in a resistance exercise program three times per week for 12 weeks (82 men) or to a waiting list control group (73 men).",
            "The primary outcomes were fatigue and disease-specific quality of life as assessed by self-reported questionnaires after 12 weeks.",
            "Secondary outcomes were muscular fitness and body composition.",
            "Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.",
            "Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.",
            "The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.",
            "Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.",
            "This form of exercise can be an important component of supportive care for these patients."
        ],
        "labels": [
            null,
            "Claim",
            "Claim",
            "Claim",
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "11438417": {
        "sentences": [
            "Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.",
            " To assess comparatively, in terms of quality-adjusted survival, three front-line treatments in patients with stage B- or C-chronic lymphocytic leukemia (CLL).",
            "To describe better and compare the survival after randomization of patients from the CLL90 trial that randomly compared ChOP (cyclophosphamide, doxorubicin, oncovin, prednisone), CAP (cyclophosphamide, doxorubicin, prednisone) and fludarabine in advanced CLL, we performed a quality-adjusted survival analysis.",
            "This consisted of defining four clinical states (toxicity, treatment free of toxicity, no treatment nor symptoms, relapse), then summing up the average times spent in each state weighted by utility coefficients that reflect relative value according to quality of life.",
            "The resulting quality-adjusted time without symptoms or toxicity (Q-TWIST) was compared between randomized groups, and sensitivity (threshold) analyses to the choice of utility coefficients was performed.",
            "Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.",
            "The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.",
            "The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.",
            "Fludarabine was consistently a better treatment than ChOP, except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.",
            "Nevertheless, from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).",
            "We conclude that patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.",
            "These two treatments are always superior to CAP."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "29611209": {
        "sentences": [
            "Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area.",
            "Data are insufficient regarding the survival benefit of surveillance for hepatocellular carcinoma (HCC).",
            "To investigate the effectiveness of HCC surveillance in a hepatitis B-endemic population.",
            "This retrospective cohort study included 1402 consecutive patients who were newly diagnosed with HCC between 2005 and 2012 at a single tertiary hospital in Korea.",
            "The primary endpoint was overall survival.",
            "Lead-time and length-time biases were adjusted (sojourn time = 140 days) and sensitivity analyses were performed.",
            "The most common aetiology was hepatitis B (80.4%).",
            "Cirrhosis was present in 78.2%.",
            "HCC was diagnosed during regular surveillance (defined as mean interval of ultrasonography <8 months, n = 834), irregular surveillance (n = 104) or nonsurveillance (n = 464).",
            "Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001).",
            "Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time.",
            "When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.",
            "HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment.",
            "Survival advantage was significant with regular surveillance but not with irregular surveillance."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "21993852": {
        "sentences": [
            "A comparison of postoperative quality of life and dysfunction after Billroth I and Roux-en-Y reconstruction following distal gastrectomy for gastric cancer: results from a multi-institutional RCT.",
            " Both Billroth I (B-I) and Roux-en-Y (R-Y) reconstructions are commonly performed as standard procedures, but it has yet to be determined which reconstruction is better for patients.",
            "A randomized prospective phase II trial with body weight loss at 1\u00a0year after surgery as a primary endpoint was performed to address this issue.",
            "The current report delivers data on the quality of life and degree of postoperative dysfunction, which were the secondary endpoints of this study.",
            "Gastric cancer patients who underwent distal gastrectomy were intraoperatively randomized to B-I or R-Y.",
            "Postsurgical QOL was evaluated using the EORTC QLQ-C30 and DAUGS 20.",
            "Between August 2005 and December 2008, 332 patients were enrolled in a randomized trial comparing B-I versus R-Y.",
            "A mail survey questionnaire sent to 327 patients was completed by 268 (86.2%) of them.",
            "EORTC QLQ-C30 scores were as follows: global health status was similar in each group (B-I 73.5\u00a0\u00b1\u00a018.8, R-Y 73.2\u00a0\u00b1\u00a020.2, p\u00a0=\u00a00.87).",
            "Scores of five functional scales were also similar.",
            "Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.6\u00a0\u00b1\u00a017.9, R-Y 8.6\u00a0\u00b1\u00a016.3, p\u00a0=\u00a00.02).",
            "With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p\u00a0=\u00a00.41).",
            "Only reflux symptoms were significantly worse for B-I than for R-Y (0.7\u00a0\u00b1\u00a00.6 vs. 0.5\u00a0\u00b1\u00a00.6, p\u00a0=\u00a00.01).",
            "The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction.",
            "Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "23749688": {
        "sentences": [
            "Feasibility and efficacy of a supervised exercise intervention in de-conditioned cancer survivors during the early survivorship phase: the PEACH trial.",
            " This study aims to evaluate the feasibility and efficacy of an 8-week supervised exercise program in de-conditioned cancer survivors within 2-6\u00a0months of chemotherapy completion.",
            "Participants were randomly assigned to an 8-week, twice-weekly, supervised aerobic exercise training regime (n\u2009=\u200923) or a usual care group (n\u2009=\u200920).",
            "Feasibility was assessed by recruitment rate, program adherence and participant feedback.",
            "The primary outcome was aerobic fitness assessed by the Modified Bruce fitness test at baseline (0 weeks), post-intervention (8 weeks) and at 3-month follow-up.",
            "Secondary outcomes included physical activity, waist circumference, fatigue and quality of life.",
            "The recruitment rate was 81\u00a0% and adherence to the supervised exercise was 78.3\u00a0%.",
            "Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0\u00a0mL kg(-1) min(-1) (95\u00a0% CI -1.1-7.0)] and 3-month follow-up [2.1\u00a0mL kg(-1) min(-1) (-2.3-6.6)] were found, although these differences did not achieve statistical significance (p values >0.14).",
            "Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p\u2009=\u20090.01) and 3-month follow-up (p\u2009=\u20090.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p\u2009=\u20090.03) and 3-month follow-up (p\u2009=\u20090.04).",
            "Improvements in fatigue (p\u2009=\u20090.01), total quality of life plus fatigue (p\u2009=\u20090.04), and a composite physical functioning score (p\u2009=\u20090.01) at the 3-month follow-up were also found.",
            "The PEACH trial suggests that 8\u00a0weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase.",
            "Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20631341": {
        "sentences": [
            "Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.",
            " The Australian and New Zealand Germ Cell Trials Group conducted a multicenter randomized phase III trial in men with good-prognosis germ cell tumors of two standard chemotherapy regimens that contained bleomycin, etoposide, and cisplatin but differed in the scheduling and total dose of cisplatin, the total dose of bleomycin, and the scheduling and dose intensity of etoposide.",
            "The trial was stopped early at a median follow-up of 33 months after a planned interim analysis found a survival benefit for the more dose-intense regimen.",
            "The aim of this analysis was to determine if this survival benefit was maintained with long-term follow-up.",
            "Between February 1994 and April 2000, 166 men with good-prognosis metastatic germ cell tumors defined by modified Memorial Sloan-Kettering criteria were randomly assigned to receive 3B(90)E(500)P (three cycles, repeated every 21 days, of 30 kU bleomycin on days 1, 8, and 15; 100 mg/m(2) etoposide on days 1-5; and 20 mg/m(2) cisplatin on days 1-5; n = 83) or 4B(30)E(360)P (four cycles, repeated every 21 days, of 30 kU bleomycin on day 1, 120 mg/m(2) etoposide on days 1-3, and 100 mg/m(2) cisplatin on day 1; n = 83).",
            "Endpoints included overall survival, progression-free survival, and quality of life and side effects, which were assessed using the Spitzer Quality of Life Index and the GLQ-8, respectively, before random assignment and during and after treatment.",
            "All analyses were by intention to treat.",
            "All P values are two-sided.",
            "The median follow-up was 8.5 years.",
            "All but five survivors (3%) were followed up for at least 5 years.",
            "Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037).",
            "Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15).",
            "At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P. After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P. The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "21901389": {
        "sentences": [
            "The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: a randomized trial.",
            " The aim of this study was determine the effectiveness of a mindfulness-based stress-reduction (MBSR) program on quality of life (QOL) and psychosocial outcomes in women with early-stage breast cancer, using a three-arm randomized controlled clinical trial (RCT).",
            "This RCT consisting of 172 women, aged 20-65 with stage I or II breast cancer consisted of the 8-week MBSR, which was compared to a nutrition education program (NEP) and usual supportive care (UC).",
            "Follow-up was performed at three post-intervention points: 4 months, 1, and 2 years.",
            "Standardized, validated self-administered questionnaires were adopted to assess psychosocial variables.",
            "Statistical analysis included descriptive and regression analyses incorporating both intention-to-treat and post hoc multivariable approaches of the 163 women with complete data at baseline, those who were randomized to MBSR experienced a significant improvement in the primary measures of QOL and coping outcomes compared to the NEP, UC, or both, including the spirituality subscale of the FACT-B as well as dealing with illness scale increases in active behavioral coping and active cognitive coping.",
            "Secondary outcome improvements resulting in significant between-group contrasts favoring the MBSR group at 4 months included meaningfulness, depression, paranoid ideation, hostility, anxiety, unhappiness, and emotional control.",
            "Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation.",
            "The MBSR intervention appears to benefit psychosocial adjustment in cancer patients, over and above the effects of usual care or a credible control condition.",
            "The universality of effects across levels of expectation indicates a potential to utilize this stress reduction approach as complementary therapy in oncologic practice."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "16462503": {
        "sentences": [
            "Will improvement in quality of life (QOL) impact fatigue in patients receiving radiation therapy for advanced cancer?",
            " Fatigue has a significant impact on the quality of life (QOL) of cancer patients.",
            "Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.",
            "In this project, we examined the impact that participation in a randomized controlled trial of a multidisciplinary intervention designed to impact overall QOL had on fatigue for advanced cancer patients actively receiving treatment.",
            "Patients with newly diagnosed cancer were randomly assigned to an 8-session structured multidisciplinary intervention or a standard-care arm at the beginning of their course of radiotherapy (RT) designed to impact QOL.",
            "Ninety-minute sessions were led by either a psychiatrist or psychologist, collaborating with a nurse, physical therapist, chaplain, or social worker, depending on the session's theme.",
            "The fatigue assessments used in this trial included the Linear Analogue Self Assessment (LASA), the Profile of Mood States (POMS), Spielberger's State-Trait Anxiety Inventory (STAI), and the Symptom Distress Scale (SDS).",
            "There were 115 participants enrolled and the 2 randomization arms were well balanced in terms of baseline characteristics and treatment received except for increased commuting distance for the patients in the intervention arm (P = 0.042).",
            "Most of scores indicated less fatigue (higher score) in the standard treatment group, but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.",
            "For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.",
            "Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.",
            "Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline.",
            "Clinically, this structured multidisciplinary intervention had no impact on fatigue, and there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment."
        ],
        "labels": [
            null,
            "Claim",
            "Claim",
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "8683634": {
        "sentences": [
            "A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer.",
            " Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer.",
            "However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient.",
            "To assess the trade-offs between improved survival and increased treatment toxicity, we reanalyzed data from a randomized clinical trial that compared the efficacy of combined adjuvant chemotherapy and radiation therapy with adjuvant radiation therapy alone in the treatment of patients with poor-prognosis resectable rectal cancer.",
            "The data were from a North Central Cancer Treatment Group trial in which 204 patients with poor-prognosis rectal cancer were randomly assigned to receive either postoperative radiation therapy alone or radiation therapy plus fluorouracil-based chemotherapy.",
            "A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis was used to account for freedom from symptomatic disease and from early and late side effects of treatment.",
            "All reported P values are two-sided.",
            "As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone.",
            "In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone.",
            "Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease.",
            "Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified, since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.",
            "The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations."
        ],
        "labels": [
            null,
            null,
            "Claim",
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence",
            "Claim"
        ]
    },
    "20625123": {
        "sentences": [
            "Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial.",
            " Fatigue is one of the most common symptoms experienced by patients with cancer.",
            "This trial was developed to evaluate the efficacy of long-acting methylphenidate for improving cancer-related fatigue and to assess its toxicities.",
            "Adults with cancer were randomly assigned in a double-blinded manner to receive methylphenidate (target dose, 54 mg/d) or placebo for 4 weeks.",
            "The Brief Fatigue Inventory was the primary outcome measure, while secondary outcome measures included a Symptom Experience Diary (SED), the Short Form-36 (SF-36) Vitality Subscale, a linear analog self-assessment, the Pittsburgh Sleep Quality Index, and the Subject Global Impression of Change.",
            "In total, 148 patients were enrolled.",
            "Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).",
            "Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.",
            "However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).",
            "There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.",
            "This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "23598172": {
        "sentences": [
            "Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.",
            " In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free survival (PFS).",
            "Here, we report overall survival and updated efficacy, quality of life, and safety results.",
            "Eligible patients had clear cell metastatic renal cell carcinoma, progressive disease after one approved systemic treatment, and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1.",
            "723 patients were stratified by ECOG PS and previous treatment and randomly allocated (1:1) to receive axitinib (5 mg twice daily; n=361) or sorafenib (400 mg twice daily; n=362).",
            "The primary endpoint was PFS assessed by a masked, independent radiology review committee.",
            "We assessed patient-reported outcomes using validated questionnaires.",
            "Baseline characteristics and development of hypertension on treatment were studied as prognostic factors.",
            "Efficacy was assessed in the intention-to-treat population, and safety was assessed in patients who received at least one dose of the study drug.",
            "Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).",
            "Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5\u00b77 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).",
            "Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment, but decreased at end-of-treatment.",
            "Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.",
            "In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).",
            "Although overall survival, a secondary endpoint for the study, did not differ between the two groups, investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.",
            "These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "8839553": {
        "sentences": [
            "A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis.",
            " Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients; approximately half such metastases are single.",
            "Previous retrospective studies and two randomized trials reported that the addition of surgical extirpation prior to radiation therapy increased survival, neurologic function, and quality of life compared with radiation alone in patients with a single brain metastasis.",
            "A randomized controlled trial was conducted in which patients with a single brain metastasis were allocated to undergo radiation alone or surgery plus radiation.",
            "Radiation consisted of 3000 centigray to the whole brain in 10 fractions.",
            "Forty-three patients received radiation alone and 41 patients surgery plus radiation.",
            "All but two of the study patients died.",
            "No difference in survival was detected between the groups; the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24).",
            "Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).",
            "There were no significant differences in the 30-day mortality, morbidity, or causes of death.",
            "Extracranial metastases was an important predictor of mortality (relative risk, 2.3).",
            "The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.",
            "This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.",
            "Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20585099": {
        "sentences": [
            "Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial.",
            " The Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 (MRC CR07/NCIC CTG C016) trial showed that, in patients with operable rectal cancer, short-course preoperative radiotherapy (PRE) reduced the rate of local recurrence compared with surgery followed by selective postoperative chemoradiotherapy for patients with a positive circumferential resection margin.",
            "However, the advantages of giving PRE to all patients needs to be balanced against any negative impact on patients' quality of life.",
            "All 1,350 patients were asked to complete the Medical Outcomes Study Short-Form 36-item (MOS SF-36) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal 38-item (EORTC QLQ-CR38) questionnaires.",
            "A priori hypotheses related to the impact of treatment on sexual, bowel, and physical function and general health.",
            "Male sexual dysfunction was significantly increased following surgery (P < .001), although there was no difference between treatment arms.",
            "However, a treatment difference had emerged at 6 months (PRE patients reporting significantly greater dysfunction; P = .004), which persisted out to at least 2 years (an insufficient number of female patients completed the sexual dysfunction questions to draw firm conclusions).",
            "Both treatment groups reported similar levels of decreased physical function at 3 months, but thereafter it returned to baseline levels.",
            "There was no evidence of any major changes between treatments or time points in terms of general health or bowel function, but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.",
            "These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery, but that PRE also affected sexual and some aspects of bowel functioning."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "18457329": {
        "sentences": [
            "Effect of exercise on upper extremity pain and dysfunction in head and neck cancer survivors: a randomized controlled trial.",
            " Shoulder pain and disability are well recognized complications associated with surgery for head and neck cancer.",
            "This study was designed to examine the effects of progressive resistance exercise training (PRET) on upper extremity pain and dysfunction in postsurgical head and neck cancer survivors.",
            "Fifty-two head and neck cancer survivors were assigned randomly to PRET (n = 27) or a standardized therapeutic exercise protocol (TP) (n = 25) for 12 weeks.",
            "The primary endpoint was change in patient-rated shoulder pain and disability from baseline to postintervention.",
            "Secondary endpoints were upper extremity strength and endurance, range of motion, fatigue, and quality of life.",
            "Follow-up assessment for the primary outcome was 92%, and adherence to the supervised PRET and TP programs were 95% and 87%, respectively.",
            "On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039).",
            "Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group but did not reach statistical significance.",
            "The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage.",
            "Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "18669464": {
        "sentences": [
            "Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.",
            " In an international, randomized phase III trial, sunitinib demonstrated statistically significant efficacy over interferon alfa (IFN-alpha) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC) (progression-free survival time, 11 v 5 months, respectively; P < .001; objective response rate, 31% v 6%, respectively; P < .001).",
            "We report health-related quality-of-life (QOL) results from this trial.",
            "Seven hundred fifty mRCC patients were randomly assigned to sunitinib (6-week cycles: 50 mg orally once daily for 4 weeks, followed by 2 weeks off) or IFN-alpha (9 million units subcutaneous injections, three times weekly).",
            "QOL measures included the Functional Assessment of Cancer Therapy-General (FACT-G), the FACT-Kidney Symptom Index-15 item (FKSI-15), and the EuroQoL-5D's utility score (EQ-5D Index) and its visual analog scale (EQ-VAS).",
            "The primary QOL end point was the FKSI Disease-Related Symptoms (FKSI-DRS) subscale.",
            "Higher scores indicated better outcomes (better QOL or fewer symptoms).",
            "Data were analyzed for the intent-to-treat population using mixed-effects models, supplemented with pattern-mixture models.",
            "Patients receiving sunitinib reported higher FKSI-15 and FKSI-DRS scores at each cycle than those receiving IFN-alpha, with a significant difference in the overall least squares means (3.27 and 1.98, respectively; P < .0001).",
            "Similarly, differences in least squares means for FACT-G (and all subscales), EQ-5D Index, and EQ-VAS were all significantly favorable for sunitinib (P < .01).",
            "Per pre-established thresholds, between-treatment differences in the mean scores were clinically meaningful after cycle 4 for FKSI-DRS and at all assessments for FKSI-15, FACT-G, and the FACT-G functional well-being subscale.",
            "Sunitinib provides superior QOL compared with IFN-alpha in mRCC patients."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "23615094": {
        "sentences": [
            "Conservative management or gamma knife radiosurgery for vestibular schwannoma: tumor growth, symptoms, and quality of life.",
            " There are few reports about the course of vestibular schwannoma (VS) patients following gamma knife radiosurgery (GKRS) compared with the course following conservative management (CM).",
            "In this study, we present prospectively collected data of 237 patients with unilateral VS extending outside the internal acoustic canal who received either GKRS (113) or CM (124).",
            "The aim was to measure the effect of GKRS compared with the natural course on tumor growth rate and hearing loss.",
            "Secondary end points were postinclusion additional treatment, quality of life (QoL), and symptom development.",
            "The patients underwent magnetic resonance imaging scans, clinical examination, and QoL assessment by SF-36 questionnaire.",
            "Statistics were performed by using Spearman correlation coefficient, Kaplan-Meier plot, Poisson regression model, mixed linear regression models, and mixed logistic regression models.",
            "Mean follow-up time was 55.0 months (26.1 standard deviation, range 10-132).",
            "Thirteen patients were lost to follow-up.",
            "Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test).",
            "There was a significant reduction in tumor volume over time in the GKRS group.",
            "The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001).",
            "Symptom and QoL development did not differ significantly between the groups.",
            "In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold.",
            "Hearing is lost at similar rates in both groups.",
            "Symptoms and QoL seem not to be significantly affected by GKRS."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "21911723": {
        "sentences": [
            "Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.",
            " Somatostatin analogs act directly on breast cancer cells and indirectly on insulin and insulin-like growth factor 1 (IGF-1) levels.",
            "This trial was undertaken to assess whether octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.",
            "The NCIC CTG MA.14 (NCIC Clinical Trials Group MA.14) trial randomly assigned postmenopausal women to 5 years of tamoxifen 20 mg daily (TAM) or TAM plus 2 years of octreotide 90 mg depot intramuscular injections monthly (TAM-OCT) as adjuvant therapy.",
            "The primary end point was event-free survival (EFS).",
            "Secondary end points were relapse-free survival (RFS), overall survival (OS), toxicity, and effects of treatment on IGF physiology.",
            "Among 667 women with a median follow-up of 7.9 years, 220 events occurred-108 with TAM-OCT and 112 with TAM.",
            "Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).",
            "Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001).",
            "At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.",
            "Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis.",
            "Octreotide-related changes in circulating IGF-1 and C-peptide levels were statistically significant.",
            "Octreotide did not add significant clinical benefit.",
            "High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome."
        ],
        "labels": [
            null,
            null,
            "Claim",
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim"
        ]
    },
    "20680680": {
        "sentences": [
            "Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).",
            " The aim of this study was to compare the effects on health-related quality of life (HRQOL) of two treatment regimens in the TEX trial during 9 month from random assignment, with emphasis on the 2- and 9-months assessments.",
            "A total of 287 patients were randomized to treatment in 3-week cycles with either epirubicin plus paclitaxel (ET, 143 patients), or epirubicin, paclitaxel and capecitabine (TEX, 144 patients).",
            "HRQOL was assessed by the EORTC-QLQ C30 and EORTC QLQ-BR23 questionnaires at five points during 9 months.",
            "A total of 252 (88%) completed questionnaires before randomization.",
            "Response rate for the following assessments was >75%.",
            "There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.",
            "Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia.",
            "At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning.",
            "Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group.",
            "At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET.",
            "However, after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "23840308": {
        "sentences": [
            "Outcomes of a Geriatric Liaison Intervention to Prevent the Development of Postoperative Delirium in Frail Elderly Cancer Patients: Report on a Multicentre, Randomized, Controlled Trial.",
            " Delirium is a serious and common postoperative complication, especially in frail elderly patients.",
            "The aim of this study was to evaluate the effect of a geriatric liaison intervention in comparison with standard care on the incidence of postoperative delirium in frail elderly cancer patients treated with an elective surgical procedure for a solid tumour.",
            "Patients over 65 years of age who were undergoing elective surgery for a solid tumour were recruited to a multicentre, prospective, randomized, controlled trial.",
            "The patients were randomized to standard treatment versus a geriatric liaison intervention.",
            "The intervention consisted of a preoperative geriatric consultation, an individual treatment plan targeted at risk factors for delirium, daily visits by a geriatric nurse during the hospital stay and advice on managing any problems encountered.",
            "The primary outcome was the incidence of postoperative delirium.",
            "The secondary outcome measures were the severity of delirium, length of hospital stay, complications, mortality, care dependency, quality of life, return to an independent preoperative living situation and additional care at home.",
            "In total, the data of 260 patients were analysed.",
            "Delirium occurred in 31 patients (11.9%), and there was no significant difference between the incidence of delirium in the intervention group and the usual-care group (9.4% vs. 14.3%, OR: 0.63, 95% CI: 0.29-1.35).",
            "Within this study, a geriatric liaison intervention based on frailty for the prevention of postoperative delirium in frail elderly cancer patients undergoing elective surgery for a solid tumour has not proven to be effective."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim"
        ]
    },
    "23632471": {
        "sentences": [
            "The effects of patient participation-based dietary intervention on nutritional and functional status for patients with gastrectomy: a randomized controlled trial.",
            " Patients undergoing gastrectomy because of stomach cancer often face weight loss in the perioperational period, which can lead to malnutrition and negative treatment outcomes.",
            "The purpose of this study was to develop a patient participation-based dietary intervention (PPDI) and evaluate its effects on patient outcomes.",
            "This was a prospective, randomized controlled trial in which the patients were recruited in a cancer center in South Korea.",
            "The participants (N = 56), who underwent gastrectomy with stomach cancer stage I to III, were randomly assigned into either the experimental or the control group.",
            "The PPDI, which was given on the day before the hospital discharge, comprised 2 face-to-face and 2 telephone interventions.",
            "The outcome variables included body weight, body mass index, muscle mass, the Patient-Generated Subjective Global Assessment, Dietary Symptom Scale, Functional Assessment Cancer Therapy-General, Karnofsky Performance Status, Adherence to Dietary Guidelines Scale, Scale of Dietary Knowledge, Patient Satisfaction Scale, and a 3-day food diary.",
            "Participants in the PPDI intervention demonstrated significant (P < .05) reductions in adverse dietary symptoms and significant improvements (P < .05) in functional status, performance status, dietary intake, adherence to dietary guidelines, dietary knowledge, and satisfaction with the intervention as compared with the control group over time.",
            "The PPDI was an effective dietary intervention for patients undergoing a gastrectomy for gastric cancer and deserves additional study in other populations of patients.",
            "Incorporating patients' perspectives into a dietary intervention after gastrectomy for gastric cancer may contribute to improved patient outcomes and quality care."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim",
            null
        ]
    },
    "23793805": {
        "sentences": [
            "Long-term outcomes of laparoscopy-assisted distal gastrectomy for early gastric cancer: result of a randomized controlled trial (COACT 0301).",
            " The purpose of this study was to evaluate laparoscopy-assisted distal gastrectomy (LADG) compared to open distal gastrectomy (ODG) in the treatment of early gastric cancer with respect to survival, surgical outcomes, complications, and quality of life (QOL).",
            "One hundred sixty-four patients with cT1N0M0 and cT1N1M0 distal gastric cancer were randomly assigned to either the LADG group or the ODG group.",
            "The primary end point was the 5-year disease-free survival (DFS) rate.",
            "Complications were classified using the accordion severity classification of postoperative complications scheme.",
            "QOL was measured using the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-STO22 preoperatively and postoperatively during regular follow-up visits.",
            "This trial is registered at ClinicalTrials.gov.",
            "The median (range) follow-up period was 74.3 (24.8-90.8) months.",
            "The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073).",
            "Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).",
            "The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups.",
            "No clinically meaningful differences were detected between the two groups in long-term QOL.",
            "LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.",
            "Marginal benefits in mild complications were observed with LADG.",
            "LADG did not show advantages over ODG regarding other complications and long-term QOL."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "16490846": {
        "sentences": [
            "Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face.",
            " To assess the cost-effectiveness of Mohs micrographic surgery (MMS) compared with the surgical excision for both primary and recurrent basal cell carcinoma (BCC).",
            "A cost-effectiveness study performed alongside a prospective randomized clinical trial in which MMS was compared with surgical excision.",
            "The study was carried out from 1999 to 2002 at the dermatology outpatient clinic of the University Hospital Maastricht, Maastricht, The Netherlands.",
            "A total of 408 primary (374 patients) and 204 recurrent (191 patients) cases of facial BCC were included.",
            "The mean total treatment costs of MMS and surgical excision for both primary and recurrent BCC and the incremental cost-effectiveness ratio, calculated as the difference in costs between MMS and surgical excision divided by their difference in effectiveness.",
            "The resulting ratio is defined as the incremental costs of MMS compared with surgical excision to prevent 1 additional recurrence.",
            "Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros).",
            "For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros.",
            "The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%.",
            "At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC.",
            "However, because a 5-year period is normally required to determine definite recurrence rates, it is possible that MMS may become a cost-effective treatment for recurrent BCC."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "15274068": {
        "sentences": [
            "A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma.",
            " Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.",
            "Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.",
            "A prospective, randomized, controlled trial was performed to determine whether aerobic exercise would reduce the incidence of fatigue and prevent deterioration in physical functioning during radiotherapy for localized prostate carcinoma.",
            "Sixty-six men were randomized before they received radical radiotherapy for localized prostate carcinoma, with 33 men randomized to an exercise group and 33 men randomized to a control group.",
            "Outcome measures were fatigue and distance walked in a modified shuttle test before and after radiotherapy.",
            "There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).",
            "Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203).",
            "A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003).",
            "Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.",
            "Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue.",
            "Improved physical functioning may be necessary to combat radiation fatigue."
        ],
        "labels": [
            null,
            "Claim",
            "Evidence",
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "18520802": {
        "sentences": [
            "Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-na\u00efve advanced non-small cell lung cancer.",
            " Performance status (PS) 2 patients with non-small cell lung cancer (NSCLC) experience more toxicity, lower response rates, and shorter survival times than healthier patients treated with standard chemotherapy.",
            "Paclitaxel poliglumex (PPX), a macromolecule drug conjugate of paclitaxel and polyglutamic acid, reduces systemic exposure to peak concentrations of free paclitaxel and may lead to increased concentrations in tumors due to enhanced vascular permeability.",
            "Chemotherapy-naive PS 2 patients with advanced NSCLC were randomized to receive carboplatin (area under the curve = 6) and either PPX (210 mg/m/10 min without routine steroid premedication) or paclitaxel (225 mg/m/3 h with standard premedication) every 3 weeks.",
            "The primary end point was overall survival.",
            "A total of 400 patients were enrolled.",
            "Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening.",
            "There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.",
            "Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769).",
            "Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel.",
            "Disease control rates were 64% and 69% for PPX and paclitaxel, respectively.",
            "Time to progression was similar: 3.9 months for PPX/carboplatin versus 4.6 months for paclitaxel/carboplatin (p = 0.210).",
            "PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC, but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            null,
            "Claim"
        ]
    },
    "23860204": {
        "sentences": [
            "Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.",
            " The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin/cyclophosphamide followed by paclitaxel (EC\u2192T) (every 3 weeks) as adjuvant treatment in high-risk breast cancer patients.",
            "The objective of this study was to evaluate the safety and efficacy of epoetin alfa in a second randomization of the intense dose-dense arm.",
            "One thousand two hundred eighty-four patients were enrolled; 658 patients were randomly assigned to the IDD-ETC treatment group.",
            "Within the IDD-ETC group, 324 patients were further randomly assigned to the epoetin alfa group, and 319 were randomly assigned to the non-erythropoiesis-stimulating agent (ESA) control group.",
            "Primary efficacy endpoints included change in hemoglobin level from baseline to Cycle 9 and the percentage of subjects requiring red blood cell transfusion.",
            "Relapse-free survival, overall survival, and intramammary relapse were secondary endpoints estimated with Kaplan-Meier and Cox regression methods.",
            "Except for the primary hypothesis, all statistical tests were two-sided.",
            "Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001).",
            "The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm.",
            "After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse.",
            "Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival.",
            "However, epoetin alfa had an adverse effect, resulting in increased thrombosis."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "15251160": {
        "sentences": [
            "Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.",
            " Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.",
            "It was the aim of the present study to assess changes in quality of life and bone pain due to intravenous (i.v.)",
            "ibandronate, a potent third-generation bisphosphonate.",
            "In a phase III randomised, double-blind, placebo-controlled trial in patients with bone metastases due to breast cancer, 466 women were randomised to receive placebo, 2 mg ibandronate or 6 mg ibandronate for up to 96 weeks.",
            "Treatment was administered i.v.",
            "at 3- or 4-weekly intervals.",
            "Clinical endpoints included the incidence of adverse events, quality of life (assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Scale - Core 30 questionnaire (QLQ-C30)), and bone pain (assessed on a 5-point scale from 0=none to 4=intolerable).",
            "Ibandronate was generally well tolerated.",
            "Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups, but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001).",
            "A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.",
            "Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05).",
            "Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.",
            "I.v.",
            "ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            null
        ]
    },
    "23788218": {
        "sentences": [
            "Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial.",
            " Major depressive disorder develops in up to half the patients undergoing treatment for head and neck cancer, resulting in significant morbidity; therefore, preventing depression during cancer treatment may be of great benefit.",
            "To determine whether prophylactic use of the antidepressant escitalopram oxalate would decrease the incidence of depression in patients receiving primary therapy for head and neck cancer.",
            "A randomized, double-blind, placebo-controlled trial of escitalopram vs placebo was conducted in a group of nondepressed patients diagnosed as having head and neck cancer who were about to enter cancer treatment.",
            "Patients were stratified by sex, site, stage (early vs advanced), and primary modality of treatment (radiation vs surgery).",
            "The primary outcome measure was the number of participants who developed moderate or greater depression (scores on the Quick Inventory of Depressive Symptomology-Self Rated of \u226511).",
            "From January 6, 2008, to December 28, 2011, 148 patients were randomized.",
            "Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P\u2009=\u2009.04).",
            "A Cox proportional hazards regression model compared the 2 treatment groups after controlling for age, baseline smoking status, and stratification variables.",
            "The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P\u2009=\u2009.04).",
            "Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P\u2009=\u2009.009).",
            "Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.",
            "In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.",
            "In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.",
            "These findings have important implications for the treatment of patients with head and neck cancer."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "17876009": {
        "sentences": [
            "Self-administered stress management training in patients undergoing radiotherapy.",
            " This study sought to continue research on psychosocial interventions for patients being treated with radiation therapy across multiple centers and to replicate positive findings of a single-center study of patients being treated with chemotherapy.",
            "The primary objective of this study was to determine if a stress management intervention was effective in improving quality of life and decreasing psychological distress in patients undergoing radiotherapy for cancer.",
            "A total of 310 patients about to begin radiotherapy treatment were randomly assigned to receive usual care only or self-administered stress management training.",
            "Quality-of-life assessments occurred at baseline and for 3 weeks after the beginning of radiotherapy treatment.",
            "Overall, patients assigned to receive stress management training did not report significantly less psychological distress on the Medical Outcomes Study 36-Item Short Form (SF-36) Mental Component Summary Scale than did those assigned to usual care.",
            "When divided into subgroups based on the SF-36 Mental Component Summary Scale scores immediately after their first radiotherapy treatment, patients with above-average levels of psychological distress (scores < or = 50) who were randomly assigned to the intervention condition reported significant improvement in their distress compared with those assigned to usual care only on the SF-36 Mental Health Subscale and the Center for Epidemiologic Studies Depression Scale.",
            "This study found that self-administered stress management training is effective only in those radiotherapy patients with initially higher levels of psychological distress.",
            "Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "9643663": {
        "sentences": [
            "A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.",
            " To evaluate the efficacy and tolerability of 'Casodex' monotherapy (150 mg daily) for metastatic and locally advanced prostate cancer.",
            "A total of 1,453 patients with either confirmed metastatic disease (M1), or T3/T4 non-metastatic disease with elevated prostate-specific antigen (M0) were recruited into one of two identical, multicentre, randomised studies to compare 'Casodex' 150 mg/day with castration.",
            "The protocols allowed for combined analysis.",
            "At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.",
            "In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).",
            "Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.",
            "'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.",
            "However, in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.",
            "An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.",
            "A further survival analysis in patients with M0 disease is therefore planned when the data are more mature.",
            "'Casodex' 150 mg is less effective than castration in patients with M1 disease.",
            "However, 'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.",
            "Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            null,
            "Claim",
            "Claim",
            null
        ]
    },
    "18591555": {
        "sentences": [
            "Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.",
            " The management of recurrent ovarian cancer remains controversial.",
            "Single-agent topotecan is an established treatment option, and preliminary evidence suggests improved tumor control by combining topotecan with etoposide or gemcitabine.",
            "Women with relapsed ovarian cancer after primary surgery and platinum-based chemotherapy were randomly assigned to topotecan monotherapy 1.25 mg/m(2)/d, topotecan 1.0 mg/m(2) plus oral etoposide 50 mg/d, or topotecan 0.5 mg/m(2)/d plus gemcitabine 800 mg/m(2) on day 1 and 600 mg/m(2) on day 8 every 3 weeks.",
            "Patients were stratified for platinum-refractory and platinum-sensitive disease according to a recurrence-free interval of less or more than 12 months, respectively.",
            "The primary end point was overall survival.",
            "Secondary end points included progression-free survival, objective response rates, toxicity, and quality of life (as measured by the European Organisation for Research and Treatment of Cancer [EORTC] 30-item Quality-of-Life Questionnaire).",
            "The trial enrolled 502 patients with a mean age of 60.5 years (+/- 10.2 years), 208 of whom were platinum resistant.",
            "Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).",
            "Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).",
            "The median progression-free survival was 7.0, 7.8, and 6.3 months, respectively.",
            "Objective response rates were 27.8%, 36.1%, and 31.6%, respectively.",
            "Patients under combined treatment were at higher risk of severe thrombocytopenia.",
            "Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer."
        ],
        "labels": [
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            null,
            "Evidence",
            null
        ]
    },
    "21892106": {
        "sentences": [
            "A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07.",
            " There are patients with stage I-III non-small cell lung cancer (NSCLC) who are not suitable for curative radical chemoradiation therapy.",
            "There are patients with an isolated solitary extracranial metastasis who have improved outcomes compared with those with cranial or multiple metastases.",
            "Patients of good performance status receiving moderate dose radiation therapy have improved survival.",
            "Two regimens of moderate dose chemoradiation therapy for such patients were compared in a randomized phase II trial.",
            "Patients were eligible if they had stage I-IIIB NSCLC, unsuitable for curative therapy, or stage IV with a PET-detected extracranial solitary metastasis.",
            "Patients were randomized to the following groups-arm A: 40 Gy/20 fractions/4 weeks with concurrent weekly vinorelbine 25 mg/m + cisplatin 20 mg/m or arm B: 30 Gy/15 fractions/3 weeks with concurrent weekly gemcitabine 200 mg. Primary end points were feasibility, response rates, and toxicity.",
            "Secondary end points were progression-free survival, overall survival, and quality of life.",
            "Eighty-four patients were randomized.",
            "Compliance was above 90% for both arms.",
            "The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).",
            "Grade 3/4 toxicity in both arms was acceptable.",
            "There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19).",
            "Patients in arm A had longer median survival but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25).",
            "No difference in quality of life was observed.",
            "Arm A was chosen for a future phase II comparison with radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "23609927": {
        "sentences": [
            "Does gender influence outcomes from a multidisciplinary intervention for quality of life designed for patients with advanced cancer?",
            " Cancer treatment can profoundly impact the patient's quality of life (QOL).",
            "It has been well documented that there are gender differences in the symptoms associated with cancer treatment.",
            "This study explores the impact of gender on QOL for patients with newly diagnosed advanced cancer.",
            "A randomized, controlled clinical trial in patients receiving radiotherapy for advanced cancer demonstrated maintenance of QOL with a six session multidisciplinary structured intervention compared to controls.",
            "This current study reports the gender differences in that trial.",
            "Outcome measures included the functional assessment of cancer therapy-general (FACT-G), linear analog self-assessment (LASA), and profile of mood states (POMS) at baseline and weeks 4, 27, and 52.",
            "Kruskal-Wallis was used to compare QOL scores.",
            "One hundred thirty-one patients (45 women and 86 men, mean age 58.7) participated in the clinical trial.",
            "At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05).",
            "Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).",
            "At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009).",
            "By week 52, there were no statistically significant gender differences in any of the QOL measures.",
            "Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer, suggesting that early interventions can be tailored for each gender."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "20809177": {
        "sentences": [
            "Extent of gastric resection impacts patient quality of life: the Dysfunction After Upper Gastrointestinal Surgery for Cancer (DAUGS32) scoring system.",
            " Quality of life is an important outcome measure in the care of patients with cancer.",
            "We developed a new scoring system specifically for the evaluation of patients with upper gastrointestinal cancer and postoperative gastrointestinal dysfunction.",
            "This study was undertaken to evaluate the scoring system's validity in comparing outcomes after gastric resection.",
            "Patients with gastric cancer, 3 months to 3 years postoperatively, were surveyed using the survey instrument.",
            "Postoperative dysfunction scores and the status of resuming activities of daily living were compared with the surgical procedure performed by analysis of variance and multiple-comparison techniques.",
            "Of 211 patients surveyed, 165 (119 men, 46 women; mean age, 65.1 \u00b1 10.5 years) responded.",
            "Procedures included distal gastrectomy in 100, total gastrectomy in 57, and pylorus-preserving gastrectomy in 8.",
            "The overall dysfunction score was 61.8 \u00b1 15.5.",
            "The dysfunction score was 58.9 \u00b1 15.0 after distal gastrectomy, 66.8 \u00b1 14.1 after total gastrectomy, and 62.4 \u00b1 21.6 after pylorus-preserving gastrectomy.",
            "These values differed significantly among the groups (P = .007).",
            "Dysfunction scores according to postoperative activity status were 49.1 \u00b1 15.6 in 71 patients who resumed their activities, 56.9 \u00b1 15.7 in 39 patients with reduced activities, 57.3 \u00b1 8.8 in 15 patients with minimal activities, and 63.3 \u00b1 11.8 (P < .05) in 16 patients who did not resume activities because of poor physical condition.",
            "This scoring system for postoperative gastrointestinal dysfunction provides an objective measure of dysfunction related to specific surgical procedures and correlates with activities of daily living in the postoperative period."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "15157043": {
        "sentences": [
            "The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events.",
            " Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life.",
            "The purpose of the present study was to measure the impact of erythropoietin on hemoglobin and mood state in patients with metastatic breast cancer and mild anemia (Hgb < 12.0 g/dL).",
            "Women were randomized to receive usual care (G1) or usual care plus r-HuEPO (G2).",
            "Usual care included transfusions as necessary and fatigue education.",
            "R-HuEPO was begun at 40,000U subcutaneously per week.",
            "At 4 weeks, the dose was increased to 60,000U if Hgb had not increased > or = 1.0 g/dL.",
            "The drug was discontinued at 8 weeks if hemoglobin improvement was < 1.0 g/dL.",
            "The study was terminated early (n = 27, G1 = 13, G2 = 14) when 4/14 (28.5%) subjects in G2 developed thrombotic events (deep vein thrombosis [DVT] in 1; DVT plus pulmonary embolism [PE] in 1; DVT plus PE 1 month after drug discontinuation in 1; and brachial vein thrombosis with infected Mediport in 1).",
            "In all four patients, Hgb levels were normal at the time of the event.",
            "No patient in G1 developed a thrombotic event.",
            "There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.",
            "The decision to terminate the trial was made after considerable deliberation.",
            "The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.",
            "This may relate to the administration of r-HuEPO in this high-risk population, but the small sample size and possible predisposing risk factors preclude definitive conclusions."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Claim"
        ]
    },
    "23820680": {
        "sentences": [
            "Comparison of the health-related quality of life in patients with narrow gastric tube and whole stomach reconstruction after oncologic esophagectomy: a prospective randomized study.",
            " To compare the health-related quality of life in patients with narrow gastric tube and whole stomach reconstructions after oncologic esophagectomy.",
            "In a prospective randomized single-center study from 2007 to 2008, 104 patients underwent esophagectomy for cancer.",
            "To assess health-related quality of life, the questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the Oesophagus-Specific Quality of Life Questionnaire 18) was administered at 3 weeks, 6 months, 1 year, and 2 years after surgery.",
            "The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).",
            "At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem.",
            "At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group; meanwhile, the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function.",
            "Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery, which suggested that patients in whole stomach group suffered more severe nausea and vomiting.",
            "Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "8648360": {
        "sentences": [
            "Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study.",
            " To investigate the effects of medroxyprogesterone acetate (MPA) on appetite, weight, and quality of life (QL) in patients with advanced-stage, incurable, non-hormone-sensitive cancer.",
            "Two hundred six eligible patients were randomized between double-blind MPA 500 mg twice daily or placebo.",
            "Appetite (0 to 10 numerical rating scale), weight, and QL (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ-C30]) were assessed before the start of treatment (t = 0), and 6 weeks (t = 6) and 12 weeks (t = 12) thereafter.",
            "One hundred thirty-four patients (68 MPA and 66 placebo) were assessable at t = 6 and 99 patients (53 MPA and 46 placebo) at t = 12.",
            "A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.",
            "After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group.",
            "This difference of 2.0 kg was statistically significant (P = .04).",
            "During the study, several areas of QL deteriorated in the total group of patients.",
            "With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated.",
            "The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.",
            "In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss.",
            "However, general QL in the present study was not measurably influenced by MPA treatment."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20821047": {
        "sentences": [
            "Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.",
            " Previous studies have demonstrated that both anastrozole and letrozole are well tolerated.",
            "Letrozole suppresses estrogen to a greater degree than anastrozole in the serum and breast tumor.",
            "Concerns have been raised that greater potency may adversely affect patients' quality of life (QOL).",
            "One hundred eighty-one postmenopausal women with invasive estrogen receptor-positive breast cancers were randomized to receive either 12\u00a0weeks of letrozole followed by 12\u00a0weeks of anastrozole or the reverse sequence.",
            "One hundred and six received immediate adjuvant aromatase inhibitors (AIs) following surgery, and 75 received extended adjuvant therapy.",
            "The Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-B-ES) QOL questionnaires were completed to assess QOL on each drug.",
            "Additional side-effect profiles were collected.",
            "Each patient completed a patient preference form.",
            "Twenty-one patients withdrew before study end, 10/179 (5.6%) while taking letrozole and 4/173 (2.3%) while taking anastrozole (P\u00a0=\u00a00.12).",
            "Tamoxifen-na\u00efve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P\u00a0=\u00a00.001).",
            "There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.",
            "Nearly 80% of patients reported one or more side effects with either agent.",
            "No differences in frequency, grade, or range of side effects were seen between drugs.",
            "Of 160 patients, 49 (30.6%) preferred letrozole, 57 (35.6%) preferred anastrozole, and 54 (33.8%) had no preference (P\u00a0=\u00a00.26, Pearson's Chi-squared test).",
            "In conclusion, both AIs are equally well tolerated.",
            "There were no significant differences in QOL scores between the two drugs."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim"
        ]
    },
    "16571129": {
        "sentences": [
            "A pilot, prospective evaluation of a novel alternative for maintenance therapy of breast cancer-associated lymphedema [ISRCTN76522412].",
            " Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.",
            "However, CDPT demands substantial time and effort from patients to maintain these benefits; the treatments are not always well-accepted, and patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.",
            "A new device designed for home use by the patient, the Flexitouch, has been developed to mechanically simulate MLD.",
            "We have undertaken a prospective, randomized, crossover study of the efficacy of the Flexitouch, when compared to massage, in the self-administered maintenance therapy of lymphedema.",
            "A prospective, randomized, crossover study of maintenance therapy was performed in 10 patients with unilateral breast cancer-associated lymphedema of the arm.",
            "Each observation phase included self-administered treatment with the Flexitouch or massage, 1 hour daily for 14 days, respectively, followed by crossover to the alternate treatment phase.",
            "Each treatment phase was preceded by a 1 week treatment washout, with use of garment only.",
            "The sequence of treatment was randomly assigned.",
            "The potential impact of treatment modality on quality of life was assessed with serial administration of the SF-36.",
            "Statistical analysis disclosed that the order of treatment had no outcome influence, permitting 10 comparisons within each treatment group.",
            "Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.",
            "The patients' mean weight decreased significantly with Flexitouch use, but not with massage.",
            "The Flexitouch device was apparently well-tolerated and accepted by patients.",
            "Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements; there were no statistical differences in scores when the two treatment modalities were compared.",
            "This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.",
            "The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted."
        ],
        "labels": [
            null,
            "Claim",
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "24151326": {
        "sentences": [
            "Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial.",
            " Exercise improves physical functioning and symptom management during breast cancer chemotherapy, but the effects of different doses and types of exercise are unknown.",
            "A multicenter trial in Canada randomized 301 breast cancer patients to thrice-weekly supervised exercise during chemotherapy consisting of either a standard dose of 25 to 30 minutes of aerobic exercise (STAN; n = 96), a higher dose of 50 to 60 minutes of aerobic exercise (HIGH; n = 101), or a combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB; n = 104).",
            "The primary endpoint was physical functioning assessed by the Medical Outcomes Survey-Short Form (SF)-36.",
            "Secondary endpoints were other physical functioning scales, symptoms, fitness, and chemotherapy completion.",
            "All statistical tests were linear mixed model analyses, and the P values were two-sided.",
            "Follow-up assessment of patient-reported outcomes was 99.0%.",
            "Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.",
            "In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02).",
            "COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.",
            "HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).",
            "No differences emerged for body composition or chemotherapy completion.",
            "A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "23771714": {
        "sentences": [
            "Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.",
            " Capecitabine/taxane combinations are highly active in metastatic breast cancer (MBC).",
            "We conducted a randomized, phase III, noninferiority trial comparing capecitabine plus paclitaxel (XP) with epirubicin plus paclitaxel (EP) as first-line therapy for MBC, regarding progression-free survival (PFS) as primary efficacy endpoint.",
            "Females who had received no prior chemotherapy for MBC were randomized to six 3-weekly cycles of XP (capecitabine 1000\u00a0mg/m(2) b.i.d., days 1-14; paclitaxel 175\u00a0mg/m(2) 3-h infusion, day 1) or EP (epirubicin 60\u00a0mg/m(2) 1-h infusion, day 1; paclitaxel as above).",
            "Secondary endpoints included response rate, overall survival, tolerability, and quality of life (QoL).",
            "Each arm included 170 patients, most of whom received all six cycles as planned.",
            "The difference in means of (logarithmic) PFS times (-0.205) did not meet the pre-defined level for noninferiority (-0.186).",
            "However, PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95\u00a0% CI 0.785-1.304); median 10.4\u00a0months XP vs. 9.2\u00a0months EP].",
            "Overall survival was also similar [HR 1.027 (95\u00a0% CI 0.740-1.424); median 22.0 vs. 26.1\u00a0months], and response rate was 47\u00a0% versus 42\u00a0%.",
            "Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.",
            "There were no major differences in QoL.",
            "Although, noninferiority of XP to EP was formally not proven, first-line XP was active and feasible.",
            "XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "16446330": {
        "sentences": [
            "Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.",
            " The objective of this study was to compare the quality of life (QoL) of ovarian cancer patients treated with paclitaxel/carboplatin (TC) versus paclitaxel/cisplatin (PT) and to determine the impact of treatment toxicity on the various QoL domains.",
            "In this phase III trial, 798 patients with ovarian cancer stages IIB-IV were randomly assigned to receive TC or PT.",
            "The primary end point was progression-free survival; secondary end points included toxicity, QoL, and response to treatment.",
            "Patients completed the European Organisation for Research and Treatment of Cancer QLQ-C30 before treatment, within 3 days before the second and the fourth chemotherapy cycle, and 3 weeks after completion of chemotherapy.",
            "Previously reported data showed that patients undergoing TC or PT did not differ in progression-free survival and overall survival.",
            "However, the TC arm was superior, indicating a better overall QoL compared with the PT arm.",
            "Controlling for toxicity and age, a significant treatment by assessment time interaction was found for four QoL functioning scales and three symptoms scales.",
            "Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm.",
            "Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT.",
            "The TC regimen achieved better QoL outcomes compared with the PT regimen.",
            "Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "24127364": {
        "sentences": [
            "Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.",
            " The CO.20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo).",
            "Quality of life (QoL) was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 at baseline and at 2, 4, 6, 8, 12, 16, and 24 weeks until disease progression.",
            "Predefined coprimary QoL endpoints were time to deterioration (first worsening from baseline of \u2265 10 points) on the Physical Function (PF) and Global (GHS) scales.",
            "Of 750 randomized patients, 721 (358 of whom received CET/BRIV) were assessable for QoL.",
            "QoL compliance and baseline PF and GHS scores did not differ by treatment arm.",
            "The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.",
            "Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales.",
            "A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).",
            "Clinical adverse events of \u2265 grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia.",
            "Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30.",
            "This result may be due to higher rates of fatigue and gastrointestinal adverse events."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20600809": {
        "sentences": [
            "Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.",
            " Patients receiving chemoradiation for cervical cancer are at risk for distress, chemoradiation-related side-effects, and immunosuppression.",
            "This prospective randomized clinical trial examined effects of a complementary therapy, Healing Touch (HT), versus relaxation training (RT) and usual care (UC) for (1) supporting cellular immunity, (2) improving mood and quality of life (QOL), and (3) reducing treatment-associated toxicities and treatment delay in cervical cancer patients receiving chemoradiation.",
            "Sixty women with stages IB1 to IVA cervical cancer were randomly assigned to receive UC or 4 \u00d7/weekly individual sessions of either HT or RT immediately following radiation during their 6-week chemoradiation treatment.",
            "Patients completed psychosocial assessments and blood sampling before chemoradiation at baseline, weeks 4 and 6.",
            "Multilevel regression analyses using orthogonal contrasts tested for differences between treatment conditions over time.",
            "HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018).",
            "HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05).",
            "No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities.",
            "HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity.",
            "Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed.",
            "Long-term clinical implications of findings are not known."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            null
        ]
    },
    "15288288": {
        "sentences": [
            "Quality of life after palliative treatment for oesophageal carcinoma -- a prospective comparison between stent placement and single dose brachytherapy.",
            " Metal stent placement and single dose brachytherapy are commonly used treatment modalities for the palliation of inoperable oesophageal carcinoma.",
            "We investigated generic and disease-specific health-related quality of life (HRQoL) after these palliative treatments.",
            "Patients with dysphagia from inoperable oesophageal carcinoma were randomised to placement of a covered Ultraflex stent (n = 108) or single dose (12 Gy) brachytherapy (n = 101).",
            "We obtained longitudinal data on disease-specific (dysphagia score, European Organisation for Research and Treatment of Cancer (EORTC) OES-23, visual analogue pain scale) and generic (EORTC Quality of Life-Core 30 Questionnaire (QLQ-C30), Euroqol (EQ)-5D) HRQoL at monthly home visits by a specially-trained research nurse.",
            "We compared HRQoL between the two treatments and analysed changes in HRQoL during follow-up.",
            "Dysphagia improved more rapidly after stent placement than after brachytherapy, but long-term relief of dysphagia was better after brachytherapy.",
            "For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).",
            "Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).",
            "This decline was more pronounced in the stent group.",
            "Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.",
            "Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups, general pain levels increased to a minor extent.",
            "The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.",
            "Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales, since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence"
        ]
    },
    "21905158": {
        "sentences": [
            "Home-based physical activity intervention for colorectal cancer survivors.",
            " The efficacy of a home-based physical activity (PA) intervention for colorectal cancer patients versus contact control was evaluated in a randomized controlled trial.",
            "Forty-six patients (mean age = 57.3 years [SD = 9.7], 57% female, mean = 2.99 years post-diagnosis [SD = 1.64]) who had completed treatment for stages 1-3 colorectal cancer were randomized to telephone counseling to support PA (PA group, n = 20) or contact control (control group, n = 26).",
            "PA group participants received 3 months of PA counseling (based on the transtheoretical model and the social cognitive theory) delivered via telephone, as well as weekly PA tip sheets.",
            "Assessments of PA (Seven-day Physical Activity Recall [7-day PAR] and Community Healthy Activities Model Program for Seniors [CHAMPS]), submaximal aerobic fitness (Treadwalk test), motivational readiness for PA, and psychosocial outcomes were conducted at baseline, 3, 6, and 12 months post-baseline.",
            "Objective accelerometer data were collected at the same time points.",
            "The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group, but the group differences were attenuated over time.",
            "The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group.",
            "Improvements in motivational readiness for PA were reported in the PA group only at 3 months.",
            "No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months.",
            "A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "20733132": {
        "sentences": [
            "Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.",
            " One attempt to improve long-term survival in patients with advanced ovarian cancer was thought to be the addition of more non-cross-resistant drugs to platinum-paclitaxel combination regimens.",
            "Gemcitabine was among the candidates for a third drug.",
            "We performed a prospective, randomized, phase III, intergroup trial to compare carboplatin plus paclitaxel (TC; area under the curve [AUC] 5 and 175 mg/m(2), respectively) with the same combination and additional gemcitabine 800 mg/m(2) on days 1 and 8 (TCG) in previously untreated patients with advanced epithelial ovarian cancer.",
            "TC was administered intravenously (IV) on day 1 every 21 days for a planned minimum of six courses.",
            "Gemcitabine was administered by IV on days 1 and 8 of each cycle in the TCG arm.",
            "Between 2002 and 2004, 1,742 patients were randomly assigned; 882 and 860 patients received TC and TCG, respectively.",
            "Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.",
            "Accordingly, quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.",
            "Although objective response was slightly higher in the TCG arm, this did not translate into improved progression-free survival (PFS) or overall survival (OS).",
            "Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044).",
            "Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106).",
            "The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer.",
            "Therefore, we recommend no additional clinical use of TCG in this population."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "18448745": {
        "sentences": [
            "CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial.",
            " To evaluate whether 3-month administration of CDB-2914, a selective progesterone receptor modulator, reduces leiomyoma size and symptoms.",
            "Premenopausal women with symptomatic uterine leiomyomata were randomly assigned to CDB-2914 at 10 mg (T1) or 20 mg (T2) daily or to placebo (PLC) for 3 cycles or 90-102 days if no menses occurred.",
            "The primary outcome was leiomyoma volume change determined by magnetic resonance imaging at study entry and within 2 weeks of hysterectomy.",
            "Secondary outcomes included the proportion of amenorrhea, change in hemoglobin and hematocrit, ovulation inhibition, and quality-of-life assessment.",
            "Twenty-two patients were allocated, and 18 completed the trial.",
            "Age and body mass index were similar among groups.",
            "Leiomyoma volume was significantly reduced with CDB-2914 administration (PLC 6%; CDB-2914 -29%; P=.01), decreasing 36% and 21% in the T1 and T2 groups, respectively.",
            "During treatment, hemoglobin was unchanged, and the median estradiol was greater than 50 pg/mL in all groups.",
            "CDB-2914 eliminated menstrual bleeding and inhibited ovulation (% ovulatory cycles: CDB-2914, 20%; PLC, 83%; P=.001).",
            "CDB-2914 improved the concern scores of the uterine leiomyoma symptom quality-of-life subscale (P=.04).",
            "One CDB-2914 woman developed endometrial cystic hyperplasia without evidence of atypia.",
            "No serious adverse events were reported.",
            "Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days.",
            "CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment.",
            "In this small study, CDB-2914 was well-tolerated without serious adverse events.",
            "Thus, there may be a role for CDB-2914 in the treatment of leiomyomata."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20697941": {
        "sentences": [
            "Alleviation of cancerous pain by external compress with Xiaozheng Zhitong Paste.",
            " To observe the clinical effectiveness of a topical application of Xiaozheng Zhitong: Paste (, XZP) in alleviating the cancerous pain of patients with middle/late stage cancer By: adopting a random number table, 124 patients enrolled were randomized into the treatment group (64 patients) and the control group (60 patients).",
            "In addition to the basic therapy [including the three-ladder (3L) analgesia] used in both groups, topical application of XZP was given to patients in the treatment group for pain alleviation.",
            "The analgesic efficacy was recorded in terms of pain intensity, analgesia initiating time and sustaining time, and the optimal analgesic effect revealing time.",
            "Meanwhile, the quality of life (QOL) and adverse reactions that occurred in patients were recorded as well.",
            "The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05), but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).",
            "Moreover, XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).",
            "Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).",
            "Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "17852440": {
        "sentences": [
            "Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.",
            " Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).",
            "Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).",
            "To demonstrate the effectiveness of once-weekly (QW) rHuEPO dosing to effect improved hemoglobin levels, decreased transfusion use, and improved functional outcomes and QOL in pediatric leukemic patients (ALL) receiving maintenance chemotherapy.",
            "This was a prospective randomized, single-center, open-label, 12-week case-control study of epoetin alfa in pediatric patients with acute lymphoblastic leukemia (ALL) in remission receiving maintenance chemotherapy.",
            "Sixty patients were randomly assigned to receive either epoetin alfa (rHuEPO group = 30 cases, 17 males and 13 females, age; 6.8 +/- 2.33 years), or no epoetin alfa (control group = 30 cases, 16 males and 14 females, age; 6.76 +/- 2.28 years).",
            "Both groups were matched as regard age, sex, baseline Hb concentration, remission state, chemotherapy regimen, numbers and amount of blood transfusion, and leukemia state (both were low and standard risk).",
            "Epoetin alfa was administered at a dose of 450 IU/kg, once weekly, subcutaneously (s.c.) for 12 consecutive weeks.",
            "Endpoints were changes in hematologic and QOL parameters.",
            "Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).",
            "An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.",
            "The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).",
            "In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.",
            "QW epoetin-alpha was found to be well tolerated.",
            "Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.",
            "The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
        ],
        "labels": [
            null,
            "Claim",
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20651011": {
        "sentences": [
            "Cancer-related fatigue and rehabilitation: a randomized controlled multicenter trial comparing physical training combined with cognitive-behavioral therapy with physical training only and with no intervention.",
            " Research suggests that cancer rehabilitation reduces fatigue in survivors of cancer.",
            "To date, it is unclear what type of rehabilitation is most beneficial.",
            "This randomized controlled trial compared the effect on cancer-related fatigue of physical training combined with cognitive behavioral therapy with physical training alone and with no intervention.",
            "In this multicenter randomized controlled trial, 147 survivors of cancer were randomly assigned to a group that received physical training combined with cognitive-behavioral therapy (PT+CBT group, n=76) or to a group that received physical training alone (PT group, n=71).",
            "In addition, a nonintervention control group (WLC group) consisting of 62 survivors of cancer who were on the waiting lists of rehabilitation centers elsewhere was included.",
            "The study was conducted at 4 rehabilitation centers in the Netherlands.",
            "All patients were survivors of cancer.",
            "Physical training consisting of 2 hours of individual training and group sports took place twice weekly, and cognitive-behavioral therapy took place once weekly for 2 hours.",
            "Fatigue was assessed with the Multidimensional Fatigue Inventory before and immediately after intervention (12 weeks after enrollment).",
            "The WLC group completed questionnaires at the same time points.",
            "Baseline fatigue did not differ significantly among the 3 groups.",
            "Over time, levels of fatigue significantly decreased in all domains in all groups, except in mental fatigue in the WLC group.",
            "Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation.",
            "Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only.",
            "No significant differences in decline in fatigue were found between the PT+CBT and PT groups.",
            "Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.",
            "Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue, suggesting that cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "24246508": {
        "sentences": [
            "Short and long-term effects of supervised versus unsupervised exercise training on health-related quality of life and functional outcomes following lung cancer surgery - a randomized controlled trial.",
            " Surgical resection enhances long-term survival after lung cancer, but survivors face functional deficits and report on poor quality of life long time after surgery.",
            "This study evaluated short and long-term effects of supervised group exercise training on health-related quality of life and physical performance in patients, who were radically operated for lung cancer.",
            "A randomized, assessor-blinded, controlled trial was performed on 78 patients undergoing lung cancer surgery.",
            "The intervention group (IG, n=41) participated in supervised out-patient exercise training sessions, one hour once a week for ten weeks.",
            "The sessions were based on aerobic exercises with target intensity of 60-80% of work capacity, resistance training and dyspnoea management.",
            "The control group (CG, n=37) received one individual instruction in exercise training.",
            "Measurements consisted of: health-related quality of life (SF36), six minute walk test (6MWT) and lung function (spirometry), assessed three weeks after surgery and after four and twelve months.",
            "Both groups were comparable at baseline on demographic characteristic and outcome values.",
            "We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).",
            "At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.",
            "We found no effect of the intervention on 6MWT or lung volumes at any time-point.",
            "Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life, except for the bodily pain domain, four months after lung cancer surgery.",
            "No effects of the intervention were found for any outcome after one year."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "24007947": {
        "sentences": [
            "Epidural analgesia is associated with an increased incidence of postoperative complications in patients requiring an abdominal hysterectomy for early stage endometrial cancer.",
            " Analgesia and early quality of recovery may be improved by epidural analgesia.",
            "We aimed to assess the effect of receiving epidural analgesia on surgical adverse events and quality of life after laparotomy for endometrial cancer.",
            "Patients were enrolled in an international, multicentre, prospective randomised trial of outcomes for laparoscopic versus open surgical treatment for the management of apparent stage I endometrial cancer (LACE trial).",
            "The current analysis focussed on patients who received an open abdominal hysterectomy via vertical midline incision only (n=257), examining outcomes in patients who did (n=108) and did not (n=149) receive epidural analgesia.",
            "Baseline characteristics were comparable between patients with or without epidural analgesia.",
            "More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).",
            "Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01) but there was no difference in serious adverse events (p=0.19).",
            "Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).",
            "There was no difference in postoperative quality of life up to six months after surgery.",
            "Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy.",
            "Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events, especially as the present data do not support a quality of life benefit with epidural analgesia."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            null,
            "Claim"
        ]
    },
    "17674351": {
        "sentences": [
            "A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.",
            " Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.",
            "The current study was designed to determine whether etanercept (a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75-kilodalton TNF receptor linked to the Fc portion of human immunoglobulin [Ig] G1) could palliate this syndrome.",
            "A total of 63 evaluable patients were randomly assigned to receive either etanercept at a dose of 25 mg subcutaneously twice weekly versus a comparably administered placebo.",
            "All patients had an incurable malignancy, acknowledged loss of weight and/or appetite as a concern, and reported a weight loss of >2.27 kg over 2 months and/or a daily intake of <20 calories/kg body weight.",
            "Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.",
            "Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.",
            "The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).",
            "Finally, preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).",
            "Infection rates were negligible in both groups.",
            "Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.",
            "Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "15226325": {
        "sentences": [
            "Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.",
            " To compare health-related quality of life (HRQOL) in patients with metastatic breast cancer receiving the combination of doxorubicin and paclitaxel (AT) or doxorubicin and cyclophosphamide (AC) as first-line chemotherapy treatment.",
            "Eligible patients (n = 275) with anthracycline-naive measurable metastatic breast cancer were randomly assigned to AT (doxorubicin 60 mg/m(2) as an intravenous bolus plus paclitaxel 175 mg/m(2) as a 3-hour infusion) or AC (doxorubicin 60 mg/m(2) plus cyclophosphamide 600 mg/m(2)) every 3 weeks for a maximum of six cycles.",
            "Dose escalation of paclitaxel (200 mg/m(2)) and cyclophosphamide (750 mg/m(2)) was planned at cycle 2 to reach equivalent myelosuppression in the two groups.",
            "HRQOL was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 and the EORTC Breast Module at baseline and the start of cycles 2, 4, and 6, and 3 months after the last cycle.",
            "Seventy-nine percent of the patients (n = 219) completed a baseline measure.",
            "However, there were no statistically significant differences in HRQOL between the two treatment groups.",
            "In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue, although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time.",
            "Overall, global quality of life was maintained in both treatment groups.",
            "This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "10210927": {
        "sentences": [
            "[Octreotide in the treatment of advanced pancreatic tumor. Preliminary study].",
            " Data from experimental studies suggest that octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer.",
            "To assess the antitumour effect of octreotide, a randomized trial was performed comparing octreotide with supportive care in advanced pancreatic cancer patients.",
            "All patients, aged 59-75 years, were not liable to radical surgical treatment and were not submitted to other treatments (chemo and/or radiotherapy).",
            "Six patients were enrolled, 4 of these treated with octreotide (500 micrograms two times a day subcutaneous for six months) and the other 2 were inserted a control group.",
            "The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score.",
            "Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients, whereas neoplasm grew according to an almost exponential trend in untreated patients.",
            "Also survival was better in treated patients: in particular, 2 patients out of 4 who completed the study underwent follow-up until they died 12 and 16 months after beginning of treatment, respectively.",
            "Karnofsky performance score was particularly high in both patients.",
            "This supports the view that octreotide is endowed with antiproliferative activity.",
            "In conclusion octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.",
            "Additional studies are needed to confirm these results and to clarify other questions about dose and somatostatin receptors in this kind of tumour."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            null
        ]
    },
    "24038913": {
        "sentences": [
            "Long-term survival of children less than six years of age enrolled on the CCG-945 phase III trial for newly-diagnosed high-grade glioma: a report from the Children's Oncology Group.",
            " We analyzed the long-term survival of children under 6 years of age (<6 years) enrolled upon the Children's Cancer Group (CCG)-945 high-grade glioma (HGG) study to determine the impact of intrinsic biological characteristics as well as treatment upon both survival and quality of life (QOL) in this younger age population.",
            "Analyses were undertaken on patients <6 years with institutionally diagnosed HGG enrolled on the CCG-945 trial.",
            "Comparisons of survival were performed for patients <3 years of age (<3 years) (treated with intent to avoid irradiation) versus those between 3 and 6 years of age (3-6 years) (treated with irradiation and chemotherapy) at diagnosis.",
            "Discordance between the institutional diagnoses of HGG and consensus-reviewed diagnoses led us to perform further survival analyses for both groups.",
            "We compared the two groups of patients for biological markers, and evaluated the neuropsychological and QOL outcomes of long-term survivors.",
            "Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29 \u00b1 6.5% and 37.5 \u00b1 7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35 \u00b1 8% and 36 \u00b1 8%, respectively.",
            "Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05).",
            "Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results.",
            "QOL and survival data were similar for the two groups.",
            "A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "15284262": {
        "sentences": [
            "Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.",
            " To determine whether cisplatin plus paclitaxel (C+P) improved response rate, progression-free survival (PFS), or survival compared with cisplatin alone in patients with stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix.",
            "PATIENTS AND METHODS Eligible: patients with measurable disease, performance status (PS) 0 to 2, and adequate hematologic, hepatic, and renal function received either cisplatin 50 mg/m2 or C+P (cisplatin 50 mg/m2 plus paclitaxel 135 mg/m2) every 3 weeks for six cycles.",
            "Tumor measurements and quality-of-life (QOL) assessments were obtained before each treatment cycle.",
            "Of 280 patients entered, 6% were ineligible.",
            "Among 264 eligible patients, 134 received cisplatin and 130 received C+P.",
            "Groups were well matched with respect to age, ethnicity, PS, tumor grade, disease site, and number of cycles received.",
            "The majority of all patients had prior radiation therapy (cisplatin, 92%; C+P, 91%).",
            "Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).",
            "The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001).",
            "There was no difference in median survival (8.8 months v 9.7 months).",
            "Grade 3 to 4 anemia and neutropenia were more common in the combination arm.",
            "There was no significant difference in QOL scores, although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death.",
            "C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "18589314": {
        "sentences": [
            "Economic evaluation of uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: results from the randomized EMMY trial.",
            " To investigate whether uterine artery embolization (UAE) is a cost-effective alternative to hysterectomy for patients with symptomatic uterine fibroids, the authors performed an economic evaluation alongside the multicenter randomized EMMY (EMbolization versus hysterectoMY) trial.",
            "Between February 2002 and February 2004, 177 patients were randomized to undergo UAE (n = 88) or hysterectomy (n = 89) and followed up until 24 months after initial treatment allocation.",
            "Conditional on the equivalence of clinical outcome, a cost minimization analysis was performed according to the intention to treat principle.",
            "Costs included health care costs inside and outside the hospital as well as costs related to absence from work (societal perspective).",
            "Cumulative standardized costs were estimated as volumes multiplied with prices.",
            "The nonparametric bootstrap method was used to quantify differences in mean (95% confidence interval [CI]) costs between the strategies.",
            "In total, 81 patients underwent UAE and 75 underwent hysterectomy.",
            "In the UAE group, 19 patients (23%) underwent secondary hysterectomies.",
            "The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281).",
            "The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586).",
            "Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy).",
            "The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107).",
            "The costs of absence from work accounted for 79% of the difference in total costs.",
            "The 24-month cumulative cost of UAE is lower than that of hysterectomy.",
            "From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Claim"
        ]
    },
    "16505413": {
        "sentences": [
            "Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).",
            " Hepatic metastases derive most of their blood supply from the hepatic artery; therefore, for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.",
            "In a multi-institutional trial, 135 patients were randomly assigned to receive HAI versus systemic bolus fluorouracil and leucovorin.",
            "The primary end point was survival; secondary end points were response, recurrence, toxicity, quality of life, cost, and the influence of molecular markers.",
            "Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034).",
            "Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.",
            "Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.",
            "Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively.",
            "A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05).",
            "For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17).",
            "HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy.",
            "Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20679600": {
        "sentences": [
            "Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32.",
            " Sentinel lymph node resection (SNR) may reduce morbidity while providing the same clinical utility as conventional axillary dissection (AD).",
            "National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 is a randomized phase III trial comparing SNR immediately followed by AD (SNAD) to SNR and subsequent AD if SN is positive.",
            "We report the definitive patient-reported outcomes (PRO) comparisons.",
            "Eligible patients had clinically node-negative, operable invasive breast cancer.",
            "The PRO substudy included all SN-negative participants enrolled May 2001 to February 2004 at community institutions in the United States (n = 749; 78% age > or = 50; 87% clinical tumor size < or = 2.0 cm; 84% lumpectomy; 87% white).",
            "They completed questionnaires presurgery, 1 and 2 to 3 weeks postoperatively, and every 6 months through year 3.",
            "Arm symptoms, arm use avoidance, activity limitations, and quality of life (QOL) were compared with intent-to-treat two-sample t-tests and repeated measures analyses.",
            "Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006).",
            "Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items).",
            "From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation.",
            "Arm morbidity was greater with SNAD than with SNR.",
            "Despite considerable fears about complications from AD for breast cancer, this study demonstrates that initial problems with either surgery resolve over time."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "10403690": {
        "sentences": [
            "Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy.",
            " In a prospective randomized study, 287 patients with advanced non-small cell lung cancer (NSCLC) stage IIIb or IV with ECOG performance status (PS) 0-1 or 2 were randomly assigned to receive either best supportive care (BSC) or supportive care plus combination chemotherapy (IEP regimen: ifosfamide 3 gm/m2 IV with mesna uroprotection, epirubicin 60 mg/m2 IV on day 1 and cisplatin 60 mg/m2 IV on day 2; or MVP regimen: mitomycin-C 8 mg/m2, cisplatin 100 mg/m2 IV on day 1, vinblastine 4 mg/m2 IV on days 1 and 15).",
            "Serial assessment of Karnofsky performance status (KPS), modified Functional Living Index-Cancer (T-FLIC) and modified Quality of Life-Index (T-QLI) were used to estimate the quality of life.",
            "Interviews were done at entry, at the third month and at 2 months post complete treatment.",
            "At least two courses of chemotherapy were considered to be adequate for response evaluation.",
            "Patients were treated for a total of four to six courses or until progression of disease.",
            "Partial response rates were 40 and 41.7% in IEP and MVP arms.",
            "Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003).",
            "One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively.",
            "Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively.",
            "Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm.",
            "We conclude that combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "23814044": {
        "sentences": [
            "Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.",
            " This study aims to describe and compare health-related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast cancer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-based regimens alone.",
            "Eligible patients (n = 3,222) were randomly assigned to either four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC\u2192T) or one of two trastuzumab-containing regimens: adjuvant doxorubicin and cyclophosphamide followed by docetaxel plus trastuzumab administered for 1 year (AC\u2192TH) or six cycles of docetaxel plus carboplatin combined with trastuzumab administered for 1 year (TCH).",
            "The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 and BR-23 were administered at baseline, the start of cycle 4 (mid), and the end of chemotherapy (EOC), as well as at 6, 12, and 24 months after chemotherapy.",
            "Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment.",
            "Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC\u2192TH and AC\u2192T at EOC, suggesting improved tolerability.",
            "Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC\u2192TH regimen, but was otherwise similar between arms.",
            "All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up.",
            "HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "23816967": {
        "sentences": [
            "Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.",
            " Patient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed.",
            "Three hundred forty-five patients with advanced epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma were randomly assigned 2:1 to afatinib 40 mg per day or up to six cycles of cisplatin/pemetrexed.",
            "Lung cancer symptoms and health-related QoL were assessed every 21 days until progression using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and Lung Cancer-13 questionnaires.",
            "Analyses of cough, dyspnea, and pain were preplanned, including percentage of patients who improved on therapy, time to deterioration of symptoms, and change in symptoms over time.",
            "Questionnaire compliance was high.",
            "Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19).",
            "More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).",
            "Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).",
            "Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy.",
            "Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01).",
            "In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse.",
            "Global health status/QoL was also improved over time with afatinib compared with chemotherapy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "18485819": {
        "sentences": [
            "Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study.",
            " Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.",
            "Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.",
            "We did a pilot study to investigate our hypothesis that stellate-ganglion block can be a safe and effective treatment for hot flushes and sleep dysfunction in this patient population.",
            "13 survivors of breast cancer (in remission) with severe hot flushes and night awakenings were treated with stellate-ganglion block at the anterolateral aspect of the C6 vertebra on the right side under fluoroscopy.",
            "Patients recorded hot flushes in a daily diary by use of the Hot-Flash Score, devised by Sloan and colleagues, and night awakenings by use of the Pittsburgh Sleep Quality Index.",
            "Both instruments were used 1 week before the procedure [A40] and then weekly after the procedure for 12 weeks.",
            "We used the generalised-estimating-equations method to analyse the longitudinal measurements of the number of hot flushes and night awakenings over time.",
            "This method is a popular approach to analysing datasets that have repeated measures from the same person, and is robust because it does not need the complete distribution of the outcomes to be specified.",
            "This trial is registered on the International Standard Randomised Controlled Trial Number register (ISRCTN14318565).",
            "There were no adverse events resulting from the stellate-ganglion block, although patients had temporary Horner's syndrome indicating the effectiveness of the block.",
            "Five patients had only one stellate-ganglion block and eight had two stellate-ganglion blocks.",
            "The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).",
            "The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).",
            "The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).",
            "Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).",
            "The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).",
            "The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.",
            "Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "16524633": {
        "sentences": [
            "The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires.",
            " Morbidity is an important issue in cancer research.",
            "The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study, but like other toxicity scoring systems it has not been formally validated.",
            "Conversely, the EORTC quality of life questionnaire (QLQ) has been validated as a tool for collecting information about the consequences of disease and treatment on the well being of cancer patients.",
            "The purpose of this study was to examine the relationship between the two methods of side effect recording.",
            "One hundred and sixteen recurrence free patients with laryngeal (n=44), pharyngeal (n=34) and oral cavity (n=38) cancer attending follow-up after radiotherapy (n=83) or surgery (n=33) completed EORTC C30, the core questionnaire concerning general symptoms and function and EORTC H&amp;N35 the head and neck specific questionnaire.",
            "The attending physicians in the follow-up clinic evaluated and recorded DAHANCA toxicity scores on the same patients.",
            "The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.",
            "The conceptually similar endpoints of the two methods correlated significantly.",
            "The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.",
            "The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.",
            "A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.",
            "The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.",
            "This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
        ],
        "labels": [
            null,
            null,
            "Claim",
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "23768153": {
        "sentences": [
            "Case management vocational rehabilitation for women with breast cancer after surgery: a feasibility study incorporating a pilot randomised controlled trial.",
            " There is a paucity of methodologically robust vocational rehabilitation (VR) intervention trials.",
            "This study assessed the feasibility and acceptability of a VR trial of women with breast cancer to inform the development of a larger interventional study.",
            "Women were recruited in Scotland and randomised to either a case management VR service or to usual care.",
            "Data were collected on eligibility, recruitment and attrition rates to assess trial feasibility, and interviews conducted to determine trial acceptability.",
            "Sick leave days (primary outcome) were self-reported via postal questionnaire every 4 weeks during the first 6 months post-surgery and at 12 months.",
            "Secondary outcome measures were change in employment pattern, quality of life and fatigue.",
            "Of the 1,114 women assessed for eligibility, 163 (15%) were eligible.",
            "The main reason for ineligibility was age (>65 years, n = 637, 67%).",
            "Of those eligible, 111 (68%) received study information, of which 23 (21%) consented to participate in the study.",
            "Data for 18 (78%) women were analysed (intervention: n = 7; control: n = 11).",
            "Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group; however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).",
            "No statistically significant differences were found for secondary outcomes.",
            "Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.",
            "Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable, but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.",
            "VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "17848814": {
        "sentences": [
            "Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue.",
            " Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.",
            "The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.",
            "In a randomized controlled study the effects of a structured physical training program on fatigue and health-related quality of life were evaluated.",
            "63 breast cancer patients with cancer-related chronic fatigue were randomized at the beginning of the inpatient rehabilitation.",
            "The control group received the standard complex rehabilitation program, the intervention group a structured physical training program and additional muscle strength and aerobic exercises.",
            "The effects of the treatment were evaluated by questionnaires at the start of rehabilitation (t1), end of rehabilitation (t2), and 3 months after t2 (t3).",
            "Isometric muscle strength and aerobic capacity were evaluated at t1 and t2.",
            "There was an improvement of muscle strength at the end of rehabilitation for both groups.",
            "The increase from t1 to t2 was significantly higher for the training group.",
            "The scores for global quality of life, physical well-being, and functionality increased from t1 to t2, but further improvement in the follow-up (t3) was only observed in the training group.",
            "The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group.",
            "Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients."
        ],
        "labels": [
            null,
            "Claim",
            "Evidence",
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "17690882": {
        "sentences": [
            "A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer.",
            " To evaluate if raising baseline and maintaining hemoglobin (Hb) levels with red blood cell (RBC) transfusion could improve the outcomes of chemotherapy for advanced gastric cancer (AGC).",
            "Patients were randomized to receive RBC transfusion to maintain their Hb levels >or=10 g/dl (arm 1) or >or=12 (arm 2) before the start of their 5-fluorouracil-based first-line chemotherapy.",
            "Objective response, KPS and quality of life (QOL) data were measured.",
            "For 87 patients enrolled, mean baseline Hb was 10.1 g/dl, and 54 patients received RBC prior to chemotherapy initiation.",
            "Despite transfusion, we failed to maintain the Hb level above the predefined target range.",
            "Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema.",
            "KPS was improved from baseline to post-chemotherapy in both arms.",
            "QOL data showed improvement in some symptom scores, but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.",
            "Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%).",
            "Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months).",
            "Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.",
            "The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "18591549": {
        "sentences": [
            "Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer.",
            " Persistent insomnia is a common complaint in cancer survivors, but is seldom satisfactorily addressed.",
            "The adaptation to cancer care of a validated, cost-effective intervention may offer a practicable solution.",
            "The aim of this study was to investigate the clinical effectiveness of protocol-driven cognitive behavior therapy (CBT) for insomnia, delivered by oncology nurses.",
            "Randomized, controlled, pragmatic, two-center trial of CBT versus treatment as usual (TAU) in 150 patients (103 females; mean age, 61 years.)",
            "who had completed active therapy for breast, prostate, colorectal, or gynecological cancer.",
            "The study conformed to CONSORT guidelines.",
            "Primary outcomes were sleep diary measures at baseline, post-treatment, and 6-month follow-up.",
            "Actigraphic sleep, health-related quality of life (QOL), psychopathology, and fatigue were secondary measures.",
            "CBT comprised five, small group sessions across consecutive weeks, after a manualized protocol.",
            "TAU represented normal clinical practice; the appropriate control for a clinical effectiveness study.",
            "CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU.",
            "These outcomes were sustained 6 months after treatment.",
            "Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep).",
            "CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue.",
            "There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics.",
            "CBT for insomnia may be both clinically effective and feasible to deliver in real world practice."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12925071": {
        "sentences": [
            "Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.",
            " The standard treatment for patients with clinically resectable rectal cancer is surgery.",
            "Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).",
            "In recent years, encouraging results of pre-operative radiotherapy have been reported.",
            "This prospective randomized phase-III-trial (CAO/ARO/AIO-94) compares the efficacy of neoadjuvant RCT to standard postoperative RCT.",
            "We report on the design of the study and first results with regard to toxicity of RCT and postoperative morbidity.",
            "Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre or postoperative RCT: A total dose of 50.4 Gy (single dose 1.8 Gy) was applied to the tumour and the pelvic lymph nodes.",
            "5-FU (1000 mg/m2/d) was administered concomitantly in the 1th and 5th week of radiation as 120 h-continuous infusion.",
            "Four additional cycles of 5-FU-chemotherapy (500 mg/m2/d, i.v.-bolus) were applied.",
            "RCT was identical in both arms except for a small-volume boost of 5.4 Gy postoperatively.",
            "The time interval between RCT and surgery was 4-6 weeks in both arms.",
            "Techniques of surgery were standardized and included total mesorectal excision.",
            "Primary endpoints of the study are 5-year survival and local and distant control.",
            "Secondary endpoints include the rate of curative (R0) resection and sphincter saving procedures, toxicity of RCT, surgical complications and quality of life.",
            "As of July 2002, 805 patients were randomized from 26 participating institutions.",
            "Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity: The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.",
            "Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.",
            "Postoperative complication rates were similar in both arms, with 12% (postop.",
            "RCT) and 12% (pre-op.",
            "RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop.",
            "RCT) and 3% (pre-op.",
            "RCT) from postoperative bleeding, and 6% (postop.",
            "RCT) and 4% (pre-op.",
            "RCT) from delayed wound healing.",
            "The patient accrual to the trial is satisfactory.",
            "Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity."
        ],
        "labels": [
            null,
            null,
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            null,
            null,
            null,
            null,
            null,
            "Claim",
            "Claim"
        ]
    },
    "23803270": {
        "sentences": [
            "A pilot randomized trial evaluating low-level laser therapy as an alternative treatment to manual lymphatic drainage for breast cancer-related lymphedema.",
            " To examine the impact of advanced practice nurse (APN)-administered low-level laser therapy (LLLT) as both a stand-alone and complementary treatment for arm volume, symptoms, and quality of life (QOL) in women with breast cancer-related lymphedema.",
            "A three-group, pilot, randomized clinical trial.",
            "A private rehabilitation practice in the southeastern United States.",
            "46 breast cancer survivors with treatment-related lymphedema.",
            "Patients were screened for eligibility and then randomized to either manual lymphatic drainage (MLD) for 40 minutes, LLLT for 20 minutes, or 20 minutes of MLD followed by 20 minutes of LLLT.",
            "Compression bandaging was applied after each treatment.",
            "Data were collected pretreatment, daily, weekly, and at the end of treatment.",
            "Independent variables consisted of three types of APN-administered lymphedema treatment.",
            "Outcome variables included limb volume, extracellular fluid, psychological and physical symptoms, and QOL.",
            "No statistically significant between-group differences were found in volume reduction; however, all groups had clinically and statistically significant reduction in volume.",
            "No group differences were noted in psychological and physical symptoms or QOL; however, treatment-related improvements were noted in symptom burden within all groups.",
            "Skin improvement was noted in each group that received LLLT.",
            "LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.",
            "Alternatively, compression bandaging alone could account for the demonstrated volume reduction.",
            "APNs can effectively treat lymphedema.",
            "APNs in private healthcare practices can serve as valuable research collaborators.",
            "Lasers may provide effective, less burdensome treatment for lymphedema.",
            "APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.",
            "In addition, bioelectrical impedance and tape measurements can be used to assess lymphedema."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim",
            null,
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "23735703": {
        "sentences": [
            "A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).",
            " There will be a detectable increase in overall survival (OS) using preoperative (PRE) as opposed to perioperative (PERI) chemotherapy in resectable StageI-II non-small-cell lung cancer (NSCLC).",
            "This multicenter, open-label, randomised trial with a 2\u00d72 factorial design first compared two chemotherapy strategies (PRE versus PERI), then two chemotherapy regimens (gemcitabine-cisplatin [GP] versus paclitaxel-carboplatin [TC]).",
            "The PRE group received two preoperative cycles followed by two additional preoperative cycles, while the PERI group underwent two preoperative cycles followed by two postoperative cycles, the 3rd and 4th cycles being given only to responders in both cases.",
            "A total of 528 patients were randomised, 267 of which were assigned to the PRE group and 261 to the PERI group.",
            "Three-year OS did not differ between the two groups (67.4% and 67.7%, respectively; hazard ratio (HR)=1.01 [0.79-1.30], p=0.92), nor did 3-year disease-free survival, response rates, toxicity, or postoperative mortality.",
            "Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.",
            "Although quality of life did not differ significantly, chemotherapy compliance was significantly higher in the PRE group.",
            "The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001).",
            "In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007).",
            "There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates.",
            "However, the regimens' toxicity profiles differed.",
            "This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.",
            "The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20734132": {
        "sentences": [
            "Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation.",
            " To evaluate the efficacy and economic efficiency of a multimedia, multimodal physical activity program for women undergoing adjuvant therapy following surgery for breast cancer.",
            "We conducted a randomized trial with concurrent incremental cost-effectiveness analysis and blinded baseline, 3, 6 and 12-month follow-up assessments amongst women undergoing adjuvant therapy following surgery for breast cancer (n = 89).",
            "The intervention was a multimedia, multimodal exercise program comprising strength, balance and endurance training elements.",
            "The control was sham flexibility and relaxation program delivered using similar materials.",
            "The primary outcome was health-related quality of life (EQ-5D &amp; VAS, EORTC C30, BR23).",
            "Economic outcomes included direct health care costs and productivity gains and losses.",
            "Participants in the intervention group demonstrated greater improvement in health-related quality of life between baseline and the 3-month assessment [mean (sd) EQ-5D VAS (0-100) baseline: 72.6 (15.6), 3 month: 80.6 (11.6)] when compared to control group participants [baseline: 77.5 (13.5), 3 month: 74.1 (20.6), P = 0.006] and also improved more in terms of physical function [mean (sd) EORTC C30 physical function scale intervention (0-100) baseline: 84.9 (14.8), 3 month: 86.9 (10.7), control baseline: 91.3 (9.6), 3 month: 86.7 (14.9), P = 0.02].",
            "These improvements were not sustained beyond this point.",
            "Upper limb volumes were also lower amongst intervention group participants.",
            "However, there was low probability that the intervention would be both less costly and more effective than the control condition (range probability = 0.05-50.02% depending on approach).",
            "Provision of multimodal exercise programs will improve the short-term health of women undergoing adjuvant therapy for breast cancer but are of questionable economic efficiency."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "9626213": {
        "sentences": [
            "Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.",
            " To compare two cisplatin based chemotherapy schedules in patients with advanced non-small-cell lung cancer (NSCLC).",
            "A total of 332 patients with advanced NSCLC were randomized to receive cisplatin 80 mg/m2 on day 1 either in combination with teniposide 100 mg/m2 on days 1, 3, and 5 (arm A) or paclitaxel 175 mg/m2 by 3-hour infusion on day 1 (arm B); cycles were repeated every 3 weeks.",
            "Fifteen patients were ineligible; patient characteristics were well balanced between the two arms: 71% were male, 71% had less than 5% weight loss, 89% had a World Health Organization (WHO) performance status of 0 to 1, 51% had adenocarcinoma, and 61% had stage IV disease.",
            "Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.",
            "There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.",
            "In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.",
            "The frequency and severity of other toxicities were comparable between the two arms.",
            "Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).",
            "There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B. Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.",
            "Selected centers participated in a quality-of-life (QoL) assessment, which was performed by the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and LC-13 administered at baseline and every 6 weeks thereafter.",
            "Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.",
            "In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.",
            "Although survival was not improved, arm B offers a better palliation for advanced NSCLC patients than arm A."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "15226773": {
        "sentences": [
            "Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area.",
            " Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes.",
            "The aim of this study is to determine the impact of early and intensive nutrition intervention (NI) on body weight, body composition, nutritional status, global quality of life (QoL) and physical function compared to usual practice in oncology outpatients receiving radiotherapy to the GI or head and neck area.",
            "Outpatients commencing at least 20 fractions of radiotherapy to the GI or head and neck area were randomised to receive intensive, individualised nutrition counselling by a dietitian using a standard protocol and oral supplements if required, or the usual practice of the centre (general advice and nutrition booklet).",
            "Outcome parameters were measured at baseline and 4, 8 and 12 weeks after commencing radiotherapy using valid and reliable tools.",
            "A total of 60 patients (51 M : 9 F; mean age 61.9+/-14.0 years) were randomised to receive either NI (n=29) or usual care (UC) (n=31).",
            "The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC.",
            "Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195).",
            "Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area.",
            "Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "16446335": {
        "sentences": [
            "Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial.",
            " The primary goal of this study was to evaluate the feasibility and effectiveness of a structured, multidisciplinary intervention targeted to maintain the overall quality of life (QOL), which is more comprehensive than psychosocial distress, of patients undergoing radiation therapy for advanced-stage cancer.",
            "Radiation therapy patients with advanced cancer and an estimated 5-year survival rate of 0% to 50% were randomly assigned to either an eight-session structured multidisciplinary intervention arm or a standard care arm.",
            "The eight 90-minute sessions addressed the five domains of QOL including cognitive, physical, emotional, spiritual, and social functioning.",
            "The primary end point of maintaining overall QOL was assessed by a single-item linear analog scale (Linear Analog Scale of Assessment or modified Spitzer Uniscale).",
            "QOL was assessed at baseline, week 4 (end of multidisciplinary intervention), week 8, and week 27.",
            "Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54).",
            "This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009).",
            "Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period.",
            "Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL.",
            "Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "24019545": {
        "sentences": [
            "Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.",
            " Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3.",
            "This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC).",
            "Patients with metastatic RCC, with a clear cell component, prior nephrectomy, measurable disease, and 0 or 1 prior therapies for metastatic RCC were randomly assigned to tivozanib or sorafenib.",
            "Prior VEGF-targeted therapy and mammalian target of rapamycin inhibitor were not permitted.",
            "The primary end point was progression-free survival (PFS) by independent review.",
            "A total of 517 patients were randomly assigned to tivozanib (n = 260) or sorafenib (n = 257).",
            "PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042).",
            "One hundred fifty-six patients (61%) who progressed on sorafenib crossed over to receive tivozanib.",
            "The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105).",
            "Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).",
            "AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).",
            "Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "24028441": {
        "sentences": [
            "Postoperative pain and perioperative outcomes after laparoscopic radical hysterectomy and abdominal radical hysterectomy in patients with early cervical cancer: a randomised controlled trial.",
            " Non-randomised studies have suggested that the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy.",
            "However, no study evaluating postoperative pain comparing both techniques has been published thus far.",
            "Our objective was to compare pain intensity and other perioperative outcomes between laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) in early cervical cancer.",
            "This single centre, randomised, controlled trial enrolled 30 cervical cancer patients who were clinically staged IA2 with lymph vascular invasion and IB according to the FIGO (International Federation of Gynaecology and Obstetrics) classification, and underwent LRH or ARH between late 1999 and early 2004.",
            "Postoperative pain, as measured by a 10-point numerical rate scale, was considered the primary endpoint.",
            "Postoperative pain was assessed every six hours during a patient's usual postoperative care.",
            "Perioperative outcomes were also registered.",
            "Both surgical techniques were executed by the same surgical team.",
            "Secondary outcomes included intraoperative and other postoperative surgicopathological factors and 5-year survival rates.",
            "IA2 patients with lymphatic vascular space invasion and IB cervical cancer patients were randomised to either the LRH group (16 patients) or the ARH group (14 patients).",
            "Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.",
            "All of the transoperative complications occurred in the LRH group.",
            "The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P\u2009=\u20090.694.",
            "LRH group mean pain score was significantly lower than ARH after 36 h of observation (P\u2009=\u20090.044; mean difference score: 1.42; 95% CI: 0.04-2.80).",
            "The survival results will be published elsewhere.",
            "LRH provided lower pain scores after 36 h of observation in this series.",
            "The perioperative and serious postoperative complications ratios were comparable between the groups."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim"
        ]
    },
    "15139072": {
        "sentences": [
            "Psychological adjustment and sleep quality in a randomized trial of the effects of a Tibetan yoga intervention in patients with lymphoma.",
            " Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.",
            "Yoga, an ancient Eastern science, incorporates stress-reduction techniques that include regulated breathing, visual imagery, and meditation as well as various postures.",
            "The authors examined the effects of the Tibetan yoga (TY) practices of Tsa lung and Trul khor, which incorporate controlled breathing and visualization, mindfulness techniques, and low-impact postures in patients with lymphoma.",
            "Thirty-nine patients with lymphoma who were undergoing treatment or who had concluded treatment within the past 12 months were assigned to a TY group or to a wait-list control group.",
            "Patients in the TY group participated in 7 weekly yoga sessions, and patients in the wait-list control group were free to participate in the TY program after the 3-month follow-up assessment.",
            "Eighty nine percent of TY participants completed at least 2-3 three yoga sessions, and 58% completed at least 5 sessions.",
            "Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).",
            "This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02).",
            "There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue.",
            "The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.",
            "However, there were no significant differences between groups for the other outcomes."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence"
        ]
    },
    "9640214": {
        "sentences": [
            "Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG).",
            " In 1980 the EORTC-BCCG initiated a multicentre randomised clinical trial comparing modified radical mastectomy (MRM) with breast-conserving therapy (BCT) in stage I and II breast cancer.",
            "The main endpoint of the trial was survival.",
            "A brief quality of life (QoL) questionnaire consisting of two multi-item scales (body image and fear of recurrence) and two single items (satisfaction with treatment and cosmetic result) was included in the trial.",
            "A cosmetic evaluation of the breast after conservative surgery was also performed.",
            "This report concentrates on the results of the QoL study and the cosmetic evaluation.",
            "Multitrait scaling analysis was employed to verify the hypothesised scale structure of the questionnaire.",
            "Treatment comparison of the QoL scores at 2 years post-treatment was performed using a stratified Wilcoxon rank sum test.",
            "Both patients' and doctors' ratings of the cosmetic result were documented on the clinical follow-up form.",
            "A multivariate analysis was performed to identify which factors influenced the cosmetic outcome.",
            "In total, 127 patients in the MRM arm and 151 in the BCT arm completed a QoL questionnaire at approximately 2 years after randomisation (months 25-36).",
            "The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively.",
            "Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.",
            "No significant difference was observed in fear of recurrence between the two groups.",
            "Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy.",
            "Wide excision appeared to be the most important predictive factor for poor cosmetic result.",
            "In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "24040301": {
        "sentences": [
            "Magnetic resonance spectroscopic imaging and volumetric measurements of the brain in patients with postcancer fatigue: a randomized controlled trial.",
            " Postcancer fatigue is a frequently occurring problem, impairing quality of life.",
            "Until now, little is known about (neuro) physiological factors determining postcancer fatigue.",
            "For non-cancer patients with chronic fatigue syndrome, certain characteristics of brain morphology and metabolism have been identified in previous studies.",
            "We investigated whether these volumetric and metabolic traits are a reflection of fatigue in general and thus also of importance for postcancer fatigue.",
            "Fatigued patients were randomly assigned to either the intervention condition (cognitive behavior therapy) or the waiting list condition.",
            "Twenty-five patients in the intervention condition and fourteen patients in the waiting list condition were assessed twice, at baseline and six months later.",
            "Baseline measurements of 20 fatigued patients were compared with 20 matched non-fatigued controls.",
            "All participants had completed treatment of a malignant, solid tumor minimal one year earlier.",
            "Global brain volumes, subcortical brain volumes, metabolite tissue concentrations, and metabolite ratios were primary outcome measures.",
            "Volumetric and metabolic parameters were not significantly different between fatigued and non-fatigued patients.",
            "Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group.",
            "Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group.",
            "No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.",
            "This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "17717452": {
        "sentences": [
            "A randomized multicenter trial to compare long-term functional outcome, quality of life, and complications of surgical procedures for low rectal cancers.",
            " Colonic pouches have been used for 20 years to provide reservoir function after reconstructive proctectomy for rectal cancer.",
            "More recently coloplasty has been advocated as an alternative to a colonic pouch.",
            "However there have been no long-term randomized, controlled trials to compare functional outcomes of coloplasty, colonic J-Pouch (JP), or a straight anastomosis (SA) after the treatment of low rectal cancer.",
            ": To compare the complications, long-term functional outcome, and quality of life (QOL) of patients undergoing a coloplasty, JP, or an SA in reconstruction of the lower gastrointestinal tract after proctectomy for low rectal cancer.",
            "A multicenter study enrolled patients with low rectal cancer, who were randomized intraoperatively to coloplasty (CP-1) or SA if JP was not feasible, or JP or coloplasty (CP-2) if a JP was feasible.",
            "Patients were followed for 24 months with SF-36 surveys to evaluate the QOL.",
            "Bowel function was measured quantitatively and using Fecal Incontinence Severity Index (FISI).",
            "Urinary function and sexual function were also assessed.",
            "Three hundred sixty-four patients were randomized.",
            "All patients were evaluated for complications and recurrence.",
            "Mean age was 60 +/-12 years, 71% were male.",
            "Twenty-three (7.4%) died within 24 months of surgery.",
            "No significant difference was observed in the complications among the 4 groups.",
            "Two hundred ninety-seven of 364 were evaluated for functional outcome at 24 months.",
            "There was no difference in bowel function between the CP-1 and SA groups.",
            "JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group.",
            "Other parameters were not statistically different.",
            "QOL scores at 24 months were similar for each of the 4 groups.",
            "In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty.",
            "In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
        ],
        "labels": [
            null,
            null,
            "Claim",
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "24178750": {
        "sentences": [
            "Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.",
            " Intravenous (IV) granulocyte colony stimulating factor (G-CSF) might be safer and more convenient than subcutaneous (SC) administration to hospitalized hemato-oncological patients receiving chemotherapy.",
            "To compare IV vs. SC G-CSF administration, we conducted a randomized, open-label trial.",
            "We included inpatients receiving chemotherapy for acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma or multiple myeloma, and allogeneic or autologous hematopoietic cell transplantation (HCT).",
            "Patients were randomized to 5 mcg/kg single daily dose of IV bolus versus SC filgrastim given for its clinical indications.",
            "Patients were crossed-over to the alternate study arm on the subsequent chemotherapy course.",
            "The primary outcomes were time from initiation of filgrastim to recovery of stable neutrophil count of >500 cells/\u00b5L and a composite clinical outcome of infection or death assessed for the first course post-randomization.",
            "The study was stopped on the second interim analysis.",
            "Of 120 patients randomized, 118 were evaluated in the first treatment course.",
            "The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001.",
            "Longer neutropenia duration was observed in all patient subgroups, except for patients undergoing autologous HCT.",
            "There was no significant difference between groups in the occurrence of infection or death, but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196.",
            "Similar results were observed when all 158 courses following cross-over were analyzed.",
            "Patients reported similar pain and satisfaction scores in both groups.",
            "Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim"
        ]
    },
    "21921953": {
        "sentences": [
            "Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial.",
            "\ufeff",
            "To verify the safety and efficacy of Ologen (OLO) implant as adjuvant compared with low-dosage mitomycin-C (MMC) in trabeculectomy.",
            "This was a prospective randomized clinical trial with a 24-month follow-up.",
            "Forty glaucoma patients (40 eyes) were assigned to trabeculectomy with MMC or OLO.",
            "Primary outcome includes target IOP at \u226421, \u226417, and \u226415 mmHg; complete (target IOP without medications), and qualified success (target IOP regardless of medications).",
            "Secondary outcomes include bleb evaluation, according to Moorfields Bleb Grading System (MBGS); spectral domain optical coherence tomography (SD-OCT) examination; number of glaucoma medications; and frequency of postoperative adjunctive procedures and complications.",
            "The mean preoperative IOP was 26.5 (\u00b15.2) in MMC and 27.3 (\u00b16.0) in OLO eyes, without statistical significance.",
            "One-day postoperatively, the IOP dropped to 5.2 (\u00b13.5) and 9.2 (\u00b15.5) mm Hg, respectively (P=0.009).",
            "The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (\u00b12.9) and 16.5 (\u00b12.1) mm Hg in MMC and OLO, respectively.",
            "The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.",
            "The bleb height in OLO group was higher than MMC one (P<0.05).",
            "SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP =17  mm Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.",
            "No adverse reaction to OLO was noted.",
            "Our results suggest that OLO implant could be a new, safe, and effective alternative to MMC, with similar long-term success rate."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "15474813": {
        "sentences": [
            "Primary viscocanalostomy versus trabeculectomy for primary open-angle glaucoma: three-year prospective randomized clinical trial.",
            "To compare the efficacy and safety of viscocanalostomy and trabeculectomy in patients with primary open-angle glaucoma (POAG).",
            "Department of Ophthalmology, Ankara Education and Research Hospital, Ankara, Turkey.",
            "In this prospective randomized trial, 50 eyes of 50 patients with medically uncontrolled POAG were randomized to have a trabeculectomy (25 eyes) or a viscocanalostomy (25 eyes).",
            "Visual acuity, intraocular pressure (IOP), and slitlamp examinations were performed before surgery and 1 day, 1 week, 1, 3, and 6 months, and 1, 2, and 3 years postoperatively.",
            "At 3 years, the mean IOP was 16.0 mmHg +/- 7.07 (SD) in the trabeculectomy group and 17.8 +/- 4.6 mmHg in the viscocanalostomy group (P=.694).",
            "Complete success (IOP 6 to 21 mm Hg without medication) was achieved in 66.2% of eyes at 6 months and 55.1% at 3 years in the trabeculectomy group and in 52.9% and 35.3%, respectively, in the viscocanalostomy group (P>.05).",
            "Qualified success (IOP 6 to 21 mmHg with medication) was achieved in 95.8% of eyes at 6 months and 79.2% at 3 years in the trabeculectomy group and in 90.7% and 73.9%, respectively, in the viscocanalostomy group (P>.05).",
            "Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).",
            "Primary trabeculectomy lowered IOP more than viscocanalostomy in POAG patients.",
            "However, the complication rate was lower in the viscocanalostomy group."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "17397924": {
        "sentences": [
            "Randomized comparison of the intraocular pressure-lowering effect of phacoviscocanalostomy and phacotrabeculectomy.",
            "To compare the intraocular pressure (IOP)-lowering effect of combined viscocanalostomy and phacoemulsification and combined trabeculectomy and phacoemulsification with mitomycin C in eyes with primary open-angle glaucoma.",
            "Prospective randomized 1-year trial.",
            "Forty consecutive patients (40 eyes) with primary open-angle glaucoma and cataract.",
            "Eyes were assigned randomly either to trabeculectomy with mitomycin C or to viscocanalostomy in combination with phacoemulsification and intraocular lens implantation.",
            "Success rate based on IOP.",
            "Mean baseline IOP was 24.0+/-2.0 mmHg in the viscocanalostomy group and 23.7+/-2.6 mmHg in the trabeculectomy group (P = 0.7).",
            "Mean postoperative IOP was 13.7+/-2.2 mmHg at 3 months, 14.8+/-3.3 mmHg at 6 months, and 14.9+/-3.0 mmHg at 12 months in the viscocanalostomy group and 12.1+/-4.0 mmHg at 3 months, 13.8+/-4.7 mmHg at 6 months, and 14.1+/-4.4 mmHg at 12 months in the trabeculectomy group.",
            "There was no significant difference in the mean IOP between the groups at any time.",
            "At 12 months, 17 patients (85%) in the viscocanalostomy group and 16 patients (80%) in the trabeculectomy group achieved an IOP of 20 mmHg or less without medication (P = 0.7).",
            "Complications included 2 cases (10%) of flat/shallow anterior chamber and 4 cases (20%) of hypotony in the trabeculectomy group, whereas intraoperative microperforation of Descemet's membrane occurred in 3 cases (15%) in the viscocanalostomy group.",
            "There was no significant difference in IOP reduction between viscocanalostomy and trabeculectomy with mitomycin C in combination with phacoemulsification and intraocular lens implantation in patients with primary open-angle glaucoma."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Claim",
            "Evidence",
            null,
            null
        ]
    },
    "20472226": {
        "sentences": [
            "Laser peripheral iridotomy with and without iridoplasty for primary angle-closure glaucoma: 1-year results of a randomized pilot study.",
            "To compare the efficacy and safety of laser peripheral iridotomy with or without laser peripheral iridoplasty in the treatment of eyes with synechial primary angle-closure or primary angle-closure glaucoma.",
            "Randomized, controlled clinical trial.",
            "Consecutive patients older than 40 years with synechial primary angle-closure or primary angle closure glaucoma were recruited.",
            "Eligible patients were randomized to 1 of 2 treatment options, iridotomy or iridotomy plus iridoplasty, and were followed up for 1 year.",
            "Main outcome measures were intraocular pressure (IOP), peripheral anterior synechiae, corneal endothelial cell count, and complications.",
            "Seventy-seven eyes (77 patients) were randomized to the iridotomy group, and 81 eyes (81 patients) were randomized to the iridotomy plus iridoplasty group.",
            "Sixty-one patients (79.2%) in the iridotomy and 65 patients (80.2%) from the iridotomy plus iridoplasty groups completed 1 year of follow-up.",
            "There were no significant differences between the groups in the baseline data.",
            "IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).",
            "Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).",
            "There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.",
            "In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.",
            "There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "19476406": {
        "sentences": [
            "Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.",
            "Fixed combinations of 0.2% brimonidine-0.5% timolol and 2% dorzolamide-0.5% timolol are used to lower intraocular pressure (IOP).",
            "The objective of this study was to evaluate the IOP-lowering efficacy and ocular tolerability of brimonidine-timolol compared with dorzolamide-timolol when used as monotherapy or as adjunctive therapy to a prostaglandin analog (PGA) in patients with glaucoma or ocular hypertension.",
            "Pooled data analysis of two randomized, investigator-masked, 3-month, parallel-group studies with identical protocols (ten sites).",
            "In all, 180 patients with open-angle glaucoma or ocular hypertension who were in need of lower IOP received topical brimonidine-timolol BID or dorzolamide-timolol BID as monotherapy (n = 101) or as adjunctive therapy to a PGA (latanoprost, bimatoprost, or travoprost) (n = 79).",
            "IOP was measured at 10 a.m. (peak effect) at baseline and at months 1 and 3.",
            "Tolerability/comfort was evaluated using a patient questionnaire.",
            "There were no statistically significant between-group differences in patient demographics.",
            "Most patients were Caucasian, and the mean age was 68 years.",
            "There were also no statistically significant differences between treatment groups in baseline IOP.",
            "At month 3, the mean (SD) reduction from baseline IOP for patients on fixed-combination monotherapy was 7.7 (4.2) mmHg (32.3%) with brimonidine-timolol versus 6.7 (5.0) mmHg (26.1%) with dorzolamide-timolol (p = 0.040).",
            "The mean reduction from PGA-treated baseline IOP for patients on fixed-combination adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimonidine-timolol versus 5.2 (3.7) mmHg (23.5%) with dorzolamide-timolol (p = 0.213).",
            "Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.",
            "Fixed-combination brimonidine-timolol provided the same or greater IOP lowering compared with fixed-combination dorzolamide-timolol.",
            "Both fixed-combination medications were safe and well-tolerated.",
            "Brimonidine-timolol received higher ratings of ocular comfort than dorzolamide-timolol.",
            "The duration of the studies was 3 months, and additional studies will be needed to compare the efficacy and tolerability of brimonidine-timolol and dorzolamide-timolol during long-term treatment."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            null,
            null
        ]
    },
    "18826749": {
        "sentences": [
            "Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma .",
            "\ufeff",
            "To compare the IOP-lowering efficacy of a.m.-dosed travoprost and latanoprost at 24-h post-dose.",
            "Open-angle glaucoma patients not na\u00efve to prostaglandin therapy and currently controlled on p.m.-dosed (2100) latanoprost (n = 21) or travoprost (n = 30) had baseline IOPs measured at 0900.",
            "In a randomized, single-masked, crossover design, patients received travoprost (Travatan \u2020 ) or latanoprost (Xalatan \u2021 ) at 0900 for 4 weeks, then were crossed over to receive the second prostaglandin for another 4 weeks.",
            "Treatment IOP was measured at 0900 prior to morning dose at both 4 and 8 week visits.",
            "Patient dosing preference (a.m./p.m.)",
            "was surveyed on exit.",
            "Main outcome measure: Intraocular pressure (IOP).",
            "\u2020 Travatan is a registered trade name of Alcon Laboratories, Inc., Fort Worth, TX, USA \u2021 Xalatan is a registered trade name of Pfizer, New York, NY, USA.",
            "The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).",
            "In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).",
            "In the exit survey, 51% of patients preferred a.m.-dosing.",
            "a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "10682964": {
        "sentences": [
            "The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.",
            "Oral carbonic anhydrase inhibitors used to treat glaucoma have significant systemic side effects.",
            "Brinzolamide 1.0%, a new topical ocular carbonic anhydrase inhibitor, is effective apparently without significant systemic side effects.",
            "This study was performed to establish the long-term safety and efficacy of brinzolamide 1.0% two and three times daily for primary open-angle glaucoma and ocular hypertension.",
            "An 18-month, multicenter, double-masked, parallel, controlled study was conducted.",
            "Patients were randomized to brinzolamide two or three times daily or timolol 0.5% twice daily in a 2:2:1 ratio (n = 150, 153, and 75, respectively).",
            "Intraocular pressure was measured at 8:00 AM at eligibility and months 1, 3, 6, 9, 12, 15, and 18.",
            "Efficacy was based on intraocular pressure reduction from baseline.",
            "Safety was also evaluated.",
            "All regimens produced clinically relevant and statistically significant (P<.05) intraocular pressure reductions from baseline.",
            "Mean changes in intraocular pressure trough measurements ranged from -2.7 to -3.9 mm Hg with brinzolamide twice-daily dosing and -2.8 to -3.8 mm Hg three times daily dosing compared with -4.7 to -5.6 mm Hg with timolol.",
            "The intraocular pressure reductions with brinzolamide two and three times daily were clinically and statistically equivalent.",
            "One hundred forty-four patients were discontinued from the study after randomization with the most common reasons being the occurrence of an adverse event (46), inadequate intraocular pressure control (23), patient decision unrelated to study medication (11), lost to follow-up (16), and noncompliance (9).",
            "Adverse events were nonserious and resolved without sequelae.",
            "There were no clinically relevant changes in safety parameters.",
            "Brinzolamide produced less ocular discomfort (burning/stinging) than timolol, and total carbonic anhydrase inhibition levels remained below that known to cause systemic side effects.",
            "Brinzolamide produced significant and equivalent reductions in intraocular pressure when dosed two and three times daily for 18 months.",
            "Brinzolamide was safe and well tolerated by patients, with minimal ocular discomfort."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            null,
            "Evidence",
            null,
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "12169965": {
        "sentences": [
            "A prospective randomized trial of viscocanalostomy versus trabeculectomy in open-angle glaucoma: a 1-year follow-up study.",
            "To assess the intraocular pressure-lowering efficacy and the postoperative complication profile of viscocanalostomy versus trabeculectomy.",
            "Sixty eyes of 60 patients with medically uncontrolled open-angle glaucoma were randomized either to the viscocanalostomy or to the trabeculectomy group of the trial.",
            "Viscocanalostomy was performed according to Stegmann's technique using high-molecular-weight sodium hyaluronate to fill the ostia of the Schlemm canal.",
            "For trabeculectomy, a modified Cairns-trabeculectomy was performed.",
            "Examinations were performed before surgery and postoperatively daily for 1 week.",
            "Follow-up visits were scheduled 1, 6, and 12 months after surgery.",
            "The mean (SD) preoperative intraocular pressure was 27.1 (7.1) mm Hg for all patients enrolled.",
            "One day after surgery, mean (SD) intraocular pressure was 15.9 (5.2) for the trabeculectomy group (P <0.001) and 15.7 (3.6) for the viscocanalostomy group (P <0.001), respectively.",
            "The success rate, defined as an intraocular pressure lower than 22 mm Hg without medication, was 56.7% in the trabeculectomy group and 30% in the viscocanalostomy group at 12 months postoperatively (P = 0.041).",
            "The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.",
            "In eyes with open-angle glaucoma, viscocanalostomy is less effective in reducing intraocular pressure than standard filtering surgery.",
            "However, postoperative complications are more frequent after filtering surgery."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "21543992": {
        "sentences": [
            "Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma:  a prospective, randomized trial.",
            "To compare outcomes of selective laser trabeculoplasty (SLT) with drug therapy for glaucoma patients in a prospective randomized clinical trial.",
            "Sixty-nine patients (127 eyes) with open-angle glaucoma or ocular hypertension were randomized to SLT or medical therapy.",
            "Target intraocular pressure (IOP) was determined using the Collaborative Initial Glaucoma Treatment Study formula.",
            "Patients were treated with SLT (100 applications 360 degrees) or medical therapy (prostaglandin analog).",
            "Six visits over 1 year followed initial treatment.",
            "If target IOP range was not attained with SLT, additional SLT was the next step, or in the medical arm additional medications were added.",
            "Primary outcome: IOP; secondary: number of steps.",
            "Sixty-nine patients were treated.",
            "Data collection terminated with 54 patients reaching 9 to 12-months follow-up.",
            "Twenty-nine patients were in the SLT group, 25 patients in the medical group.",
            "Baseline mean IOP for all eyes was 24.5 mm Hg in the SLT group, 24.7 mm Hg in the medical group.",
            "Mean IOP (both eyes) at last follow-up was 18.2 mm Hg (6.3 mm Hg reduction) in the SLT arm, 17.7 mm Hg (7.0 mm Hg reduction) in the medical arm.",
            "By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.",
            "There was not a statistically significant difference between the SLT and medication groups.",
            "IOP reduction was similar in both arms after 9 to 12-months follow-up.",
            "More treatment steps were necessary to maintain target IOP in the medication group, although there was not a statistically significant difference between groups.",
            "These results support the option of SLT as a safe and effective initial therapy in open-angle glaucoma or ocular hypertension."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "16899528": {
        "sentences": [
            "Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial.",
            "To compare selective laser trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT), in terms of intraocular pressure (IOP) lowering, in patients with open-angle glaucoma.",
            "176 eyes of 152 patients were enrolled in this study, 89 in the SLT and 87 in the ALT groups.",
            "Patients were randomised to receive either SLT or ALT treatment to 180 degrees of the trabecular meshwork.",
            "Patients were followed up to 12 months after treatment.",
            "The main outcome measured was IOP lowering at 12 months after treatment, compared between the SLT and ALT groups.",
            "No significant difference (p = 0.846) was found in mean decrease in IOP between the SLT (5.86 mm Hg) and ALT (6.04 mm Hg) groups at 1 year or at any other time points, nor were there any significant differences in the rate of early or late complications between the two groups.",
            "SLT is equivalent to ALT in terms of IOP lowering at 1 year, and is a safe and effective procedure for patients with open-angle glaucoma."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim"
        ]
    },
    "1565457": {
        "sentences": [
            "Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery.",
            "In a randomized clinical trial, the authors compared the use of postoperative subconjunctival injections of 5-fluorouracil (5-FU) in 19 eyes with a single intraoperative application of subconjunctival mitomycin (MMC) at the filtering site in 20 eyes at high risk for failure of glaucoma filtering surgery.",
            "Six months after surgery, intraocular pressures averaged 10.9 +/- 5.3 mmHg (mean +/- standard deviation) in the MMC-treated eyes versus 14.2 +/- 5.5 mmHg in the 5-FU-treated eyes (P = 0.08) and were less than or equal to 12 mmHg in 60.0% of MMC-treated eyes and 21.1% of 5-FU-treated eyes (P = 0.03).",
            "Mitomycin-treated eyes were receiving an average of 0.3 +/- 0.5 medications for intraocular pressure control, and 5-FU-treated eyes were receiving an average of 1.1 +/- 1.1 medications (P = 0.01).",
            "Drug-induced corneal epithelial defects were seen in nine 5-FU-treated eyes and in no MMC-treated eyes (P = 0.0004).",
            "These results suggest that intraoperative MMC may be a viable alternative to postoperative 5-FU, with lower overall intraocular pressures, decreased dependence on postoperative ocular antihypertensive medications, and decreased corneal toxicity."
        ],
        "labels": [
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Claim"
        ]
    },
    "17293790": {
        "sentences": [
            "Viscocanalostomy versus trabeculectomy for primary open angle glaucoma: 4-year prospective randomized clinical trial.",
            "The purpose of this randomized clinical trial was to compare the effectiveness and safety of viscocanalostomy (visco) with trabeculectomy (trab) in the management of primary open angle glaucoma (POAG).",
            "Patients were randomized to have a viscocanalostomy (25 eyes) or a trabeculectomy (25 eyes) performed by one surgeon (TDM) and followed up prospectively.",
            "Patients were examined preoperatively, at day 1, day 3 if required, day 6, week 2 and thereafter as near as possible to 1, 3, 6, 12, 18, 24, 30, 36, 48, 54, and 60 months.",
            "We recorded intraocular pressure (IOP), presence or absence of any complications, presence and description of any bleb, visual acuity with glasses, and full examinations as routine to monitor any progression of the glaucoma.",
            "Bleb interventions including needling and antimetabolites were allowed and recorded in both groups.",
            "YAG laser goniopuncture was allowed in the viscocanalostomy group.",
            "Mean follow-up was 40 months (SD 15), with a range from 6 to 60 months.",
            "Forty-two percent (n=10) of the patients in the trabeculectomy group had a successful outcome (IOP<18 mm Hg with no treatment) at last follow-up visit, compared to 21% (n=5) in the viscocanalostomy group.",
            "IOP was lower in the trab group with differences in IOP being statistically significant at month 12 (P=<0.001), 24 (P=<0.001), 30 (P=0.030), 36 (P=<0.001), and 48 (P=0.018).",
            "The trabeculectomy group required less postoperative topical IOP-lowering medication (P=0.011).",
            "In this study, we found trabeculectomy to be more effective at lowering IOP than viscocanalostomy in POAG patients."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "21035866": {
        "sentences": [
            "YAG laser peripheral iridotomy for the prevention of pigment dispersion glaucoma a prospective, randomized, controlled trial.",
            "To test the hypothesis that neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).",
            "Prospective, randomized, controlled 3-year trial.",
            "One hundred sixteen eyes of 116 patients with PDS and OHT.",
            "Patients were assigned randomly either to Nd:YAG LPI or to a control group (no laser).",
            "The primary outcome measure was conversion to PG within 3 years, based on full-threshold visual field (VF) analysis using the Ocular Hypertension Treatment Study criteria.",
            "Secondary outcome measures were whether eyes required topical antiglaucoma medications during the study period and the time to conversion or medication.",
            "Fifty-seven patients were randomized to undergo laser treatment and 59 were randomized to no laser (controls).",
            "Age, gender, spherical equivalent refraction, and intraocular pressure at baseline were similar between groups.",
            "Outcome data were available for 105 (90%) of recruited subjects, 52 in the laser treatment group and 53 in the no laser treatment group.",
            "Patients were followed up for a median of 35.9 months (range, 10-36 months) in the laser arm and 35.9 months (range, 1-36 months) in the control arm.",
            "Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.",
            "The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.",
            "Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.",
            "Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).",
            "This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence",
            "Claim"
        ]
    },
    "15741820": {
        "sentences": [
            "Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.",
            "To compare the efficacy and tolerability of latanoprost or brimonidine in patients with elevated intraocular pressure (IOP).",
            "This prospective, randomized, masked-evaluator, parallel-group, multicenter study in the United States included patients with primary open angle glaucoma or ocular hypertension.",
            "Patients received latanoprost 0.005% once daily (8:00 AM; n = 152) or brimonidine tartrate 0.2% twice daily (8:00 AM and 8:00 PM; n = 151).",
            "Patients underwent evaluation at screening, baseline (randomization), and after 0.5, 3, and 6 months of treatment.",
            "IOP was measured at 8:00 AM, 10:00 AM, noon, and 4:00 PM at baseline and the months 3 and 6 visits, and at 8:00 AM only at week 2.",
            "The main outcome measure was the difference in diurnal IOP change from baseline to month 6 between treatment groups.",
            "Adverse events were recorded at each visit.",
            "Baseline mean diurnal IOP levels were similar between groups.",
            "At month 6, the adjusted mean (+/- SEM) diurnal IOP reduction was 5.7 +/- 0.3 mm Hg in the latanoprost group and 3.1 +/- 0.3 mm Hg in patients receiving brimonidine (P < 0.001).",
            "The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).",
            "Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.",
            "Latanoprost instilled once daily is more effective and better tolerated than brimonidine administered twice daily for the treatment of patients with glaucoma or ocular hypertension.",
            "During therapy, the range of daily fluctuation of IOP is less for latanoprost compared with brimonidine."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20420586": {
        "sentences": [
            "Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.",
            "The objective of the study was to compare the long-term efficacy and safety of tafluprost 0.0015% with latanoprost 0.005% eye drops in patients with open-angle glaucoma or ocular hypertension.",
            "This double-masked, active-controlled, parallel-group, multinational, multicentre, phase III study was conducted at 49 centres in 8 countries.",
            "Eligible patients were assigned to treatment administered once daily at 20:00 hrs for up to 24 months.",
            "Change from baseline intraocular pressure (IOP) was the primary efficacy variable.",
            "Adverse events were recorded and ocular safety was evaluated.",
            "Both tafluprost and latanoprost were preserved with benzalkonium chloride.",
            "From 533 patients randomized, 402 patients completed 24 months of therapy.",
            "Both treatments had a substantial IOP-lowering effect which persisted throughout the study (-7.1 mmHg for tafluprost and -7.7 mmHg for latanoprost at 24 months).",
            "Although the IOP-lowering effect during the study was slightly larger with latanoprost, this difference was clinically small and the noninferiority of tafluprost to latanoprost over all diurnal IOP measurements was shown with anova and almost reached with ancova (upper limits of the 95% confidence intervals 1.38 and 1.52 for the overall period, respectively).",
            "The noninferiority limit was 1.5 mmHg.",
            "Tafluprost is a new effective and well-tolerated treatment for glaucoma and ocular hypertension."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "15037889": {
        "sentences": [
            "A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients.",
            "To compare the longitudinal effects of treatment on intraocular pressure (IOP) and visual field performance in Japanese normal-tension glaucoma (NTG) between latanoprost and timolol.",
            "This is an open-label, randomized, study.",
            "A total of 62 NTG patients were prospectively, consecutively enrolled.",
            "All study subjects were randomly assigned to 0.005% latanoprost instillation once daily in the morning or 0.5% timolol instillation twice daily for a prospective 3-year follow-up, and underwent a routine ocular examination every month.",
            "Automated perimetry was performed every 6 months using Humphrey field analysers.",
            "Stereophotographs of optic discs were also obtained every 6 months.",
            "Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).",
            "In the visual field, the estimated rate of change in the MD value (dB/year) was -0.34+/-0.17 (SE) for the latanoprost group, and -0.10+/-0.18 (SE) for the timolol group.",
            "The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.",
            "No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.",
            "There were no patients who dropped out due to the side effects of treatment regimens.",
            "Both latanoprost and timolol single treatments reduced IOP by 13-15% at their trough effects for 3 years in Japanese NTG patients; both showed similar effects on visual field performance."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "18603947": {
        "sentences": [
            "Effectiveness of combination of permanent and releasable scleral flap sutures in trabeculectomy: a randomized clinical trial.",
            "Trabeculectomy is a commonly used surgical treatment for glaucoma.",
            "To evaluate the effectiveness of combination of permanent and releasable scleral flap sutures to minimize the immediate postoperative complications of trabeculectomy.",
            "This study was carried out in Department of Ophthalmology, B P Koirala Institute of Health Sciences, Dharan, Nepal.",
            "Forty one eyes of 34 patients undergoing trabeculectomy were randomized to undergo either conventional trabeculectomy (Group A= 20 eyes) or trabeculectomy with combination of permanent and releasable scleral flap sutures (Group B =21 eyes).",
            "The parameters studied were intraocular pressure (IOP), anterior chamber depth (ACD) and surgical complications over a period of 6 weeks.",
            "Significantly higher number of eyes belonging to group A (14 eyes) had shallower anterior chamber than group B (7 eyes) on first post operative day (p=0.042).",
            "Six eyes (30%) in group A had peripheral or central irido-corneal touch in early postoperative period as compared to only one in Group B. Hypotony was noted in 3 eyes in each group.",
            "Two patients in group A required reformation of anterior chamber.",
            "Other surgical complications in the two groups were similar.",
            "Both the groups had a significant drop in IOP following surgery.",
            "However, there was no significant difference in the IOP between the two groups after 6 weeks (Group A: 10.95 +/- 3.03 mmHg vs. Group B: 12.29 +/- 4.67 mmHg; p=0.87).",
            "There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.",
            "Use of combination of permanent and releasable scleral flap sutures is a safe technique that significantly reduces the incidence of immediate postoperative shallow anterior chamber after trabeculectomy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            null,
            "Claim",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "11730649": {
        "sentences": [
            "Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%.",
            "To evaluate the intraocular pressure-lowering efficacy and safety of travoprost 0.0015% and 0.004%, dosed daily in the evening compared with vehicle, in patients with open-angle glaucoma or ocular hypertension, whose intraocular pressure was not adequately controlled on timolol 0.5% twice daily (twice daily).",
            "Subjects who qualified at screening began a run-in period dosing timolol twice daily for 3 weeks.",
            "If the subjects had an intraocular pressure of 24 to 36 mm Hg at 8 AM and 21 to 36 mm Hg at 10 AM and 4 pm in at least one eye on timolol, they were randomized to one of two concentrations of travoprost (0.0015% or 0.004%) or vehicle solution every day and were followed for 6 months.",
            "Four hundred twenty-six subjects were randomized.",
            "The mean intraocular pressure at 8 AM, 10 AM, and 4 PM in the patient's eye with the higher intraocular pressure was used for the analysis.",
            "Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.",
            "The intraocular pressure was lowered an additional -5.7 to -7.2 mm Hg and -5.1 to -6.7 mm Hg in the travoprost 0.004% and 0.0015% concentrations, respectively.",
            "These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).",
            "The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.",
            "Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.",
            "No iris pigmentation changes were observed in any patient during this study.",
            "There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.",
            "There were no serious adverse events reported for any treatment group.",
            "Travoprost produced clinically relevant and statistically significant additional intraocular pressure reductions from baseline when used adjunctively with timolol in subjects with open-angle glaucoma or ocular hypertension."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "20545217": {
        "sentences": [
            "[Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study].",
            "To compare the efficacy and safety of 0.0015% tafluprost ophthalmic solution (Tafluprost) with Placebo ophthalmic solution (Placebo) in normal tension glaucoma (NTG).",
            "Total of 94 patients enrolled in a randomized, double-blind, parallel-group and multicenter study.",
            "Patients with NTG were randomly assigned to either Tafluprost or Placebo.",
            "Both ophthalmic solutions were instilled once a day in the morning for 4 weeks.",
            "Mean intraocular pressure (IOP) changes from baseline were -4.0 +/- 1.7 mmHg in Tafluprost administered patients and -1.4 +/- 1.8 mmHg in Placebo administered patients at 4 weeks, with a statistically significant difference (p<0.001).",
            "IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo.",
            "A total of 51.0% in Tafluprost treated group and 8.9% in Placebo treated group reported adverse drug reactions.",
            "These results indicate that Tafluprost is clinically useful in the treatment of NTG."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "18164068": {
        "sentences": [
            "Efficacy of the Ahmed S2 glaucoma valve compared with the Baerveldt 250-mm2 glaucoma implant.",
            "To compare the efficacy of the Ahmed S2 Glaucoma Valve with the Baerveldt 250-mm(2) Glaucoma Implant in the treatment of adult glaucoma.",
            "Comparative case series.",
            "Fifty-nine eyes of 59 patients who received the Ahmed S2 Glaucoma Valve and 133 eyes of 133 patients who received the Baerveldt 250-mm(2) Glaucoma Implant by the Indiana University Glaucoma Service from 1996 to 2003.",
            "Eyes that had previous drainage implant procedures were excluded from both groups.",
            "If both eyes of a single patient received an implant, the second eye to undergo implantation was excluded from the study.",
            "Kaplan-Meier survival with success defined as intraocular pressure (IOP) > 5 mmHg and < 22 mmHg and at least 20% reduction from preoperative IOP (with or without antiglaucoma medications) and without loss of light perception.",
            "Secondary outcome measures included intraocular pressure, visual acuity, number of glaucoma medications, and surgical complications.",
            "The 2 groups were similar with regards to age, gender, race, neovascular glaucoma diagnosis, number of prior ocular surgeries, preoperative IOP, and number of preoperative glaucoma medications.",
            "Mean durations of follow-up were 20.0 months for Ahmed eyes and 22.9 months for Baerveldt eyes.",
            "Cumulative successes in the Ahmed group were 0.73 at 1 year and 0.62 at 2 years, whereas cumulative successes in the Baerveldt group were 0.92 at 1 year and 0.85 at 2 years (Kaplan-Meier survival functions: P = 0.03, log rank test).",
            "Male gender, African descent, neovascular glaucoma, and Ahmed implantation were found to be significant predictors of failure.",
            "At last follow-up visit, eyes in the Ahmed group had a significantly higher mean IOP (19.8+/-9.5 vs. 15.8+/-7.9 mmHg, P = 0.003, t test) and more antiglaucoma medications (1.4+/-1.2 vs. 0.9+/-1.1 medications, P = 0.008, Mann-Whitney test) than eyes in the Baerveldt group.",
            "Two methods for avoiding hypotony after Baerveldt 250-mm(2) implantation had similar outcomes.",
            "Our study suggests that the Ahmed S2 Glaucoma Valve may be less effective at lowering IOP than the Baerveldt 250-mm(2) Glaucoma Implant."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "10901475": {
        "sentences": [
            "The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.",
            "To compare the additional intraocular pressure-lowering effect of latanoprost 0.005% administered once daily with that of pilocarpine 2% administered three times daily in patients with primary open-angle glaucoma or ocular hypertension currently on monotherapy with timolol 0.5% twice daily.",
            "In a 6-month, multicenter, randomized, open-label study 242 patients with POAG or OH whose IOP was not controlled with timolol 0.5% b.i.d.",
            "were enrolled.",
            "Eyes had not been treated with pilocarpine and latanoprost for at least 2 years.",
            "An analysis of covariance with diurnal IOP change from baseline to month 6 for study eyes was performed.",
            "Four patients on latanoprost 0.005% and 35 on pilocarpine 2% did not complete the study (P<0.001).",
            "Two hundred and forty patients were included in the intent-to-treat analysis.",
            "For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).",
            "IOP (mean+/-SD) was reduced from 23.3+/-2.8 to 17.8+/-2.8 (-5.6) mmHg in the latanoprost 0.005% group and from 23.0+/-3.2 to 18.5+/-2.4 (-4.8) mmHg in pilocarpine 2% t.i.d.-treated eyes.",
            "The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.",
            "Two eyes treated with latanoprost showed an iris color change.",
            "Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).",
            "From the data we conclude that the additivity of latanoprost 0.005% is at least as effective as pilocarpine 2% t.i.d.",
            "in reducing IOP when added to eyes currently on monotherapy with timolol 0.5% b.i.d.",
            "Latanoprost was better tolerated than pilocarpine 2% eye drops in this study.",
            "The increase in iris pigmentation requires further investigation."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null,
            "Claim",
            "Claim"
        ]
    },
    "1841578": {
        "sentences": [
            "Trabeculectomy with mitomycin. A comparative study with fluorouracil.",
            "We conducted a prospective, randomized study to compare mitomycin with fluorouracil for efficacy and safety as an adjunct to trabeculectomy in eyes with glaucoma with poor surgical prognosis.",
            "Thirty-two eyes of 32 patients were randomly allocated to either mitomycin (17 eyes) or fluorouracil therapy (15 eyes).",
            "Mitomycin (0.2 mg) was applied only once during trabeculectomy, and fluorouracil (5 mg) was subconjunctivally injected 10 times in the 2 weeks after surgery.",
            "Fifteen eyes (88%) in the mitomycin group and seven (47%) in the fluorouracil group achieved an intraocular pressure of less than or equal to 20 mm Hg without antiglaucoma medication.",
            "The follow-up period was 7 to 12 months.",
            "Corneal complications were less common in the group given mitomycin than in that given fluorouracil (12% vs 53%).",
            "The incidence of other complications was similar between the two groups."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Claim"
        ]
    },
    "21631670": {
        "sentences": [
            "Comparison of standard trabeculectomy versus microtrabeculectomy as a surgical treatment for glaucoma: a randomized clinical trial.",
            "To determine the effect of scleral flap size on the medium-term intraocular pressure control and complication rates after augmented trabeculectomy.",
            "Prospective randomized clinical trial.",
            "Glaucoma patients undergoing primary trabeculectomy.",
            "Exclusion criteria included previous ocular surgery apart from cataract surgery, secondary glaucoma and age under 18.",
            "Patients were randomized to either standard trabeculectomy (4 \u00d7 4 mm scleral flap) or microtrabeculectomy (2 \u00d7 2 mm scleral flap), both with adjustable sutures and antimetabolites.",
            "Bleb needling was performed as required.",
            "Patients were evaluated at day 1, weeks 1, 3, 6 and months 3, 6, 12, 18 and 24 postoperatively.",
            "Vision, intraocular pressure, complications and failure (intraocular pressure \u2265 21 mmHg or not reduced by \u226520% from baseline, intraocular pressure \u2264 5 mmHg, repeat glaucoma surgery and no light perception vision).",
            "Forty-one patients were recruited; 20 had standard trabeculectomy, and 21 had microtrabeculectomy.",
            "At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 \u00b1 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 \u00b1 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).",
            "One patient in each group required Baerveldt device implantation.",
            "Vision reduced \u22652 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).",
            "Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.",
            "Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "8628544": {
        "sentences": [
            "Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.",
            "Latanoprost, a new prostaglandin analogue, was compared with timolol for ocular hypotensive efficacy and side effects.",
            "In a multicenter, randomized, double-masked, parallel group study, 268 patients with ocular hypertension or early primary open-angle glaucoma received either 0.005% latanoprost once daily or 0.5% timolol twice daily for 6 months.",
            "All except ten patients from each group successfully completed the study.",
            "Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.",
            "Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).",
            "Four patients treated with timolol and none treated with latanoprost were withdrawn from the study because of inadequate IOP control.",
            "Pulse rate was significantly reduced with timolol, but not with latanoprost.",
            "Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.",
            "Fewer subjective side effects occurred in latanoprost-treated eyes.",
            "Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.",
            "Three additional patients treated with latanoprost were suspects for this color change.",
            "Otherwise, no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.",
            "Latanoprost has the potential for becoming a new first-line treatment for glaucoma."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence",
            null,
            "Claim",
            null
        ]
    },
    "14704542": {
        "sentences": [
            "Baerveldt-350 implant versus Ahmed valve for refractory glaucoma: a case-controlled comparison.",
            "To compare the efficacy of intraocular pressure (IOP) control of the Baerveldt-350 implant with tube ligature and the Ahmed valve in patients with refractory glaucoma.",
            "Four hundred seventy glaucoma drainage device procedures from July 1995 to July 2001 (6 years) were reviewed retrospectively.",
            "Thirty-two cases of Baerveldt-350 implantation performed in patients with glaucoma refractory to medical treatment and filtering procedures, without previous drainage device or cyclodestructive procedures, and with a minimum of 1-year follow-up were identified.",
            "Thirty-two cases of Ahmed valve implantation were matched case by case with 32 Baerveldt-350 cases for age, race, gender, glaucoma subtype, previous ocular history, preoperative IOP, and surgeon who performed the implantation.",
            "The two groups were compared for IOP control, visual outcome, complication rate, and surgical success rate.",
            "Surgical success rate was defined as an IOP reduction greater than or equal to 30% and final IOP more than 5 mm Hg and less than 22 mm Hg, without devastating complications.",
            "Over a follow-up period of 1 year, no statistically significant differences were detected between the Baerveldt-350 implant versus Ahmed valve for IOP control (12.1 +/- 5.3 mm Hg vs 13.6 +/- 5.6 mm Hg respectively, at a power of 90% to detect a difference of 3.2 mm Hg between the two groups and P = 0.05), surgical success rate (65.6% vs. 65.6% respectively, complete and qualified combined), postoperative hypotony rate (37.5% vs. 34.4% respectively), and visual acuity changes of more than 1 line in Snellen visual acuity (43.3% vs. 29.0% respectively).",
            "In a case-controlled comparison, the Baerveldt-350 implant and the Ahmed valve had similar IOP control and surgical outcomes in patients with refractory glaucoma at 1-year follow-up."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12908569": {
        "sentences": [
            "The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.",
            "Brimonidine is a highly selective alpha-2 adrenergic receptor agonist with intraocular pressure (IOP) reducing effect.",
            "We conducted this study in Taiwan to compare the safety and efficacy of brimonidine 0.2% with timolol 0.5% for the treatment of glaucoma.",
            "A prospective, randomized, single-masked, 1-month clinical efficacy and safety trial was conducted from March to September 2000.",
            "Forty glaucoma patients were enrolled--29 in the brimonidine group and 11 in the timolol group.",
            "Patients instilled their study medications twice daily for 4 weeks, and were followed at baseline visit, weeks 2 and 4.",
            "Demographic data, reduction of IOP, safety and adverse events were obtained and analyzed.",
            "Both drugs showed sustained ocular hypotensive efficacy in the study period.",
            "At baseline, the mean IOP was 24.48 +/- 2.29 mmHg in the brimonidine group and 23.32 +/- 0.82 mmHg in the timolol group.",
            "The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).",
            "At peak, the mean decreases from the baseline IOP ranged from 5.22 +/- 0.30 mmHg to 6.96 +/- 0.33 mmHg for brimonidine and from 4.55 +/- 0.49 mmHg to 6.64 +/- 0.53 mmHg for timolol.",
            "At trough, the mean decreases from baseline ranged from 3.72 +/- 0.32 mmHg to 4.55 +/- 0.32 mmHg for brimonidine and 3.82 +/- 0.52 mmHg to 4.27 +/- 0.51 mmHg for timolol.",
            "No significant between-group differences were seen at peak or trough at all visits.",
            "The clinical success rate was 86.2% in the brimonidine group and 81.8% in the timolol group, making no statistically significant difference between them (p = 0.817).",
            "17.2% of patients in brimonidine group and 9.0% patients in timolol group reported mild adverse events.",
            "Ocular allergy occurred in 10.3% of patients in brimonidine group.",
            "No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.",
            "Mean systolic and diastolic blood pressure remained relatively stable in both groups except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.",
            "However, brimonidine showed no significant difference in week 4 from baseline.",
            "The mean heart rate in the brimonidine group was relatively unchanged over the study period.",
            "Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.",
            "Topically applied twice daily for one month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.",
            "It has a safe systemic profile with minimum effect on the heart."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "19900212": {
        "sentences": [
            "A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.",
            "To compare the effect of time on therapy, efficacy, tolerability and resource utilization of latanoprost or non-prostaglandin analogues (non-PGs) in patients who required a change in intraocular pressure (IOP)-lowering monotherapy.",
            "This open-label, multicentre study (Sweden, 19 sites; Finland, seven sites) included adults with glaucoma or ocular hypertension with mean diurnal IOP > or = 21 mmHg on ocular hypotensive monotherapy.",
            "Patients were randomized to latanoprost monotherapy or non-PG therapy (commercially available therapy other than a PG) and followed for 36 months.",
            "End-points included: time to treatment failure (baseline to visit with a change in/addition to treatment); diurnal IOP (mean of 08.00, 12.00 and 16:00 hr measurements) at months 6, 12, 24 and 36; tolerability; and resource utilization, where analyses used Swedish and Finnish 2006 unit costs.",
            "Three hundred and twenty-six patients received >or = 1 dose of latanoprost (n = 162) or non-PGs (n = 164).",
            "Median time to treatment failure was longer for latanoprost (36 months) than for non-PGs (12 months; p < 0.001); 51% and 24% of patients remained on randomized therapy after 36 months, respectively (p < 0.001).",
            "Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).",
            "No serious adverse events were judged to be treatment-related.",
            "Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.",
            "Patients who failed previous monotherapy remained on therapy longer when switched to latanoprost.",
            "The IOP-reducing effect of latanoprost and tolerability were sustained over the long term.",
            "Resource utilization and costs were generally similar in those initiating latanoprost or non-PG therapy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "18402717": {
        "sentences": [
            "Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.",
            "To evaluate the efficacy and tolerability of brimonidine purite 0.1% in comparison to brinzolamide 1% when used as adjunctive therapy to latanoprost 0.005% in patients with glaucoma or ocular hypertension.",
            "Randomized, single-center, investigator-masked, parallel-group clinical study.",
            "Patients with IOP >or= 18 mmHg while on once-daily latanoprost were randomized to adjunctive treatment with brimonidine purite TID (n = 20) or brinzolamide TID (n = 20) for 3 months.",
            "Intraocular pressure (IOP) was measured at 8 a.m., 10 a.m., and 4 p.m. at latanoprost-treated baseline and after 1 and 3 months of latanoprost and adjunctive therapy.",
            "A patient questionnaire was administered to evaluate the tolerability of eye drop instillation.",
            "Baseline mean diurnal IOP (+/- standard deviation, mmHg) on latanoprost was comparable between groups (brimonidine purite: 19.6 +/- 2.94; brinzolamide: 19.8 +/- 3.25; p = 0.846).",
            "Mean diurnal IOP at Month 3 was 16.3 +/- 2.63 mmHg with brimonidine purite and 17.8 +/- 2.19 mmHg with brinzolamide (p = 0.028).",
            "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).",
            "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.",
            "Brimonidine purite 0.1% provided significantly lower IOP compared with brinzolamide 1% when used as adjunctive therapy to latanoprost.",
            "Both adjunctive therapies were well tolerated.",
            "Limitations of this study include the use of a single site and the sample size.",
            "Additional studies are needed to further evaluate these drugs as adjunctive therapy to prostaglandin analogs."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Evidence",
            "Claim"
        ]
    },
    "21701528": {
        "sentences": [
            "Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.",
            "The purpose of this study is to compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost/timolol in a benzalkonium chloride (BAK)-free fixed combination preserved with polyquaternium-1 (TRA/TIM BAK-free), with travoprost/timolol-fixed combination preserved with BAK (TRA/TIM), in patients with open-angle glaucoma or ocular hypertension.",
            "In this prospective randomized controlled trial, subjects with IOP of at least 22 mm Hg in one or both eyes at 0900 h, and IOP of at least 21  mm Hg in one or both eyes at 1100  h and 1600  h at two eligibility visits were randomly assigned to receive either TRA/TIM BAK-free (n=195) or TRA/TIM (n=193), dosed once daily in the morning (0900  h) for 6 weeks.",
            "IOP was assessed at 0900  h, 1100  h, and 1600  h at each scheduled visit (baseline, 2 and 6 weeks after randomization).",
            "Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).",
            "The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8), demonstrating equivalence of the two formulations.",
            "The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.",
            "Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.",
            "No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "15177955": {
        "sentences": [
            "Efficacy and safety of adjunctive mitomycin C during Ahmed Glaucoma Valve implantation: a prospective randomized clinical trial.",
            "To evaluate the efficacy and safety of intraoperative mitomycin C (MMC) in eyes undergoing Ahmed Glaucoma Valve implantation.",
            "Randomized controlled clinical trial.",
            "Sixty patients with refractory glaucoma.",
            "Sixty eyes of 60 patients with refractory glaucoma were randomized to receive intraoperative MMC (0.5 mg/ml for 5 minutes) (n = 34) or balanced salt solution (n = 26) during Ahmed Glaucoma Valve implantation.",
            "Surgical success was defined according to 2 different criteria: (1) postoperative intraocular pressure (IOP) between 6 and 21 mmHg, with or without antiglaucoma medications, and (2) IOP reduction of at least 30% relative to preoperative values.",
            "Eyes requiring additional glaucoma surgery, developing phthisis, or showing loss of light perception were classified as failures.",
            "Success rates in both groups were compared using Kaplan-Meier survival curves and the log rank test.",
            "Other outcome measures were mean IOP, number of glaucoma medications, and complications.",
            "After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).",
            "When an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.",
            "There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).",
            "After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.",
            "Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.",
            "There was no significant difference between the incidences of postoperative complications in both groups.",
            "Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "20584708": {
        "sentences": [
            "Comparison of corneal changes after phacoemulsification using BSS Plus versus Lactated Ringer's irrigating solution: a prospective randomised trial.",
            "To compare two intraocular irrigating solutions, Balanced Salt Solution Plus (BSS Plus) versus Lactated Ringer's (Ringer), for the preservation of corneal integrity after phacoemulsification.",
            "110 patients undergoing phacoemulsification were randomised to either BSS Plus (n=55) or Ringer (n=55) as the irrigating solution.",
            "Patients were examined at baseline and at 1, 8, 15, 30 and 60 days postoperatively.",
            "Evaluations included specular microscopy to evaluate endothelial cell density (ECD) and endothelial cell size variability (CV), and corneal pachymetry for central corneal thickness (CCT) measurement.",
            "Groups were well balanced regarding baseline ECD, CV and CCT (p>0.05).",
            "There was no statistically significant difference between ECD reduction in group BSS Plus 13.1 \u00b1 2.0% and Ringer 9.2 \u00b1 1.9% (p<0.05) at day 60 or in any study visit.",
            "There was no statistically significant difference between CV increase in group BSS Plus 23.0 \u00b1 3.0% and Ringer 20.2 \u00b1 4.0% (p<0.05) at day 60 or in any study visit.",
            "CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.",
            "There was no significant difference in CCT increase in both groups at any visit.",
            "Interestingly, there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.",
            "Ringers solution was similar to BSS Plus for corneal preservation in atraumatic cataract surgery.",
            "However, our study demonstrates that there is a trend towards lower postoperative endothelial cell density for surgeries with longer phacoemulsification time and higher irrigation volumes if Ringer is used."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20092592": {
        "sentences": [
            "Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery.",
            "To determine if postoperative topical cyclosporine 0.05% has any beneficial effect following trabeculectomy.",
            "This was an interventional, randomized, prospective, double-masked clinical trial of 44 consecutive patients with uncontrolled glaucoma requiring filtration surgery.",
            "Ocular surface disease index questionnaire and comprehensive ocular exam, including Schirmer's tear test 1, were performed.",
            "Patients underwent routine trabeculectomy, with or without phacoemulsification.",
            "The study group (n = 22) received cyclosporine 0.05%, and the control group (n = 22) received artificial tears.",
            "Patients were evaluated at 1 and 6 months post surgery.",
            "Outcome measures were intraocular pressure, success rate, bleb appearance, ocular surface disease index, Schirmer's tear test 1 and conjunctival inflammation.",
            "Thirty-nine patients completed the study (19 in the study group, 20 in the control group).",
            "The mean baseline intraocular pressure was 23.8 +/- 12.6 mmHg in the study group and 25.9 +/- 10.6 mmHg in the control group (P = 0.513).",
            "Mean intraocular pressure at postoperative month 6 was 14.88 +/- 6.2 and 14.62 +/- 5.46 mmHg in the study group and control group, respectively (P = 0.837).",
            "There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.",
            "The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.",
            "Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "10837379": {
        "sentences": [
            "A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group.",
            "To compare the effects on intraocular pressure (IOP) and side effects of monotherapy with either latanoprost or dorzolamide in patients with glaucoma or ocular hypertension.",
            "224 patients with open angle glaucoma or ocular hypertension were recruited to a 3 month open labelled study.",
            "Previous glaucoma medications were washed out and the patients were randomised to receive either latanoprost 0.005% once daily or dorzolamide 2% three times daily.",
            "Of 224 patients 213 were included in the analysis of efficacy.",
            "After 3 months, latanoprost reduced mean baseline diurnal IOP from 27.2 (SD 3.0) mm Hg by 8.5 (3.3) mm Hg.",
            "The corresponding figures for dorzolamide were 27.2 (3.4) and 5.6 (2.6) mm Hg.",
            "The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).",
            "Latanoprost reduced IOP at peak by 8.6 mm Hg (32%) compared with 6.2 mm Hg (23%) for dorzolamide, and the difference of 2.4 mm Hg was significant (p<0.001, ANCOVA).",
            "The corresponding figures at trough were 8.1 mm Hg (31%) for latanoprost and 4.7 mm Hg (17%) for dorzolamide, a significant difference of 3.4 mm Hg (p<0.001, ANCOVA).",
            "Both drugs were well tolerated systemically and locally.",
            "Latanoprost was superior to dorzolamide in reducing the IOP, judged both from the effect on IOP at peak and trough and by the effect on diurnal IOP."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "21680022": {
        "sentences": [
            "Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.",
            "To compare the efficacy and safety of latanoprost versus timolol in pediatric patients with glaucoma.",
            "Prospective, randomized, double-masked, 12-week, multicenter study.",
            "Individuals aged <18 years with glaucoma.",
            "Stratified by age, diagnosis, and intraocular pressure (IOP) level, subjects were randomized (1:1) to latanoprost vehicle at 8 am and latanoprost 0.005% at 8 pm or timolol 0.5% (0.25% for those aged <3 years) twice daily (8 am, 8 pm).",
            "At baseline and weeks 1, 4, and 12, IOP and ocular safety were assessed and adverse events were recorded.",
            "Therapy was switched to open-label latanoprost pm and timolol am and pm for uncontrolled IOP.",
            "Mean IOP reduction from baseline to week 12.",
            "Latanoprost was considered noninferior to timolol if the lower limit of the 95% confidence interval (CI) of the difference was >-3 mmHg.",
            "A proportion of responders (subjects with 15% IOP reduction at weeks 4 and 12) were evaluated.",
            "Analyses were performed in diagnosis subgroups: primary congenital glaucoma (PCG) and non-PCG.",
            "In total, 137 subjects were treated (safety population; 12-18 years, n=48; 3-<12 years, n=55; 0-<3 years, n=34).",
            "Mean age was 8.8\u00b15.5 years, and mean baseline IOP was 27.7\u00b16.17 mmHg; 125 subjects completed the study, and 107 subjects were in the per protocol population.",
            "Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).",
            "Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).",
            "Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.",
            "Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.",
            "Both therapies were well tolerated.",
            "Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.",
            "Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "11167277": {
        "sentences": [
            "Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma.",
            "To compare the effect on intraocular pressure of latanoprost versus timolol plus dorzolamide in open-angle glaucoma.",
            "Thirty-five patients with open-angle glaucoma were randomized, 18 to latanoprost once daily and 17 to timolol plus dorzolamide twice daily.",
            "Intraocular pressure and ocular side effects were recorded at baseline, and after 2 weeks and 3 months of treatment.",
            "Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.",
            "These differences were statistically significant (p<0.05) at the end of the study.",
            "After 3 months of treatment, 32.3% of the eyes in the latanoprost group reduced the intraocular pressure in 30% or more with respect to baseline, while 15.6% of the eyes in the timolol plus dorzolamide group achieved this reduction.",
            "Latanoprost administered once daily reduced the intraocular pressure at least as well as timolol plus dorzolamide twice daily in patients with open-angle glaucoma."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "19243831": {
        "sentences": [
            "Phacoemulsification versus combined phacotrabeculectomy in medically uncontrolled chronic angle closure glaucoma with cataracts.",
            "To compare phacoemulsification alone versus combined phacotrabeculectomy in medically uncontrolled chronic angle closure glaucoma (CACG) with coexisting cataract.",
            "Prospective randomized clinical trial.",
            "Fifty-one medically uncontrolled CACG eyes with coexisting cataract of 51 patients.",
            "Recruited patients were randomized into group 1 (phacoemulsification alone) or group 2 (combined phacotrabeculectomy with adjunctive mitomycin C).",
            "Postoperatively, patients were reviewed every 3 months for 2 years.",
            "Intraocular pressure (IOP) and requirement for topical glaucoma drugs.",
            "Twenty-seven CACG eyes were randomized into group 1, and 24 CACG eyes were randomized into group 2.",
            "Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs 17.0 mmHg, P = 0.01), 15 months (13.2 vs 15.4 mmHg, P = 0.02), and 18 months (13.6 vs 15.9 mmHg, P = 0.01).",
            "Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.",
            "Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.",
            "Combined phacotrabeculectomy with adjunctive mitomycin C is more effective than phacoemulsification alone in controlling IOP in medically uncontrolled CACG eyes with coexisting cataract.",
            "Combined phacotrabeculectomy is associated with more postoperative complications."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "17244215": {
        "sentences": [
            "Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.",
            "To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol-dorzolamide combination in patients with primary open-angle glaucoma (POAG) or ocular hypertension during 6 months of treatment.",
            "A sample of 65 patients with a diagnosis of POAG or ocular hypertension were randomized to receive either bimatoprost 0.03% once daily or timolol-dorzolamide combination twice daily.",
            "Study visits occurred at baseline and after 2 weeks and 1, 3 and 6 months of therapy.",
            "Intraocular pressure (IOP) measurements were performed at 12.00 hours at all study visits and also at 08.00 hours and 16.00 hours at baseline and 6-month visits.",
            "At each visit, local and systemic side-effects that occurred during the treatment period were recorded.",
            "Student's t-test was used to compare the differences between IOP values.",
            "Differences in IOP between the bimatoprost and timolol-dorzolamide groups were statistically insignificant at all study visits (p > 0.05).",
            "In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment.",
            "The difference was not statistically significant (p = 0.48).",
            "The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up.",
            "Both bimatoprost and the timolol-dorzolamide combination were well tolerated.",
            "Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "15598478": {
        "sentences": [
            "Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.",
            "Approximately 40% of patients with glaucoma are concomitantly prescribed >or=2 different intraocular pressure (IOP)-lowering medications.",
            "An effective and well-tolerated fixed combination of agents requiring once-daily instillation may improve patient compliance.",
            "The purpose of this study was to compare the efficacy and safety profile of the fixed combination latanoprost 0.005% + timolol maleate 0.5% QD with those of latanoprost 0.005% monotherapy QD in patients whose elevated IOP (>or=21 mm Hg) was inadequately controlled by latanoprost.",
            "This 21-day, randomized, double-masked, active-control study was conducted at 49 study sites in Argentina, Brazil, Colombia, Mexico, Peru, the United States, and Venezuela.",
            "Adults with glaucoma or ocular hypertension who had failed to reach an IOP of <21 mm Hg while receiving latanoprost for at least 28 days were enrolled.",
            "After an additional 28 days of latanoprost run-in, patients were randomly assigned to continue latanoprost monotherapy or to switch to the fixed combination for 21 days.",
            "The intent-to-treat (ITT) population included all patients who received at least 1 dose of double-masked study medication; the per-protocol (PP) analysis included patients who completed the study without a major protocol violation and who had IOP measurements both at baseline and at day 21.",
            "The primary end point was the proportion of patients whose IOP was decreased >or=2 mm Hg from the baseline level on day 21.",
            "Proportions of patients demonstrating IOP decreases >or=3, >or=4, or >or=5 mm Hg from the baseline level and of patients reaching an 10P <or=18 mm Hg were evaluated.",
            "Adverse events (AEs) were also assessed.",
            "A total of 350 patients were enrolled.",
            "In all, 348 patients were included in the ITT and tolerability analyses (fixed combination, n = 175; latanoprost, n = 173; mean [SD] age, 64.4 [13.2] and 63.2 [14.0] years, respectively; 103 women in each group).",
            "Baseline demographic and clinical characteristics were similar between groups.",
            "A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).",
            "PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).",
            "Both treatments were well tolerated.",
            "Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).",
            "In this selected population of patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence",
            "Claim"
        ]
    },
    "22310086": {
        "sentences": [
            "Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.",
            "To compare the efficacy and safety of tafluprost, a preservative-free (PF) prostaglandin analogue, with PF timolol in patients with open-angle glaucoma or ocular hypertension.",
            "Randomized, double-masked, multicenter clinical trial.",
            "After discontinuation and washout of existing ocular hypotensive treatment, patients who had intraocular pressure (IOP) =23 and =36 mm Hg in at least 1 eye at the 08:00 hour time point were randomized 1:1 to 12 weeks of treatment with either PF tafluprost 0.0015% or PF timolol 0.5%.",
            "IOP was measured 3 times during the day (08:00, 10:00, 16:00 hours) at baseline and at weeks 2, 6, and 12.",
            "It was hypothesized that PF tafluprost would be noninferior to PF timolol over 12 weeks with regard to change from baseline IOP.",
            "The trial was powered for a noninferiority margin of 1.5 mm Hg at each of the 9 time points assessed.",
            "A total of 643 patients were randomized and 618 completed (PF tafluprost = 306, PF timolol = 312).",
            "IOPs at the 3 time points assessed during the baseline visit ranged from 23.8 to 26.1 mm Hg in the PF tafluprost group and 23.5 to 26.0 mm Hg in the PF timolol group.",
            "IOPs at the 3 time points assessed during the 12-week visit ranged from 17.4 to 18.6 mm Hg for PF tafluprost and 17.9 to 18.5 mm Hg for PF timolol.",
            "At all 9 time points, the upper limits of the 2-sided 95% confidence intervals for the difference between treatments in IOP lowering were less than the prespecified noninferiority margin.",
            "Similar percentages of PF tafluprost and PF timolol patients reported ocular pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).",
            "The percentages of PF tafluprost and PF timolol patients reporting conjunctival hyperemia were 4.4% vs 1.2% (nominal P = .016).",
            "The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.",
            "PF tafluprost is an efficacious and generally well-tolerated ocular hypotensive agent."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "21141017": {
        "sentences": [
            "A randomised clinical trial comparing the outcome of trabeculectomy using triangular versus rectangular scleral flaps.",
            "trabeculectomy is the standard surgical procedure for management of glaucoma.",
            "to compare the outcome of triangular and rectangular scleral flaps in trabeculectomy.",
            "this study was carried out in the Department ofOphthalmology, BPKIHS, Dharan, over a period of one year.",
            "A total of 22 patients undergoing trabeculectomy were randomized to undergo either trabeculectomy with triangular scleral flap (Group A= 11 eyes) or trabeculectomy with rectangular flap (Group B = 11 eyes).",
            "the parameters studied were intraocular pressure (IOP), anterior chamber depth (ACD), bleb characteristics and surgical complications.",
            "P value of<0.05 was considered significant.",
            "All calculations were executed using SPSS 11.0 software program.",
            "the age ranged between 40 to 76 years with the mean of 56.5 +/- 9.25 years.",
            "The most common preoperative diagnosis was angle closure glaucoma.",
            "The postoperative percentage of IOP reduction (Group A 68.9%; Group B 66.51%) was statically significant in both the groups (p=0.001).",
            "Trabeculectomy was almost equally effective with complete surgical success of 91% in group A, and 82% in group B (p=0.534).",
            "Final bleb scores were almost similar in both the groups with 3.27 +/- 1.5 in group A and 3.36 +/- 1.21 in group B (p=0.877).",
            "Hypotony with the IOP less than 6 mmHg was found in the first post-operative day in 2 patients in Group A and in 1 in Group B.",
            "All of them improved spontaneously within a week.",
            "both triangular and rectangular scleral flaps in trabeculectomy are equally effective in terms of post surgical IOP control, bleb characteristics and complications."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "11813932": {
        "sentences": [
            "A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.",
            "Many physicians recommend either brimonidine or latanoprost as firstline therapy for chronic open-angle glaucoma or ocular hypertension.",
            "However, a search of MEDLINE indicates that there have been few head-to-head comparisons of the 2 monotherapies in a clinical setting.",
            "This study compared the clinical efficacy and tolerability of brimonidine 0.2% twice daily with those of latanoprost 0.005% once daily as monotherapy in patients with open-angle glaucoma or ocular hypertension.",
            "In this 3-month, multicenter, double-masked, parallel-group, 4-visit study, treatment-naive and previously treated patients with open-angle glaucoma or ocular hypertension and bilateral intraocular pressure (IOP) after washout of between 22 and 34 mm Hg were randomized to receive either brimonidine or latanoprost.",
            "Patients who had received previous treatment with either study drug were excluded from the study.",
            "The primary outcome measure was response rate, defined as the percentage of patients achieving > or = 20% reduction in IOP from baseline to month 3.",
            "Secondary outcome measures were mean IOP reduction from baseline to month 3 and clinical success, defined as the investigator's recommendation that the patient continue using the assigned study medication.",
            "A total of 127 patients (55 treatment naive) were enrolled, 66 in the brimonidine group and 61 in the latanoprost group.",
            "After 3 months of treatment, 80% of patients in the brimonidine group and 74% of patients in the latanoprost group had achieved > or = 20% reduction in IOP from baseline.",
            "The mean reduction in IOP from baseline at month 3 was 6.8 mm Hg with brimonidine and 6.5 mm Hg with latanoprost (27.8% vs 27.0%, respectively).",
            "Among treatment-naive patients, a significantly higher percentage of brimonidine-treated patients achieved > or = 20% decrease in IOP compared with latanoprost-treated patients (88% vs 59%, respectively; P = 0.01).",
            "In previously treated patients, a higher percentage of the latanoprost group achieved > or = 20% reduction in IOP compared with the brimonidine group (88% vs 74%, respectively); however, the difference was not statistically significant.",
            "Significantly more patients in the brimonidine group achieved clinical success at month 3 compared with patients in the latanoprost group (91% vs 74%; P = 0.01).",
            "At peak effect, brimonidine twice daily was as effective as latanoprost once daily in lowering IOP.",
            "In treatment-naive patients, latanoprost was associated with a significantly higher rate of nonresponse after 3 months of treatment compared with brimonidine.",
            "This suggests that brimonidine may be the more reliable choice for first-line therapy of newly diagnosed open-angle glaucoma or ocular hypertension.",
            "In previously treated patients, however, latanoprost provided greater mean IOP reduction than did brimonidine.",
            "Significantly more patients achieved clinical success with brimonidine monotherapy than with latanoprost monotherapy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null,
            "Claim"
        ]
    },
    "12660585": {
        "sentences": [
            "[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].",
            "Carteolol is a beta-adrenoceptor antagonist with intrinsic sympathomimetic activity.",
            "Used topically to reduce intraocular pressure, it is typically applied twice daily.",
            "In an effort to provide a once-daily dosing regimen, carteolol was formulated with 1% alginic acid.",
            "Sodium alginate is a natural polymer product with bioadhesive properties providing increased corneal contact time and a better carteolol penetration through the cornea.",
            "The objective of this study was to evaluate the efficacy and safety of long-acting 1% carteolol alginate solution compared to standard 1% carteolol solution.",
            "This was a double-masked, parallel group, multicentre study.",
            "Patients with ocular hypertension or open angle glaucoma (n=151) were randomly assigned to receive either 1% carteolol alginate once daily (AM) or standard 1% carteolol solution twice daily for 2 months.",
            "The masking was maintained through the use of a placebo in the evening for the alginate group.",
            "Entry into the study required unmedicated intraocular pressure (IOP) between 23 mmHg and 32 mmHg at 9 AM and 11 AM.",
            "Patients using ocular hypotensive medication were required to undergo a washout.",
            "All patients provided written informed consent.",
            "Excluded from the study were patients with angle closure, congenital, secondary glaucoma or advanced glaucoma; any intraocular infection or inflammation, ocular trauma, ocular surgery or laser trabeculoplasty within the previous 3 months; contraindications to the use of beta adrenoceptor antagonists; systemic medications likely to modify IOP prescribed or modified during the previous 3 months; ocular steroid use; contact lens wear; and pregnant and lactating women.",
            "Patients were evaluated at baseline, 15 and 60 days, with IOP measurements at 9 AM and 11 AM.",
            "At day 15 and day 60, IOP was measured just before instillation of medication (9 AM) and 2 hours after (11 AM).",
            "Slit lamp examinations were performed at each follow-up examination, together with measurement of heart rate and blood pressure (10 AM) and ocular tolerance after medication (11 AM).",
            "The primary efficacy criterion was the decrease in IOP from baseline at day 60 for each measurement at 9 AM and 11 AM.",
            "The study eye was the eye with the higher IOP at day 0 or, if equal, the right eye.",
            "Efficacy-of the 151 patients included in the study, 149 were evaluated (two patients were lost to follow-up after day 0): 74 in the alginate group and 75 in the standard group.",
            "Both treatment groups were comparable at day 0 except for sex, diastolic blood pressure, and IOP in the fellow eye.",
            "At 09.00 hours (presumed trough) on day 60, mean reductions from baseline in intraocular pressure were 6.32+/-2.87 and 5.67+/-3.30 mmHg for the alginate carteolol and standard groups, respectively.",
            "At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.",
            "At each evaluation time, the two unilateral t tests were highly significant (p<0.005), confirming the equivalence of both treatments.",
            "Conclusions were not modified taking into account sex and diastolic blood pressure.",
            "Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.",
            "Subjective tolerance upon instillation was judged good or very good at day 60 by 100% of alginate patients and by 98.7% of standard patients.",
            "Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.",
            "A blurred vision sensation was reported by 2 out of 74 patients of the alginate group.",
            "Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.",
            "No serious adverse events were reported.",
            "The new alginate formulation of long-acting carteolol 1% given once daily is as effective as standard 1% carteolol given twice daily, with no meaningful differences regarding safety.",
            "This efficacy wasy was verified at 9 AM (24 hours after the last drop of long-acting carteolol or 12 hours after that of standard carteolol) and at 11 AM (2 hours after the morning drop).",
            "The new alginate formulation of long-acting carteolol 1% given once a day is effective and well tolerated by glaucoma patients who require chronic treatment."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null,
            null
        ]
    },
    "11020403": {
        "sentences": [
            "Ahmed glaucoma valve implant vs trabeculectomy in the surgical treatment of glaucoma: a randomized clinical trial.",
            "To compare the short- and intermediate-term results of two commonly used glaucoma surgical procedures, trabeculectomy and Ahmed glaucoma valve implant.",
            "A randomized clinical trial was performed at two international centers.",
            "One eye each of consecutive patients requiring glaucoma surgery for intraocular pressure control was randomized to receive either trabeculectomy or the Ahmed implant.",
            "Of the 117 patients, 62 were randomized to trabeculectomy and 55 to the Ahmed implant.",
            "With a mean follow-up of 9.7 months, the trabeculectomy group had statistically lower intraocular pressures at weeks 6 to 15 (12.6 mm Hg vs 16.4 mm Hg) and months 11 to 13 (11.4 mm Hg vs 17.2 mm Hg) than the Ahmed implant group.",
            "Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.",
            "The cumulative probabilities of success (intraocular pressure <21 mm Hg and at least 15% reduction in intraocular pressure from preoperative level) were 83.6% for trabeculectomy and 88.1% for Ahmed implant (P =.43).",
            "However, the Ahmed implant group had a greater adjunctive medication requirement.",
            "On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).",
            "There was no statistically significant difference in the rate of complications between the two groups.",
            "Lower mean intraocular pressures were noted for the trabeculectomy group.",
            "All other results, including success (as defined in this study) and frequency of complications, were comparable between the two groups."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence"
        ]
    },
    "21573097": {
        "sentences": [
            "Augmenting trabeculectomy in glaucoma with subconjunctival mitomycin C versus subconjunctival 5-fluorouracil: a randomized clinical trial.",
            "\ufeff",
            "The aim of this study was to compare the efficacy of augmenting trabeculectomy with subconjunctival mitomycin C (TMMC) versus 5-fluorouracil (T5-FU) in lowering intraocular pressure (IOP).",
            "Forty eyes from 40 patients referred to the Nikoukari Ophthalmology University Hospital, Tabriz University of Medical Sciences, Tabriz, Iran, were enrolled in a randomized clinical trial.",
            "Patients with high-risk open angle glaucoma were allocated to receive either subconjunctival TMMC or T5-FU.",
            "Mean overall preoperative IOP was 30.8 mmHg.",
            "Mean preoperative IOPs in the TMMC and T5-FU groups were 31.2 \u00b1 9.8 and 30.6 \u00b1 9.9 mmHg, respectively.",
            "Postoperatively, mean IOPs were 11.4 \u00b1 4.9 and 13.6 \u00b1 3.9 mmHg, respectively for TMMC and T5-FU groups after 6 months.",
            "In spite of some existing descriptive differences in IOP between the groups, statistical tests showed no difference in mean and median IOP.",
            "Three cases of hypotonia (IOP < 6 mmHg) and 1 case of epithelial keratitis were detected.",
            "TMMC and T5-FU appeared to have similar efficacy in lowering IOP."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "21034177": {
        "sentences": [
            "Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.",
            "To compare the efficacy of bimatoprost and travoprost on intraocular pressure (IOP) reduction in an Egyptian population.",
            "Patients with primary open-angle glaucoma or ocular hypertension were randomized to receive either bimatoprost 0.03% or travoprost 0.004% once daily.",
            "IOPs were measured at baseline; 2 weeks; and 1, 2, 4, and 6 months using Goldman applanation tonometery.",
            "Seventy-two patients were included: 34 and 38 (P=0.142) with a baseline mean IOP 26.52 \u00b1 5.185 and 26.36 \u00b1 1.605 mm Hg (P=0.629) for bimatoprost and travoprost, respectively.",
            "Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).",
            "Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.",
            "Mean IOP reduction was 8.77 mm Hg (33.39%) and 8.42 mm Hg (31.54%) at 2 weeks (P = 0.703), and 8.47 mm Hg (31.61%) and 7.84 mm Hg (29.50%) at 6 months (P = 0.536) for bimatoprost and travoprost, respectively.",
            "IOPs at 2 weeks were 18 mm Hg in 20 (58.8%) versus 19 (50%) eyes (P = 0.603), and 16 mm Hg in 12 (35%) versus 12 (32%) eyes (P = 0.456); and at 6 months 18 mm Hg in 22 (65%) versus 14 (37%) eyes (P = 0.045), and 16 mm Hg in 12 (35%) versus 7 (18%) eyes (P = 0.037) for bimatoprost and travoprost, respectively.",
            "Ocular adverse and clinical success occurred equally with both drops.",
            "Both drops lowered IOP effectively but bimatoprost showed a greater non-significant reductions in mean IOP from baseline."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "10080213": {
        "sentences": [
            "A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.",
            "To compare the efficacy and side effects and the effect on aqueous humor dynamics of 0.005% latanoprost applied topically once daily with 0.5% timolol given twice daily for 12 months to patients with pigmentary glaucoma.",
            "Prospective, randomized, double-masked, clinical study.",
            "Thirty-six patients affected with bilateral pigmentary glaucoma controlled with no more than a single hypotensive medication were enrolled in the study.",
            "The sample population was randomly divided into 2 age- and gender-matched groups each of 18 patients.",
            "Group 1 received 0.005% latanoprost eyedrops once daily and the vehicle (placebo) once daily; group 2 was assigned to timolol 0.5% eyedrops twice daily.",
            "Diurnal curves of intraocular pressure (IOP) were performed on the baseline day and after 0.5, 3, 6, and 12 months of treatment.",
            "The IOP measurements were performed at 8:00 AM, 12:00 noon, 4:00 PM, and 8:00 PM.",
            "Outflow facility (C) was measured on the baseline day and on the last day of the study with a Schiotz electronic tonometer.",
            "A two-tailed Student's t test for paired or unpaired data was used for statistical evaluation of differences between treatment and baseline values or between the latanoprost and timolol group.",
            "Diurnal IOP measurements were compared hour by hour.",
            "Mean values of the two eyes IOP and C were used for analysis.",
            "Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.",
            "Reduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.",
            "Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.",
            "Mean C was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).",
            "Mean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.",
            "A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.",
            "Darkening of the peripheral iris stroma was suspected in two patients treated with latanoprost.",
            "In the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.",
            "Although further studies may need to confirm these data on a larger sample and to evaluate the side effect of increased iris pigmentation on long-term follow-up, in patients with pigmentary glaucoma, 0.005% latanoprost taken once daily was well tolerated and more effective in reducing IOP than 0.5% timolol taken twice daily."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Claim"
        ]
    },
    "21257146": {
        "sentences": [
            "A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.",
            "To compare the alpha2-adrenergic agonist brimonidine tartrate 0.2% to the beta-adrenergic antagonist timolol maleate 0.5% in preserving visual function in low-pressure glaucoma.",
            "Randomized, double-masked, multicenter clinical trial.",
            "Exclusion criteria included untreated intraocular pressure (IOP) >21 mm Hg, visual field mean deviation worse than -16 decibels, or contraindications to study medications.",
            "Both eyes received twice-daily monotherapy randomized in blocks of 7 (4 brimonidine to 3 timolol).",
            "Standard automated perimetry and tonometry were performed at 4-month intervals.",
            "Main outcome measure was field progression in either eye, defined as the same 3 or more points with a negative slope -1 dB/year at P<5%, on 3 consecutive tests, assessed by pointwise linear regression.",
            "Secondary outcome measures were progression based on glaucoma change probability maps (GCPM) of pattern deviation and the 3-omitting method for pointwise linear regression.",
            "Ninety-nine patients were randomized to brimonidine and 79 to timolol.",
            "Mean (+/- SE) months of follow-up for all patients was 30.0 +/- 2.",
            "Statistically fewer brimonidine-treated patients (9, 9.1%) had visual field progression by pointwise linear regression than timolol-treated patients (31, 39.2%, log-rank 12.4, P=.001).",
            "Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.",
            "More brimonidine-treated (28, 28.3%) than timolol-treated (9, 11.4%) patients discontinued study participation because of drug-related adverse events (P=.008).",
            "Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.",
            "Low-pressure glaucoma patients treated with brimonidine 0.2% who do not develop ocular allergy are less likely to have field progression than patients treated with timolol 0.5%."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "15220019": {
        "sentences": [
            "Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.",
            "The newer ocular hypotensive agents available to treat glaucoma and ocular hypertension (OHT) include latanoprost, a prostaglandin F(2alpha) analogue, and the fixed combination of dorzolamide hydrochloride, a carbonic anhydrase inhibitor, and timolol maleate, a beta-blocker.",
            "The aim of this study was to compare the efficacy and tolerability of latanoprost with that of the fixed combination of dorzolamide and timolol over 8 weeks.",
            "This interventional, 8-week, randomized, open-label, parallel-group study was conducted at 18 centers in 6 Latin American countries.",
            "Patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT were randomized to receive latanoprost, 1 drop in the affected eye QD (evening), or fixed combination dorzolamide/timolol, 1 drop in the affected eye BID (morning and evening).",
            "Medications were self-administered, 1 drop per affected eye.",
            "At baseline and week 8, intraocular pressure (IOP) was measured 3 times each at 8:30 am, 10:00 am, 2:00 pm, and 5:00 pm and after the water-drinking test, which estimates the IOP peak of diurnal tension curve, performed following the 5:00 pm IOP assessment.",
            "The primary efficacy outcome was change in diurnal IOP (the mean of IOP measurements) from baseline to week 8.",
            "Adverse effect (AE) data were recorded at each visit.",
            "A total of 229 patients were randomized (latanoprost, n = 112; dorzolamide/timolol, n = 117).",
            "Mean baseline diurnal IOP values were similar between the 2 groups.",
            "Mean (SD) diurnal IOP reductions at week 8 before the water-drinking test were 6.9 (3.0) mm Hg for the latanoprost group and 6.4 (3.2) mm Hg for the dorzolamide/timolol group.",
            "Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).",
            "After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).",
            "Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).",
            "In this study of patients with unilateral or bilateral primary open-angle, pigmentary, or exfoliative glaucoma or OHT IOP reductions generally were similar between treatment groups, except at 5:00 pm, when the mean IOP level was significantly lower in latanoprost-treated patients.",
            "Latanoprost was better tolerated than fixed-combination dorzolamide and timolol."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "21491994": {
        "sentences": [
            "Effect of oral clonidine on acute intraocular pressure rise after phacoemulsification: a prospective double-blind, randomized, clinical trial.",
            "To determine the efficacy and safety of oral clonidine in decreasing the prevalence and intensity of postoperative intraocular pressure (IOP) rise in those undergoing phacoemulsification.",
            "This was a prospective randomized, double-blind, placebo-controlled, clinical trial including 62 patients (each with 1 affected aye) with senile cataract scheduled for phacoemulsification who were randomly assigned to receive preoperative oral clonidine (5g/kg, 31 patients) or placebo (1 tablet, 31 patients).",
            "The IOP was measured preoperatively and at 6, 12, and 24h postoperatively.",
            "The prevalence and intensity of the acute postoperative IOP rise was compared between and within the groups.",
            "There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).",
            "Patients who received placebo as premedication had significantly higher IOP at 6 (17.96\u00b15.49 vs 13.61\u00b14.09; P<0.001) and 12 (16.90\u00b14.11 vs 13.96\u00b13.25; P=0.003) h postoperatively compared with those who received oral clonidine.",
            "However, there was no significant difference between the 2 groups regarding the IOP at 24h after operation (15.41\u00b13.96 vs 16.01\u00b13.41; P=0.0539).",
            "The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs 9.6%; P=0.091).",
            "Administering preoperative oral clonidine in a dosage of 5g/kg, 2h before phacoemulsification, significantly decreases the prevalence and intensity of acute postoperative IOP rise in those undergoing general anesthesia.",
            "Oral clonidine is safe, cheap, and easily accessible and, thus, it is recommended for controlling the IOP after phacoemulsification, especially in high-risk patients."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "19590523": {
        "sentences": [
            "Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial.",
            "To compare the effectiveness and safety of excimer laser trabeculotomy (ELT) ab interno vs selective laser trabeculoplasty (SLT) over 24 months of follow-up in patients with primary open-angle glaucoma (POAG) refractory to medical therapy.",
            "This prospective, randomized study included 30 consecutive eyes assigned randomly to either ELT or SLT group.",
            "ELT was carried out using a XeCl Excimer Laser with an emission wavelength of 308 nm.",
            "Eight spots were equally distributed at a distance of 500 microm from one another over the anterior trabeculum.",
            "The SLT patients were treated with a frequency-doubled q-switched neodymium:yytrium-aluminum-garnet laser (wavelength 532 nm).",
            "Approximately 50 adjacent, but not overlapping, laser spots were distributed over 180 degrees of the trabecular meshwork, using an energy level ranging from 0.7 to 1.0 mJ per pulse.",
            "The main outcome measure was intraocular pressure (IOP) lowering after ELT and SLT.",
            "Success was defined as >or=20% reduction in IOP without further glaucoma intervention.",
            "At 24 months, complete success rates were 53.3% for the ELT group and 40% for the SLT group (P=0.35, Fisher's exact test); qualified success rates were 33.3% for the ELT and 26.6% for the SLT group (P=0.5, Fisher's exact test).",
            "Mean IOP decreased from 25.0+/-1.9 to 17.6+/-2.2 mmHg (-29.6%; P<0.0001) in the ELT group and from 23.9+/-0.9 to 19.1+/-1.8 mmHg (-21%; P<0.0001) in the SLT group.",
            "Both ELT and SLT proved to be effective techniques in the treatment of POAG refractory to medical therapy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "21792284": {
        "sentences": [
            "Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost.",
            "To evaluate the additive intraocular pressure (IOP)-lowering efficacy and safety of fixed combination brimonidine 0.2%/timolol 0.5% compared with timolol 0.5% at peak and trough effect when used as therapy adjunctive to latanoprost 0.005% in patients with glaucoma or ocular hypertension who require additional IOP lowering.",
            "In this prospective, randomized, multicenter, investigator-masked, parallel-group study, patients were treated with latanoprost monotherapy for at least four weeks prior to baseline.",
            "At baseline on latanoprost, patients with IOP 21 mmHg in at least one eye were randomized to twice-daily fixed brimonidine-timolol (n = 102) or timolol (n = 102), each adjunctive to latanoprost for 12 weeks.",
            "IOP was measured at 8 am and 10 am at baseline, week 6, and week 12 and evaluated in the per protocol population.",
            "The primary efficacy endpoint was peak IOP lowering at 10 am, week 12.",
            "Safety measures included adverse events.",
            "Baseline mean IOP was similar at 10 am in the treatment groups (brimonidine-timolol 23.4 mmHg; timolol 23.0 mmHg).",
            "The mean additional reduction from latanoprost-treated baseline IOP was 8.3 mmHg (35.5%) with fixed brimonidine-timolol and 6.2 mmHg (27.0%) with timolol at 10 am, week 12 (P < 0.001).",
            "Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a  20% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.",
            "Adverse events occurred in 14.7% of fixed brimonidine-timolol patients and 12.7% of timolol patients.",
            "Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.",
            "Fixed-combination brimonidine-timolol reduced IOP significantly more effectively than timolol when used as adjunctive therapy to latanoprost in patients with glaucoma and ocular hypertension.",
            "Both fixed brimonidine-timolol and timolol were well tolerated as agents adjunctive to latanoprost."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "20733558": {
        "sentences": [
            "A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma.",
            "The aim of this study is to assess the efficacy and complications of trabeculectomy with a biodegradable implant (ologen implant) vs trabeculectomy using mitomycin C (MMC) in patients with medically uncontrolled open-angle glaucoma in a prospective randomised clinical trial.",
            "In the MMC group (10 patients), trabeculectomy was performed according to standard protocols.",
            "In the ologen group (10 patients) after standard trabeculectomy the implant was positioned on top of the scleral flap and no MMC was applied.",
            "Follow-up was continued for 12 months after surgery and included testing of intraocular pressure (IOP), visual acuity, visual field, ultrasound biomicroscopy, and filtering bleb score.",
            "The mean preoperative IOP was 24.8+/-8.9 mm Hg for all patients enrolled.",
            "At 1 year after surgery, the mean IOP was 15.6+/-2.4mm Hg in the ologen group (P<0.01, 43% reduction) and 11.5+/-4.1 mm Hg in the MMC group (P<0.01, 50% reduction).",
            "No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.",
            "The absolute success rate was 100% in the MMC group and 50% in the ologen group (P=0.01).",
            "After 1 year, filtering blebs developed significantly more avascular areas in the MMC group (score=1.4) than in the ologen group (score=2.8; P<0.01).",
            "The complete success rate using trabeculectomy with the ologen implant is lower than that achieved by trabeculectomy with MMC.",
            "However, the bleb morphology caused more problems in the MMC group (avascularity score)."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "21183518": {
        "sentences": [
            "Analgesic effect of supplemental intracameral lidocaine during phacoemulsification under topical anaesthesia: a randomised controlled trial.",
            "To determine the analgesic effect of supplemental intracameral lidocaine 1% during phacoemulsification under topical anaesthesia, and to assess the risk factors associated with pain.",
            "In a double-masked, randomised, clinical trial, 506 patients undergoing phacoemulsification under topical anaesthesia were randomised to receive a supplemental intracameral injection of either 0.5 cc of 1% lidocaine (277 patients, 54.7%) or balanced salt solution (BSS) (229 patients, 45.3%).",
            "Patients were interviewed by a trained interviewer using a standardised questionnaire.",
            "The main outcome measure was intraoperative pain, scored on a visual analogue scale of 0-10.",
            "Logistic regression was performed to assess ORs.",
            "125 of 277 patients (45.1%) experienced pain in the lidocaine group, compared with 123 of 229 patients (53.7%) in the BSS group.",
            "The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).",
            "The median pain score (range) was 0.0 for intracameral lidocaine group compared with 1.0 for BSS group (p=0.039).",
            "Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).",
            "The use of 0.5 cc of 1% intracameral lidocaine during phacoemulsification under topical anaesthesia significantly reduces pain experienced by patients.",
            "Risk factors for pain include females, non-Chinese and previous cataract surgery."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "19427617": {
        "sentences": [
            "Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range.",
            "To compare latanoprost and timolol with regard to changes in the intervisit intraocular pressure (IOP) range, a measure of long-term IOP fluctuation.",
            "Post hoc analysis of three 6-month, multicenter, randomized (1:1), double-masked registration trials of latanoprost (n = 313) vs timolol (n = 318).",
            "Analyses included patients with glaucoma or ocular hypertension who instilled latanoprost once daily in the evening and vehicle in the morning and those instilling timolol twice daily.",
            "Pretreatment intervisit IOP range: highest IOP minus lowest IOP of 4 measurements obtained at screening and baseline.",
            "Posttreatment intervisit IOP range: highest IOP minus lowest IOP of 4 measurements obtained at weeks 18 and 26.",
            "Ranges were dichotomized to high (> 6 mm Hg) and low (< or = 6 mm Hg).",
            "Both treatments resulted in significant reductions in mean intervisit IOP range during 26 weeks.",
            "Pretreatment, comparable proportions of patients treated with latanoprost and timolol had high intervisit IOP ranges (22% [70/313] and 23% [72/318], respectively; P = .934).",
            "After treatment, 6% (19/313) and 11% (35/318) of patients in the latanoprost and timolol groups, respectively, had high intervisit IOP ranges (P = .026).",
            "Significant risk factors for high posttreatment intervisit range (multivariate logistic regression) were high pretreatment intervisit IOP range, treatment with timolol, Black race, longer time since diagnosis, and higher mean pretreatment IOP.",
            "Compared with timolol, treatment with latanoprost results in significantly fewer patients with a high IOP fluctuation.",
            "The impact of reducing high IOP fluctuation on progressive glaucomatous damage deserves further investigation in prospective studies."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Claim",
            null,
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "19337705": {
        "sentences": [
            "The Ex-PRESS glaucoma shunt versus trabeculectomy in open-angle glaucoma: a prospective randomized study.",
            "The purpose of this study was to establish the efficacy and safety of the Ex-PRESS (Optonol Ltd., Neve Ilan, Israel) mini glaucoma shunt in open-angle glaucoma.",
            "This was a prospective, randomized trial.",
            "Eyes from enrolled patients were randomly assigned to either Ex-PRESS implantation under a scleral flap, or trabeculectomy.",
            "The main outcome measures were: mean intraocular pressure (IOP), postoperative medication use, visual acuity, and incidence of complications.",
            "Complete success was defined as an IOP of >4 mmHg and <or=18 mmHg without the use of antiglaucoma medications.",
            "A more stringent target of IOP >4 mmHg and <or=15 mmHg was also noted.",
            "There were 78 patients (80 eyes) with primary open-angle, pseudoexfoliative, or pigmentary glaucoma enrolled in the study.",
            "A total of 84.6% of patients receiving Ex-PRESS and 60.0% of patients receiving trabeculectomy (P=0.0230) achieved complete success.",
            "The respective proportions of patients achieving an IOP >4 mmHg and <or=15 mmHg were 76.9% and 50.0% (P=0.0193).",
            "At 1-year follow-up, complete success rates were 81.8% for Ex-PRESS and 47.5% for trabeculectomy (P=0.0020), and 71.7% and 37.5% (P=0.0070), respectively, for the more stringent target.",
            "There was a similar level of postoperative interventions and complications for each group.",
            "In open-angle glaucoma, the Ex-PRESS mini glaucoma shunt implanted under a superficial scleral flap produces significantly higher success rates, and a similar complication rate, compared with trabeculectomy.",
            "The Ex-PRESS is a safe and effective device for treating open-angle glaucoma."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "19123151": {
        "sentences": [
            "Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study.",
            "To compare the efficacy and tolerability of a once-daily evening dose of bimatoprost/timolol fixed combination (BTFC) with that of a once-daily evening dose of latanoprost/timolol fixed combination (LTFC) in patients not controlled with prostaglandins analogues monotherapy.",
            "A total of 82 patients on prostaglandin analogues monotherapy were enrolled in this prospective, multicenter, investigator masked, clinical study and were randomized to either BTFC (n=47) or LTFC (n=35) topical therapy once at night for 12 weeks.",
            "The primary endpoint of the study was to compare the mean daily intraocular pressure (IOP) reduction from baseline between the two treatment arms.",
            "Secondary endpoints included the mean daily IOP at 1 and 3 months compared to baseline and the percentage of patients showing a mean IOP reduction from baseline greater than or equal to 15% or 20%.",
            "Mean IOP at baseline was 22.7+/-2.0 and 22.1+/-2.6 mmHg in the BTFC and LTFC groups, respectively (p=0.23).",
            "Both treatments were effective in reducing the IOP from baseline.",
            "The mean IOP reduction was significantly greater in the BTFC group than in the LTFC group (-21.4% vs -13.7%, p<0.001).",
            "A higher percentage of patients in the BTFC group showed a mean IOP reduction from baseline >or=15% (72.3% vs 40.0%) and >or=20% (61.7% vs 17.1%) compared to patients in the LTFC group.",
            "Both BTFC and LTFC were more effective versus the monotherapy with prostaglandin analogues.",
            "BTFC demonstrated higher performance than LTFC in terms of relative IOP reduction."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "12644943": {
        "sentences": [
            "Results of the betaxolol versus placebo treatment trial in ocular hypertension.",
            "To determine whether treatment with betaxolol can delay or prevent the conversion from ocular hypertension to early glaucoma on the basis of visual field criteria, by means of a prospective, randomised, placebo-controlled trial.",
            "Three hundred and fifty-six ocular hypertensives were randomized to treatment with either betaxolol drops or placebo drops during the period 1992-1996.",
            "Each patient was followed prospectively with 4-monthly visits.",
            "Examination at each visit included visual field testing, intra-ocular pressure (IOP) measurement and optic disc imaging.",
            "Conversion to early glaucoma was defined on the basis of visual field change by AGIS criteria.",
            "An intent-to-treat analysis compared visual field conversion after 3 years in the treatment and placebo arms.",
            "Normal visual field survival analysis was also performed.",
            "The IOP characteristics of the two treatment groups were compared.",
            "Two hundred and fifty-five patients completed the study, which ended in 1998, with a range of follow-up of 2-6 years.",
            "Sixteen (13.2%) of 121 patients in the placebo group converted to glaucoma, compared with 12 (9.0%) of 134 patients in the betaxolol group.",
            "The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.",
            "Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.",
            "The betaxolol-treated group had significantly lower post-treatment IOP values.",
            "Converters had significantly higher pre- and post-treatment IOP values than non-converters.",
            "Betaxolol significantly lowered the IOP level compared with placebo.",
            "Conversion to glaucoma was found to be related to both the baseline and post-treatment IOP levels.",
            "However the intent-to-treat analysis did not demonstrate a statistically significant reduction in the conversion rate in the betaxolol-treated group."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "8628543": {
        "sentences": [
            "A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.",
            "To compare the intraocular pressure (IOP)-reducing effect and side effects of 0.005% latanoprost administered once daily with 0.5% timolol administered twice daily in patients with open-angle glaucoma or ocular hypertension.",
            "This was a randomized, double-masked study with two parallel groups and a treatment period of 6 months.",
            "The primary objective of the study is to compare the IOP-reducing effect of latanoprost with that of timolol at the end of the 6-month treatment period.",
            "A total of 294 patients were included: 149 were in the latanoprost group and 145 were in timolol group.",
            "Latanoprost was administered in the evening.",
            "Diurnal IOP (9:00 am, 1:00 pm, 5:00 pm) was reduced from 25.2 to 16.7 mmHg (33.7%) with lantanoprost and from 25.4 to 17.1 mmHg (32.7%) with timolol as determined at the end of the 6-month treatment period.",
            "No upward drift in IOP occurred with either drug during the treatment period.",
            "Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.",
            "However, both drugs were generally well tolerated.",
            "The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).",
            "Timolol caused more systemic side effects than latanoprost.",
            "Latanoprost 0.005% administered once daily in the evening reduced IOP at least as well as timolol 0.5% administered twice daily.",
            "Latanoprost was generally well tolerated systemically and in the eye.",
            "However, the drug has an unusual side effect of increasing the pigmentation of the iris, particularly in individuals with green-brown or blue-brown eyes."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim",
            null
        ]
    },
    "17825417": {
        "sentences": [
            "Randomized comparison of 1-Site and 2-Site phacotrabeculectomy with 3-year follow-up.",
            "To compare intraocular pressure (IOP) control and other clinical outcomes after 1-site fornix-based and 2-site limbus-based phacotrabeculectomy.",
            "Prospective randomized controlled trial.",
            "A total of 90 eyes of 76 patients with cataract and glaucoma were treated.",
            "Forty-four eyes were assigned randomly to receive a 1-site phacotrabeculectomy with a fornix-based conjunctival flap, and 46 eyes were assigned randomly to receive a 2-site phacotrabeculectomy with a limbus-based conjunctival flap.",
            "All operations were performed with mitomycin C.",
            "Intraocular pressure and number of antiglaucoma medications were recorded at baseline and during a 3-year follow-up period.",
            "Mean preoperative IOP was 20.1+/-3.8 mmHg in the 1-site group and 19.5+/-5.3 mmHg in the 2-site group (P = 0.56) using a mean of 2.3+/-0.9 and 2.5+/-0.9 antiglaucoma medications, respectively (P = 0.27).",
            "After 3 years of follow-up, the mean IOP was 12.6+/-4.8 mmHg in the 1-site group and 11.7+/-4.0 mmHg in the 2-site group (P = 0.40), receiving a mean of 0.3+/-0.7 and 0.4+/-0.9 medications, respectively (P = 0.59).",
            "At the end of the study, 73% of 1-site eyes and 78.4% of 2-site eyes had IOPs of less than 18 mmHg while receiving no antiglaucoma medications (P = 0.59).",
            "Visual acuity was similar for both groups at 3 months after surgery.",
            "There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.",
            "There were 2 major complications in each group during follow-up.",
            "Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).",
            "Operating time (in minutes) was less in the 1-site surgery group (P<0.0001).",
            "Day one postoperative IOP was higher in the 2-site group (P = 0.0.01).",
            "One-site fornix-based and 2-site limbus-based phacotrabeculectomy were similarly effective in lowering IOP and reducing the need for antiglaucoma medications over a 3-year follow-up period."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            null,
            null,
            "Claim"
        ]
    },
    "20142538": {
        "sentences": [
            "Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.",
            "To assess the efficacy and safety of fixed-combination latanoprost-timolol (FCLT) vs latanoprost or timolol monotherapy.",
            "This 12-week, randomized, double-masked, parallel-group study included patients with open-angle glaucoma or ocular hypertension treated with a beta-blocker and with baseline intraocular pressure (IOP) of 26 through 36 mm Hg.",
            "Following washout, eligible patients were randomized to once-daily FCLT in the evening, latanoprost in the evening, or timolol in the morning.",
            "Postbaseline IOP assessments at 8 am, 10 am, and 4 pm at weeks 2, 6, and 12; statistical superiority of FCLT for the 18 pairwise comparisons between FCLT and the 2 monotherapies, using analysis of variance.",
            "All therapies resulted in significant IOP reductions from baseline.",
            "Pairwise comparisons favored FCLT at all time points.",
            "When the 18 comparisons were tested simultaneously, FCLT was statistically superior to latanoprost at 7 of 9 time points and at all 9 time points when compared with timolol.",
            "In addition, FCLT was associated with greater percentage reductions in diurnal IOP levels and a greater likelihood of achieving lower mean diurnal IOP levels.",
            "Diurnal IOP reductions of 30% or more from baseline to week 12 were achieved by 73.5%, 57.5%, and 32.8% of those treated with FCLT, latanoprost, and timolol, respectively (P = .007 for FCLT vs timolol; P < .001 for FCLT vs latanoprost).",
            "All therapies were well tolerated.",
            "Fixed-combination latanoprost-timolol therapy is as safe and effective in lowering IOP in patients with either ocular hypertension or glaucoma as monotherapy with latanoprost or timolol.",
            "Combination therapy can be used to treat patients for whom monotherapy does not provide sufficient IOP reduction.",
            "The simplicity, efficacy, and tolerability of FCLT contribute to its utility in clinical practice."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            null,
            null
        ]
    },
    "14982045": {
        "sentences": [
            "Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.",
            "To compare the efficacy of the fixed dorzolamide 2%/timolol 0.5% combination (COSOPT) versus latanoprost 0.005% (XALATAN).",
            "Two 3-month, parallel group, randomized, observer-masked and patient-masked, multicentre, clinical trials were performed in patients with ocular hypertension or open-angle glaucoma.",
            "Study 1 (n=256) was conducted in the United States and Study 2 (n=288) was conducted in Europe/Israel.",
            "Patients could be included whether or not they were currently taking ocular hypotensive therapy, and regardless of the effectiveness of any previous therapy.",
            "Patients were washed out from their usual ocular hypotensive medications and then those with a baseline intraocular pressure (IOP) >/= 24 mmHg were randomized to either the dorzolamide/timolol combination eye drops twice daily or latanoprost eye drops once daily in both eyes.",
            "Efficacy was assessed by daytime diurnal IOP (the mean of measurements made at 0800, 1000, 1400 and 1600 h).",
            "At baseline, the mean daytime diurnal IOP was 26.1 mmHg in the dorzolamide/timolol combination group versus 25.6 mmHg in the latanoprost group in Study 1, and 25.3 mmHg in the dorzolamide/timolol combination group versus 24.7 mmHg in the latanoprost group in Study 2.",
            "After 3 months, the mean daytime diurnal IOP was 18.9 mmHg for the dorzolamide/timolol combination versus 18.4 mmHg for latanoprost in Study 1, and 17.4 mmHg for the dorzolamide/timolol combination versus 17.5 for latanoprost in Study 2.",
            "The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.",
            "The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.",
            "Both treatments were well tolerated over 3 months, although ocular stinging occurred more frequently with the dorzolamide/timolol combination.",
            "The dorzolamide/timolol combination and latanoprost were equally effective at lowering IOP."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "11558817": {
        "sentences": [
            "Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece.",
            "To compare the intraocular pressure-lowering effect of latanoprost with that of dorzolamide when added to timolol.",
            "This randomized, open-label study with two parallel groups was conducted in five centers in Greece.",
            "The study enrolled 148 patients with inadequately controlled open-angle or pseudoexfoliation glaucoma (intraocular pressure of at least 22 mm Hg) or ocular hypertension (intraocular pressure of at least 27 mm Hg) who were receiving monotherapy with a beta-blocker or dual therapy in which one of the agents was a beta-blocker.",
            "The patients were switched to timolol 0.5% twice daily for 2 to 4 weeks (run-in period) before the start of the study (baseline).",
            "At baseline, the patients were randomized to receive latanoprost 0.005% once daily or dorzolamide 2% twice daily as add-on therapy to timolol.",
            "The intraocular pressure was recorded at 9:30 AM, 12:30 PM, and 3:30 PM at baseline and at 3 months.",
            "Safety was followed throughout the study.",
            "The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).",
            "The mean intraocular pressure reduction from baseline was 32% for the latanoprost plus timolol group and 20% for the dorzolamide plus timolol group.",
            "The least square estimate of the mean diurnal intraocular pressure reduction after 3 months was -7.06 mm Hg in the latanoprost plus timolol group and -4.44 mm Hg in the dorzolamide plus timolol group (P < 0.001).",
            "Drugs administered in both treatment groups were well tolerated.",
            "This study clearly showed that the additive diurnal intraocular pressure-lowering effect of latanoprost is superior to that of dorzolamide in patients treated with timolol."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "9230823": {
        "sentences": [
            "A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.",
            "Brimonidin tartrate is a highly selective alpha 2-agonist.",
            "This study investigates the safety and efficacy of 0.2% brimonidine administered twice daily for 1 year in patients with glaucoma or ocular hypertension.",
            "The study design was a multicenter, double-masked, randomized, parallel-group, active-controlled comparison clinical trial.",
            "Subjects instilled 0.2% brimonidine or 0.5% timolol maleate twice daily for 12 months.",
            "Subjects were examined at baseline, week 1, and months 1, 2, 3, 6, 9, and 12.",
            "A subset of subjects was examined at week 2.",
            "Of 443 subjects enrolled in this study, 374 met the entry criteria; 186 received brimonidine and 188 received timolol.",
            "Brimonidine-treated subjects showed an overall mean peak reduction in intraocular pressure (IOP) of 6.5 mm Hg; timolol-treated subjects had a mean peak reduction in IOP of 6.1 mm Hg.",
            "Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03); no significant difference was observed between the groups for this variable at other visits throughout the 1-year course of the study.",
            "No evidence of tachyphylaxis was seen in either group.",
            "Allergy was seen in 9% of subjects treated with brimonidine.",
            "Dry mouth was more common in the brimonidine-treated group than in the timolol-treated group (33.0% vs 19.4%), but complaints of burning and stinging were more common in the timolol-treated group (41.9%) than in the brimonidine-treated patients (28.1%).",
            "Headache, fatigue, and drowsiness were similar in the 2 groups.",
            "In general, the tolerance to medication was acceptable.",
            "Brimonidine is safe and effective in lowering IOP in glaucomatous eyes.",
            "Brimonidine provides a sustained long-term ocular hypotensive effect, is well tolerated, and has a low rate of allergic response."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim"
        ]
    },
    "11124286": {
        "sentences": [
            "Randomized, controlled study of low-dose 5-fluorouracil in primary trabeculectomy.",
            "To report a randomized clinical trial of postoperative subconjunctival injections of low-dose 5-fluorouracil in patients undergoing primary trabeculectomy.",
            "In a prospective, randomized clinical trial, 40 eyes of 40 patients were randomized to the low-dose 5-fluorouracil group and received three subconjunctival injections of 5 mg each over 11 postoperative days, and 40 eyes of 40 patients were randomized to trabeculectomy without 5-fluorouracil.",
            "Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26.9 (+/-9.5) and 15.3 (+/-5.8) mm Hg, respectively.",
            "In the control group these were 25.9 (+/-8.1) mm Hg, and 15.8 (+/-5.1) mm Hg, respectively.",
            "The patients who received 5-fluorouracil had a mean reduction in intraocular pressure of 11.5 (+/-9.1) mm Hg at a median follow-up of 52.3 weeks.",
            "The control group had a mean reduction in intraocular pressure of 10.2 (+/-8.7) mm Hg at a median follow-up of 52.6 weeks.",
            "These differences were not statistically significant.",
            "Three postoperative subconjunctival 5-fluorouracil injections of 5 mg each after trabeculectomy in eyes at low risk for failure had no statistically or clinically significant effect on reduction of intraocular pressure with 1-year follow-up.",
            "Enhancement of success in this group of patients may require a larger total dose of 5-fluorouracil."
        ],
        "labels": [
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12750084": {
        "sentences": [
            "Viscocanalostomy versus trabeculectomy in white adults affected by open-angle glaucoma: a 2-year randomized, controlled trial.",
            "To compare the effectiveness and safety of viscocanalostomy and trabeculectomy in adults with uncontrolled open-angle glaucoma.",
            "Single-masked, parallel-group, prospective, randomized 24-month trial, with 90% power to detect a clinically important difference between groups.",
            "Fifty consecutive patients (50 eyes) with primary open-angle or pseudoexfoliative glaucoma.",
            "Eyes were assigned randomly to either viscocanalostomy (group 1) or trabeculectomy (group 2) with no intraoperative antifibrotics in the study eye.",
            "In group 1, no further intervention was allowed, whereas trabeculectomy eyes could receive subconjunctival 5-fluorouracil (5-FU) injections or laser suture lysis after surgery.",
            "Success rate based on intraocular pressure (IOP), visual acuity, discomfort, and other complications.",
            "At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60); an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).",
            "Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases.",
            "Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.",
            "No patient required reoperation.",
            "Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.",
            "Viscocanalostomy is an effective IOP-lowering procedure in white adults affected by open-angle glaucoma.",
            "Trabeculectomy with postoperative 5-FU can probably provides lower IOPs but, with more numerous complications, greater discomfort, and more intensive postoperative management."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "14644719": {
        "sentences": [
            "A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.",
            "To compare the efficacy and safety of topical bimatoprost (LUMIGAN; Allergan, Inc., Irvine, CA) once daily with that of topical combined timolol and dorzolamide (Cosopt; Merck and Co, Inc., Whitehouse Station, NJ) twice daily.",
            "Prospective, randomized, double-masked, multicenter clinical trial.",
            "One hundred seventy-seven patients with a diagnosis of glaucoma or ocular hypertension and inadequate control of intraocular pressure (IOP) after at least 2 weeks of topical timolol maleate 0.5% monotherapy.",
            "Patients were randomized to receive bimatoprost 0.03% once daily (n = 90) or combined timolol 0.5% and dorzolamide 2% twice daily (n = 87) over a 3-month period.",
            "Intraocular pressure, the primary end point, was measured at 8 AM and 10 AM at baseline, week 1, and months 1, 2, and 3, and also at 4 PM and 8 PM at baseline and month 3.",
            "Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.",
            "At the 8 AM measurements, bimatoprost lowered mean IOP 6.8 mmHg to 7.6 mmHg from baseline, whereas combined timolol and dorzolamide lowered mean IOP 4.4 to 5.0 mmHg from baseline (P<0.001).",
            "At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.",
            "At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).",
            "Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.",
            "In individuals with glaucoma or ocular hypertension, uncontrolled on a topical beta-blocker alone, bimatoprost lowered IOP more consistently than did combined timolol and dorzolamide."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "11158795": {
        "sentences": [
            "Primary viscocanalostomy versus trabeculectomy in white patients with open-angle glaucoma: A randomized clinical trial.",
            "To compare viscocanalostomy, a nonpenetrating procedure for glaucoma treatment, with trabeculectomy.",
            "Randomized controlled trial.",
            "Twenty white subjects (20 eyes) with open-angle glaucoma with no history of surgery were enrolled.",
            "Ten subjects were randomly assigned to viscocanalostomy according to Stegmann's technique and 10 subjects to a modified Cairns trabeculectomy.",
            "A complete ophthalmologic examination was performed the day before surgery and postoperatively.",
            "Further visits were scheduled monthly for 6 to 8 months after surgery.",
            "Success was defined as intraocular pressure (IOP) between 7 and 20 mmHg, with no medication.",
            "After a mean follow-up of 6 months (range, 6-8 months), success was obtained in 5 of 10 cases in the trabeculectomy group and in 0 of 10 case in the viscocanalostomy group.",
            "With Kaplan-Meier's method, subjects with viscocanalostomy showed shorter postoperative IOP-reduction periods than subjects undergoing trabeculectomy.",
            "According to the results of this short-term study, trabeculectomy was more effective than viscocanalostomy in lowering IOP in glaucomatous eyes of white patients."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "20828829": {
        "sentences": [
            "Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract.",
            "To assess the safety and efficacy of the iStent trabecular micro-bypass stent (Glaukos Corporation, Laguna Hills, CA) in combination with cataract surgery in subjects with mild to moderate open-angle glaucoma.",
            "Prospective, randomized, open-label, controlled, multicenter clinical trial.",
            "A total of 240 eyes with mild to moderate open-angle glaucoma with intraocular pressure (IOP) =24 mmHg controlled on 1 to 3 medications were randomized to undergo cataract surgery with iStent implantation (treatment group) or cataract surgery only (control).",
            "Fifty additional subjects were enrolled to undergo cataract surgery with iStent implantation under protocol expansion.",
            "Data in this report are based on the first 240 eyes enrolled.",
            "Implantation of the iStent trabecular micro-bypass stent in conjunction with cataract surgery or cataract surgery only.",
            "The primary efficacy measure was unmedicated IOP \u226421 mmHg at 1 year.",
            "A secondary measure was unmedicated IOP reduction \u226520% at 1 year.",
            "Safety measures included best-corrected visual acuity (BCVA), slit-lamp observations, complications, and adverse events.",
            "The study met the primary outcome, with 72% of treatment eyes versus 50% of control eyes achieving the criterion (P<0.001).",
            "At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.",
            "Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).",
            "The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.",
            "Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "10877373": {
        "sentences": [
            "Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.",
            "To compare the clinical success rates and quality of life impact of brimonidine 0.2% with timolol 0.5% in newly diagnosed patients naive to glaucoma therapy.",
            "A prospective, multicenter, randomized, double-masked, clinical effectiveness trial in which the clinical outcomes of twice daily brimonidine tartrate 0.2% were compared with those of timolol maleate 0.5% in patients with glaucoma and ocular hypertension was conducted.",
            "Two hundred nineteen patients were enrolled--111 in the brimonidine group and 108 in the timolol group.",
            "Patients instilled their study medications twice daily for 4 months.",
            "Factors for determining clinical success were reduction of intraocular pressure (IOP), safety, and adverse events.",
            "Quality of life effects were assessed with the SF-36 Health Survey and Glaucoma Disability Index questionnaires.",
            "Clinical success was 71% (75/106) with brimonidine and 70% (73/105) with timolol as initial treatment.",
            "The overall mean decrease in IOP was 6.5 mm Hg with brimonidine and 6.2 mm Hg with timolol.",
            "Few patients reported a specific adverse event and, with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.",
            "No significant chronotropic effects on the heart were seen with brimonidine, while small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.",
            "Mean systolic and diastolic blood pressure remained relatively stable in both groups.",
            "Quality of life remained stable, with no significant between-group differences.",
            "As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart.",
            "Brimonidine is a viable alternative to timolol for first-line therapy in glaucoma and ocular hypertension."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            null
        ]
    },
    "11912355": {
        "sentences": [
            "Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.",
            "To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure inadequately controlled by monotherapy or dual therapy.",
            "Three hundred seventy-nine patients with primary open-angle glaucoma or ocular hypertension were recruited for this 6-month prospective, randomized, observer-masked multicenter study involving 30 eye clinics.",
            "All patients were receiving monotherapy or dual therapy that did not adequately control intraocular pressure.",
            "After appropriate washout periods, patients were randomized to treatment with latanoprost once daily or brimonidine twice daily.",
            "The main outcome measure was change in mean diurnal intraocular pressure after 6 months of treatment compared with baseline.",
            "Of the 379 randomized patients, 375 were included in the intent-to-treat analysis.",
            "From an overall baseline mean intraocular pressure of 25.0 mm Hg, latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 +/- 3.3 mm Hg (mean +/- SD, P < 0.001), whereas brimonidine monotherapy yielded an intraocular-pressure reduction of 5.2 +/- 3.5 mm Hg (P < 0.001).",
            "This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).",
            "Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.",
            "Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after 6 months of treatment.",
            "However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal intraocular pressure.",
            "Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim",
            "Claim"
        ]
    },
    "11158796": {
        "sentences": [
            "A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension.",
            "To compare the intraocular pressure (IOP) reducing effect and safety of latanoprost 0.005% once daily with unoprostone 0.12% twice daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).",
            "An 8-week, double-masked, randomized, parallel-group, single-center clinical trial.",
            "A total of 108 patients with POAG or OH were enrolled.",
            "After completing a wash-out of ocular hypotensive medications, patients were randomized to receive either latanoprost once daily in the evening plus placebo once daily in the morning, or unoprostone twice daily (morning and evening).",
            "IOP was measured at 10:00 AM and at 5:00 PM at baseline and at week 8, and before 12:00 noon at week 2.",
            "Ocular and systemic safety assessments were performed.",
            "From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).",
            "The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.",
            "A >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.",
            "The incidence of adverse events was low and comparable between the groups.",
            "Latanoprost administered once daily was significantly more effective in reducing IOP compared with unoprostone administered twice daily in patients with POAG and OH."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim"
        ]
    },
    "11148810": {
        "sentences": [
            "Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial.",
            "Increased intraocular pressure (IOP) has been shown to be one of the most important risk factors for developing glaucoma.",
            "Yet it has not been clearly demonstrated that IOP-lowering treatment can reduce the incidence of glaucoma damage in patients with ocular hypertension.",
            "The aim of the current paper was to report the results of a long-term study addressing this very problem.",
            "We conducted a randomised, double-masked study comparing timolol and placebo treatment in 90 patients with ocular hypertension plus some additional risk factor.",
            "Patients were followed at 3-month intervals prospectively for 10 years or until glaucomatous field loss could be demonstrated with computerised perimetry.",
            "A post-study analysis was performed including all available data, thus extending maximum follow-up to 17 years.",
            "After 5 years of follow-up eight patients in the placebo group and five patients in the timolol group had developed glaucomatous field loss (NS); the corresponding figures after 10 years were 15 patients in the placebo group and seven patients in the timolol group.",
            "Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).",
            "Study attrition was large.",
            "Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.",
            "IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).",
            "In this long-term study we found a tendency but failed to prove a beneficial effect of topical timolol treatment in patients with elevated IOP, normal visual fields and some additional risk factor.",
            "The intent-to-treat analysis showed no difference between treatment groups.",
            "The high attrition shows the difficulties associated with very long follow-up."
        ],
        "labels": [
            null,
            "Claim",
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence",
            "Evidence"
        ]
    },
    "19860553": {
        "sentences": [
            "A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.",
            "Bimatoprost and the fixed combination of latanoprost with timolol maleate are 2 medications widely used to treat glaucoma and ocular hypertension (OHT).",
            "The aim of the study is to compare the efficacy of these 2 drugs in reducing intraocular pressure (IOP) after 8 weeks of treatment in patients with primary open angle glaucoma (POAG) or OHT.",
            "In this randomized, open-label trial, 44 patients with POAG or OHT were allocated to receive either bimatoprost (1 drop QD) or latanoprost/timolol (1 drop QD).",
            "Primary outcome was the mean diurnal IOP measurement at the 8th week, calculated as the mean IOP measurements taken at 8:00 am, 10:00 am, and 12:00 pm Secondary outcomes included the baseline change in IOP measured 3 times a day, after the water-drinking test (performed after the last IOP measurement), and the assessment of side effects of each therapy.",
            "The mean IOP levels of latanoprost/timolol (13.83, SD = 2.54) was significantly lower than of bimatoprost (16.16, SD = 3.28; P < 0.0001) at week 8.",
            "Also, the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).",
            "During the water-drinking test, there was no significant difference in IOP increase (absolute and percentage) between groups; however, there was a significant decrease in mean heart rate in the latanoprost/timolol group.",
            "Finally, no significant changes in blood pressure and lung spirometry were observed in either groups.",
            "The fixed combination of latanoprost/timolol was significantly superior to bimatoprost alone in reducing IOP in patients with POAG or OHT.",
            "Further studies with large sample sizes should be taken to support the superior efficacy of latanoprost/timolol, as well as to better assess its profile of side effects."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "18327364": {
        "sentences": [
            "Efficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open angle glaucoma.",
            "Efficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open angle glaucoma",
            "The study was designed as a 6 months randomized, observer-masked study comprising 120 patients with primary open-angle glaucoma in Feiz Hospital, Isfahan, Iran, from 2006 to 2007.",
            "The patients were randomized (latanoprost, n = 60; dorzolamide/timolol, n = 60) to treatment with either latanoprost, 0.005% once daily, or the combination of timolol 0.5% twice daily, and dorzolamide 2% 3 times daily.",
            "The mean intraocular pressure (IOP) after one, 3, and 6 months of treatment was compared with baseline in the 2 groups.",
            "A total of 120 patients were randomized to 2 equal treatment groups.",
            "The mean baseline IOP values were similar between the 2 groups.",
            "The mean (standard error of mean [SE]) IOP reductions at months one was 7.2 (0.4), at month 3 was 7.3 (0.4), and at month 6 was 7.1 (0.3) mm Hg for the latanoprost group and 7.5 (0.3), 7.8 (0.3), and 7.4 (0.3) mm Hg for the dorzolamide/timolol group.",
            "The 2 therapies were similarly effective.",
            "The latanoprost and dorzolamide/timolol combination were equally effective at lowering IOP compared to untreated baseline."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "19092465": {
        "sentences": [
            "An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.",
            "To compare the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure (IOP) over 8 weeks.",
            "This 8-week, multicentric, interventional, randomized, open-label, parallel group study was conducted at 4 centers in Brazil and 1 center in Argentina.",
            "Patients with open-angle glaucoma or ocular hypertension were randomized to receive bilaterally fixed combination of brimonidine/timolol maleate 0.5% or fixed combination of dorzolamide 2%/timolol 0.5% twice daily at 8:00 AM and 8:00 PM.",
            "A modified diurnal tension curve (8:00 AM, 10:30 AM, 02:00 PM, and 4:00 PM) followed by the water drinking test (WDT), which estimates IOP peak of diurnal tension curve, were performed in the baseline and week-8 visits.",
            "Adverse events data were recorded at each visit.",
            "A total of 210 patients were randomized (brimonidine/timolol, n=111; dorzolamide/timolol, n=99).",
            "Mean baseline IOP was 23.43+/-3.22 mm Hg and 23.43+/-4.06 mm Hg in the patients treated with brimonidine/timolol and dorzolamide/timolol, respectively (P=0.993).",
            "Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).",
            "The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).",
            "Mean baseline WDT peak was 27.79+/-4.29 mm Hg in the brimonidine/timolol group and 27.68+/-5.46 mm Hg in the dorzolamide/timolol group.",
            "After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.",
            "The adjusted difference between groups (analysis of covariance) was not statistically significant (P=0.469).",
            "No statistical difference in terms of adverse events was found between groups.",
            "Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment.",
            "Also, both fixed combinations are well tolerated with few side effects."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "15234141": {
        "sentences": [
            "Experience with the use of Baerveldt and Ahmed glaucoma drainage implants in an Asian population.",
            "To evaluate the efficacy and safety of Baerveldt and Ahmed glaucoma drainage implants in Asian patients with refractory glaucoma.",
            "Retrospective nonrandomized study.",
            "Forty-one patients.",
            "The authors reviewed the insertion of 18 Ahmed glaucoma valved (AGV-S2) implants and 24 350 mm(2) Baerveldt glaucoma implants performed by a single surgeon at the Department of Ophthalmology, National University Hospital, Singapore, from January 1, 2000, to December 31, 2000.",
            "A total of 42 glaucoma drainage implants was inserted into the eyes of 41 patients.",
            "All patients had at least 6 months of follow-up.",
            "Intraocular pressure (IOP), visual acuity, and complications.",
            "Both drainage implants achieved remarkable reductions in IOP; from pretreatment IOP of 40.1+/-13.8 mmHg and 43.7+/-9.3 mmHg to postoperative IOP of 17.4+/-6.2 and 14.9+/-5.5 mmHg in the Baerveldt and Ahmed groups, respectively.",
            "A decrease in IOP of 56.6% and 65.9% had been achieved.",
            "Success rates were 20 (83.3%) for Baerveldt and 12 (66.7%) for Ahmed implants, whereas qualified success occurred in 1 (4.2%) Baerveldt and 3 (16.7%) Ahmed implants.",
            "Conversely, failure to control IOP occurred in 3 (12.5%) Baerveldt implants and 3 (16.7%) Ahmed implants.",
            "More than 80% of the patients had maintained or improved visual function, whereas only 4 (16.0%) of the patients with Baerveldt implants and 2 (16.7%) patients with Ahmed implants had loss of more than 1 Snellen line.",
            "Both Baerveldt and Ahmed glaucoma drainage implants performed well in terms of IOP control, preservation of visual function, and having low complication rates."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "21423036": {
        "sentences": [
            "Silicone Ahmed glaucoma valve with and without intravitreal triamcinolone acetonide for neovascular glaucoma: randomized clinical trial.",
            "\ufeff",
            "To compare the effect on intraocular pressure (IOP) of the silicone Ahmed glaucoma valve with and without an intravitreal injection of triamcinolone acetonide.",
            "Forty-nine patients with clinically uncontrolled neovascular glaucoma were included in the study; 22 were randomly assigned to the study group (silicone Ahmed glaucoma valve implant with intravitreal triamcinolone acetonide) and 27 to the control group (silicone Ahmed glaucoma valve).",
            "IOP was the primary outcome measure in this study.",
            "The secondary outcome measure was success, defined by IOP lower than 22 mm Hg and higher than 5 mm Hg, and no serious complications.",
            "Success rates in both the groups were compared using Kaplan-Meier survival curves and the log-rank test.",
            "IOP levels were compared using mixed linear model analysis to correct for repeated measures correlation.",
            "Forty-three patients, 18 in the study group and 25 in the control group, completed the study (follow-up of 12 mo).",
            "The mean IOP was significantly lower after 1 year in both the groups (P<0.001).",
            "The mean IOP in the first month of follow-up was lower in the study group (control; 20.4\u00b19.7, study; 13.6\u00b16.5, P<0.01).",
            "The success rate at 1 year was 78% for the study group and 76% for the control group (P=0.82).",
            "Complication rates were not different between the groups.",
            "Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications.",
            "The mean IOP spike in the first month was lower in the triamcinolone group."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence"
        ]
    },
    "19336424": {
        "sentences": [
            "A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma.",
            "To compare the intraocular pressure (IOP) lowering efficacy and side effects of latanoprost 0.005% and bimatoprost 0.03% in subjects with chronic primary angle closure glaucoma (PACG).",
            "This was an observer-masked randomised crossover study of 60 PACG subjects who received either latanoprost or bimatoprost for 6 weeks, after which they were crossed over to the other medication for another 6 weeks.",
            "The IOP-reducing effect of the medications was assessed by the reduction in IOP after 6 weeks of treatment compared with baseline.",
            "Fifty-four subjects (80 eyes) completed the study.",
            "Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).",
            "Adverse events were mild in both groups; however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).",
            "Ocular irritation was the most frequently reported adverse event in both groups; 22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).",
            "Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.",
            "Both drugs were well tolerated with mild ocular adverse events."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "17083910": {
        "sentences": [
            "Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up.",
            "To report one-year results of the Tube Versus Trabeculectomy (TVT) Study.",
            "Multicenter randomized clinical trial.",
            "Setting: 17 Clinical Centers.",
            "Study Population: Patients 18 to 85 years of age who had previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure (IOP) > or =18 mm Hg and < or =40 mm Hg on maximum tolerated medical therapy.",
            "Interventions: 350 mm(2) Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC).",
            "Main Outcome Measures: IOP, visual acuity, and reoperation for glaucoma.",
            "A total of 212 eyes of 212 patients were enrolled, including 107 in the tube group and 105 in the trabeculectomy group.",
            "At one year, IOP (mean +/- SD) was 12.4 +/- 3.9 mm Hg in the tube group and 12.7 +/- 5.8 mm Hg in the trabeculectomy group (P = .73).",
            "The number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).",
            "The cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).",
            "Nonvalved tube shunt surgery was more likely to maintain IOP control and avoid persistent hypotony or reoperation for glaucoma than trabeculectomy with MMC during the first year of follow-up in the TVT Study.",
            "Both surgical procedures produced similar IOP reduction at one year, but there was less need for supplemental medical therapy following trabeculectomy with MMC."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "12470755": {
        "sentences": [
            "Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure.",
            "To compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost 0.005% once daily with that of unoprostone 0.15% twice daily for patients with primary open-angle glaucoma or ocular hypertension.",
            "Randomized clinical trial.",
            "In a prospective, 8-week, investigator-masked, parallel-group study conducted at numerous centers in the United States, 165 previously treated patients with IOP >or= 25 mm Hg in one or both eyes after washout were randomly assigned to receive either latanoprost 0.005% once daily in the evening or unoprostone 0.15% twice daily.",
            "Observations procedures were Goldmann applanation tonometry, best-corrected visual acuity, slit lamp biomicroscopy, and ophthalmoscopy.",
            "The main outcome measure was change in the mean of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM between baseline (before treatment) and after 8 weeks of treatment.",
            "The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=.001.",
            "No serious adverse event related to either medication was reported.",
            "Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.",
            "Both agents were safe and well tolerated."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "8058290": {
        "sentences": [
            "Intermediate-term results of a randomized clinical trial of the 350- versus the 500-mm2 Baerveldt implant.",
            "The Baerveldt glaucoma implant is a large equatorial aqueous shunting device that is installed through a single-quadrant conjunctival incision.",
            "The intermediate-term results of a randomized study comparing the 350- and 500-mm2 Baerveldt implants are reported.",
            "Seventy-three patients with medically uncontrollable, nonneovascular glaucomas associated with aphakia, pseudophakia, or failed filters were enrolled in a randomized, prospective study comparing 350- and 500-mm2 Baerveldt implants.",
            "Surgical success was defined as 6 mmHg < or = final intraocular pressure < or = 21 mmHg without glaucoma reoperation or devastating complication.",
            "Of patients with 350- and 500-mm2 implants, 93% and 88%, respectively, achieved surgical success (18-month life-table analysis, P = 0.93).",
            "The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).",
            "The postoperative visual acuities remained within one line of the preoperative visual acuities or improved in 62% and 66% of patients in the 350- and 500-mm2 groups, respectively (P = 0.93).",
            "Complication rates were statistically similar.",
            "The most frequent ones in the 350- and 500-mm2 groups, respectively, were serous choroidal effusion (16% and 32%), strabismus (16% and 19%), anterior uveitis (14% and 11%), and corneal or corneal graft edema (11% each).",
            "The intermediate-term results of the 350- and 500-mm2 Baerveldt implants were statistically comparable with respect to surgical and visual outcomes, as well as complications, although the larger implant was associated with a higher rate of some complications.",
            "However, the 500-mm2 Baerveldt implant afforded intraocular pressure control with fewer medications than the 350-mm2 implant."
        ],
        "labels": [
            null,
            null,
            "Claim",
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "11336940": {
        "sentences": [
            "A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.",
            "To compare the intraocular pressure)-lowering effect and side effects of latanoprost 0.005% once daily with unoprostone 0.12% twice daily.",
            "Sixty patients with primary open-angle glaucoma or ocular hypertension were randomized to receive either latanoprost once daily in the evening and placebo once daily in the morning, or unoprostone twice daily in the morning and evening.",
            "The study was double masked and followed a crossover design with two treatment periods of 1 month separated by a 3-week washout period.",
            "The intraocular pressure was measured at 9 AM and 5 PM on the baseline and day 28 visits, and at 9 AM on day 2 and day 14 visits of each treatment period.",
            "The 9 AM measurement was taken 2 hours and 13 hours after the last drop of unoprostone and latanoprost, and the 5 PM measurement was at 10 and 21 hours, respectively.",
            "The mean of the measurements was calculated.",
            "Safety parameters were also recorded.",
            "Fifty-six patients completed both treatment periods and had intraocular pressure data available for evaluation.",
            "After 1 month of treatment, latanoprost significantly reduced intraocular pressure (mean +/- SEM) by 6.1 +/- 0.5 mm Hg (P <.001) and unoprostone by 4.2 +/- 0.4 mm Hg (P <.001) adjusted from an overall baseline of 22.3 +/- 0.5 mm Hg and 23.2 +/- 0.4 mm Hg, respectively.",
            "The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].",
            "Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.",
            "Adverse ocular symptoms and findings were mild in both treatment groups.",
            "Eye redness and ocular irritation were the most frequently reported events.",
            "Latanoprost once daily was significantly more effective in reducing intraocular pressure compared with unoprostone twice daily after 1 month of treatment in patients with primary open-angle glaucoma and ocular hypertension.",
            "Both drugs were well tolerated with few ocular adverse events."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "10599663": {
        "sentences": [
            "Randomized clinical trial of the 350-mm2 versus the 500-mm2 Baerveldt implant: longer term results: is bigger better?",
            "To report the longer term results of a randomized, clinical trial comparing the 350-mm2 and the 500-mm2 Baerveldt glaucoma implants.",
            "Extended follow-up on a randomized, controlled trial.",
            "Between March 1991 and April 1993, 107 patients with uncontrolled intraocular pressure (IOP) due to non-neovascular glaucoma associated with aphakia, pseudophakia, or failed filters were randomly assigned for surgical placement of either the 350-mm2 or the 500-mm2 Baerveldt implant at the Doheny Eye Institute.",
            "A random-numbers table was used to assign each patient to one of the two groups.",
            "Preoperative IOPs and visual acuities were recorded.",
            "Clinical records were reviewed to ascertain postoperative IOPs, visual acuities, number of medications used, and implant-related complications that occurred throughout the follow-up period.",
            "Success was defined as IOP of 6 mmHg or greater and of 21 mmHg or less in two or more consecutive follow-up visits without further glaucoma surgery or loss of light perception attributable to glaucoma.",
            "The overall success rates were 87% for the 350-mm2 group and 70% for the 500-mm2 group (P = 0.05).",
            "Average follow-up was 37 months (range, 1-76 months) for the 350-mm2 group and 34 months (range, 5-77 months) for the 500-mm2 group.",
            "The life-table success rates declined over time for both implant groups, from a high of 98% for the 350-mm2 group and 92% for the 500-mm2 group at 1 year to a cumulative success rate of 79% for the 350-mm2 group and 66% for the 500-mm2 group at 5 years.",
            "Visual acuities were better or remained the same in 50% of the patients in the 350-mm2 group and 46% of those in the 500-mm2 group.",
            "Complications during the 5-year follow-up were also statistically similar.",
            "The longer term results show that the 350-mm2 Baerveldt implant is more successful than the 500-mm2 implant for overall IOP control.",
            "Interval comparisons indicate a higher rate of success for the 350-mm2 implant in the first, second, third, fourth, and fifth years of implantation.",
            "Visual acuities, implant-related complications, and average IOPs were statistically indistinguishable between the two groups."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            null,
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim",
            null
        ]
    },
    "20202537": {
        "sentences": [
            "Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma: randomized double-masked clinical trial.",
            "To compare phacoemulsification alone and phacoemulsification with micro-bypass stent implantation in eyes with primary open-angle glaucoma.",
            "Instituto di Fisiopatologia Clinica, Clinica Oculistica, Universita' di Torino, Torino, Italy.",
            "In this prospective double-masked randomized clinical trial, patients had phacoemulsification alone (control group) or phacoemulsification with iStent implantation (combined group).",
            "Primary outcomes were intraocular pressure (IOP) and reduction in medication use over 15 months and IOP after a 1-month washout of ocular hypotensive agents (ie, 16 months postoperatively).",
            "The baseline IOP was similar between groups (combined group: 17.9 mm Hg +/- 2.6 [SD]; control group: 17.3 +/- 3.0 mm Hg) (P = .512).",
            "Three patients in the control group were lost to follow-up.",
            "The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout; the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).",
            "At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).",
            "Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone; the safety profiles were similar."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "17947826": {
        "sentences": [
            "Long-term intraocular pressure control of trabeculectomy and triple procedure in primary open angle glaucoma and chronic primary angle closure glaucoma.",
            "To evaluate the long-term intraocular pressure (IOP) control of trabeculectomy and triple procedure (cataract extraction by phacoemulsification, intraocular lens implantation and trabeculectomy), 1,542 eyes of 900 patients with primary open angle glaucoma (POAG) or chronic primary angle closure glaucoma (CPACG) were included.",
            "When success was defined as an IOP reduction of at least 30% from baseline, with or without antiglaucoma medications, the overall probability of success of trabeculectomy and triple procedure was 0.613 and 0.733 at 15 years, respectively.",
            "The success probability of trabeculectomy and triple procedure in reducing IOP below 18 mm Hg was 0.748 and 0.825 at 15 years, respectively.",
            "In POAG and CPACG patients, trabeculectomy and triple procedure were effective in reducing IOP for up to 15 years after surgery."
        ],
        "labels": [
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "19383599": {
        "sentences": [
            "Combined trabeculectomy and cataract extraction versus trabeculectomy alone in primary angle-closure glaucoma.",
            "To compare the long-term efficacy and safety of combined trabeculectomy and cataract extraction versus trabeculectomy alone in primary angle-closure glaucoma (PACG).",
            "Hospital files were retrospectively examined for 99 Chinese PACG patients; 75 patients underwent combined surgery and 24 underwent trabeculectomy alone.",
            "Success rates were assessed with the Kaplan-Meier survival analysis.",
            "The main outcome was the complete success rate defined as either a >20% reduction in intraocular pressure (IOP) or an IOP that remained below 15 mm Hg, with no medications required.",
            "Patients in the combined group and trabeculectomy group had a mean follow-up period of 25.8 (SD 10.8) months and 31.4 (8.9) months, respectively.",
            "Survival analysis showed that the complete success rate at 3 years was 56% in the combined group and 54% in the trabeculectomy group (p = 0.903).",
            "There were no significant differences between groups in either IOP or the number of glaucoma medications throughout the 3-year follow-up.",
            "The incidences of postoperative complications were similar between groups (p = 0.232).",
            "No additional IOP-lowering surgical procedures were required in the combined group, while 13 (54%) eyes in the trabeculectomy group required either cataract extraction or further IOP-lowering surgical procedures (p <0.001).",
            "In patients with PACG, the long-term IOP-lowering effect and surgical complications of combined trabeculectomy and cataract extraction are comparable with those of trabeculectomy alone.",
            "However, the combined surgery incurred fewer subsequent surgical interventions."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "17601060": {
        "sentences": [
            "[Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].",
            "To compare the ocular hypotensive activity and safety profile of long-acting 1% carteolol hydrochloride eye drops (long-acting formulation) to those of 1% carteolol hydrochloride eye drops(currently prescribed drug) for reduction of intraocular pressure.",
            "Patients with primary open-angle glaucoma or ocular hypertension (146 cases) were assigned randomly to the long-acting drug group (74 cases) and the currently-prescribed drug group (72 cases).",
            "Long-acting eye drops were instilled once a day in the morning (along with one drop of placebo at night), and currently-prescribed eye drops were instilled twice a day in the morning and at night.",
            "Eye drops were administered for 8 weeks.",
            "Intraocular pressure was monitored at 2, 4, and 8 weeks after the initiation of drug instillation for evaluation of equivalence.",
            "Intraocular pressure was significantly reduced during the entire follow-up period in both groups.",
            "In the long-acting drug group, the reduction of intraocular pressure was -3.5 +/- 0.2, -4.3 +/- 0.2 and -4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).",
            "In the currently-prescribed drug group, the reduction of intraocular pressure was -4.1 +/- 0.2, -4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).",
            "The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.",
            "Because the efficacy of both drugs was equivalent, with an identical safety profile, the long-acting eye drops seem to be an efficacious formulation for clinical use in Japanese glaucoma patients."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim",
            "Claim"
        ]
    },
    "12383808": {
        "sentences": [
            "A prospective randomized trial comparing intraoperative 5-fluorouracil vs mitomycin C in primary trabeculectomy.",
            "To compare the safety and efficacy of intraoperative 5-fluorouracil (5-FU) or Intraoperative mitomycin C (MMC) in eyes undergoing primary trabeculectomy.",
            "Prospective double-masked randomized clinical trial.",
            "One hundred fifteen eyes of 103 patients with uncontrolled intraocular pressure (IOP) despite maximally tolerated medical therapy or laser were prospectively randomized in a double-masked fashion to one of two treatment groups in a single institution setting.",
            "Subject's eyes underwent primary trabeculectomy with either topical 5-FU (50 mg/ml for 5 minutes) or topical MMC (0.2 mg/ml for 2 minutes).",
            "Primary outcome measures included the number of eyes achieving target pressures of 21, 18, 15, and 12 mm Hg at 6 and 12 months postoperatively.",
            "Secondary outcome measures included IOP, best-corrected visual acuity, complications, and interventions.",
            "Of the 115 eyes, 57 received 5-FU while 58 received MMC.",
            "A target IOP of 21 mm Hg at 6 months was achieved in 53 of 56 (95%) eyes in the 5-FU group and 54 of 57 (95%) eyes in the MMC group (P = 1.00).",
            "At 12 months, 45 of 48 (94%) eyes in the 5-FU group met a target IOP of 21 mm Hg while 48 of 54 (89%) eyes in the MMC group did (P =.49).",
            "The most common complications in each group were persistent choroidal effusions and bleb leak.",
            "Our study suggests that intraoperative topical 5-FU is at least as effective as intraoperative topical MMC in reducing IOP of eyes undergoing primary trabeculectomy."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Claim"
        ]
    },
    "9034838": {
        "sentences": [
            "The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.",
            "Latanoprost is a PGF2 alpha analogue which reduces the intraocular pressure (IOP) by increasing the uveoscleral outflow.",
            "The objective of this study was to investigate the effect of two different regimens of latanoprost on the diurnal IOP and also the effect of latanoprost on the blood-aqueous barrier measured with a laser flare cell meter (Kowa FM-500).",
            "Moreover, the safety aspects of the two regimens regarding hyperemia were studied.",
            "A double-masked, randomized study was performed in 30 patients (9 males, 21 females; mean age 61.9 years) with primary open-angle glaucoma or pseudoexfoliation glaucoma.",
            "Twenty patients were treated with latanoprost 0.0015% twice daily or 0.005% once daily for 3 weeks in a cross-over design.",
            "Ten patients received timolol 0.5% twice daily as control.",
            "Latanoprost 0.005% once daily reduced IOP (+/- SEM) more effectively than latanoprost 0.0015% twice daily (9.8 +/- 0.9 mm Hg and 6.7 +/- 0.9 mm Hg, respectively).",
            "There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).",
            "There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).",
            "No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).",
            "Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P < 0.001).",
            "Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier.",
            "There was no difference in hyperemia between the two regimens.",
            "Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops."
        ],
        "labels": [
            null,
            null,
            null,
            null,
            null,
            null,
            null,
            "Evidence",
            "Evidence",
            "Evidence",
            "Evidence",
            null,
            "Claim",
            "Claim",
            "Claim"
        ]
    }
}